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 “You can’t look too far ahead. Do that and you’ll lose sight 
of what you’re doing and stumble. I’m not saying you should focus solely on the details right 
in front of you, mind you. You’ve got to look ahead a bit or else you’ll bump into something. 
You’ve got to conform to the proper order and at the same time keep an eye out for what’s 
ahead. That’s critical, no matter what you’re doing.”  
 
― Haruki Murakami, Kafka on the Shore 
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1 Abstract 
 
In the last decades the role of metals in neurodegenerative diseases assumed a great 
importance, in particular regarding copper and iron. Ceruloplasmin (Cp), an enzyme present in 
the plasma secreted by the liver and in the cerebrospinal fluid (CSF) as product of the epithelial 
cells composing the blood-CSF barrier, may play a crucial function in the metabolism of copper 
and iron in the central nervous system (CNS), being Cp able to transport copper and to oxidize 
toxic ferrous iron; Cp’s ferroxidasic function is essential for iron export outside cells of the CNS, 
thus protecting tissues from oxidative damage. Investigating Cp patterns using two-dimensional 
electrophoresis (2D-E), we found that in Parkinson’s (PD) and Alzheimer’s (AD) diseases the Cp 
profile proved to be more acidic than that found in healthy controls and patients affected by 
other neurological pathologies, suggesting a possible use of Cp 2D-E profile as a pathological 
marker. In vitro oxidation of Cp generated a 2D-E shift resembling that observed in patients, 
indicating that Cp oxidation contributes to the electrophoretic profile seen in PD and AD; Cp 
oxidation caused a decrease of ferroxidase activity, promoting intracellular iron retention in 
cultured neurons. 
Among all the possible Cp’s amino acidic modifications induced or accelerated by oxidation, the 
deamidation of asparagine appears attractive, being this reaction related to protein aging, dis-
function, degradation and/or aggregation, all phenomena observed for several proteins in AD 
and PD. In particular our attention has been focused on the asparagine present at the level of 
the two Asp-Gly-Arg (NGR) motifs present on the Cp sequence; the first, 568NGR, is exposed on 
the surface and in direct contact with the environment while the second 962NGR, is hidden within 
the tertiary structure of the protein. The function of NGR-motif has been recently discovered: 
deamidation of the asparagine at this level results in the formation of isoDGR-motif that can bind 
integrins containing RGD-binding site. This open a new interesting research field on latent 
integrin-recognition-sites, which can be activated in physiological or pathological conditions.  
We observed that the Cp exposed 568NGR site can deamidate under conditions mimicking 
accelerated asparagine aging, while the hidden 962NGR-site can deamidate exclusively when 
aging occurs under oxidative conditions; this result suggest that oxidation-induced structural 
changes foster deamidation at this site. NGR-deamidation in Cp was associated with gain of 
integrin binding function, intracellular signalling and cell pro-adhesive activity. Moreover, 
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deamidated-Cp intracellular signals in epithelial and neural stem cells caused cell proliferation 
arrest. 
In addition, also the ex-vivo aging in the CSF from Alzheimer and Parkinson disease patients, but 
not in control or peripheral neuropathies CSF, induced Cp structural changes, deamidation with 
gain of integrin-binding function, carbonylation and ferroxidase-activity reduction. These results 
indicate that in the pathological CSF are present compounds (small molecules or proteins) able 
to induce oxidative modifications on other proteins. In particular, the modifications observed in 
Cp aged in pathological CSF may be the consequence of oxidation resulting from the high H2O2 
concentration we detected in the AD’s and PD’s CSF. 
Concluding, the CSF of AD and PD patients favors Cp deamidation at NGR-sites with gain-of-
function in cell adhesion and loss of ferroxidase activity, raising Cp deamidation as an additional 
contributor to neurodegenerative diseases characterized by oxidation. 
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2 Introduction 
2.1 The CSF environment, a 
regulator of central nervous 
system development, nutrition 
and functioning 
2.1.1   The CSF: flow and composition 
The cerebrospinal fluid (CSF) is a nutrient-rich liquid 
that permeates the brain and the spinal cord, filling 
the ventricles and the spinal channel. The major site 
of CSF formation is the epithelial cells layer of the 
choroid plexus (75% of the total volume of CSF 
produced), but there is also an extra-choroidal 
secretion, which may result from ion transport by 
brain capillaries. The CSF volume, estimated to be 
about 150 ml in adults, is distributed between 125 ml 
in cranial and spinal subarachnoid spaces and 25 ml 
in the ventricles; CSF secretion in adults varies 
between 400 to 600 ml per day, such that the liquid 
and the salts components of CSF are replaced three 
or four times each day. Interestingly, during the 
aging, cerebral atrophy cause a relative increase of 
the CSF compartment compared to the brain 
parenchyma, bringing a reduction of CSF turnover 
after the age of about 70 years [9]. This mechanism 
causes an impairment in the scavenging of 
metabolites, neurotransmitters catabolites and 
aberrant proteins (like beta-amyloid) letting them to 
accumulate in specific regions of the central nervous 
system [9]. 
The CSF circulation is a dynamic phenomenon, 
propelled by three main forces: arterial pulsations in 
the choroid plexus (corresponding to the systolic 
pulse wave in choroidal arteries), hydrostatic pressure 
gradient, and ciliary motion of the ependymal cells 
lining the ventricles [3]. CSF flows from the sites of 
secretion to the sites of absorption according to a 
unidirectional rostrocaudal flow in ventricular cavities 
and a multi-directional flow in subarachnoid spaces: 
the fluid produced in the lateral ventricles passes 
through the foramina of Monro into the third 
ventricle, travels in the aqueduct of Sylvius and then 
into the fourth ventricle. From here, CSF passes 
through the foramen of Magendie to the cisterna 
magna and then circulates into the cerebral and  
 
spinal subarachnoid spaces (Figure 2.1.1). At the level 
of foramina between the ventricles obstructions can 
occur (for example by inflammation or thrombosis), 
causing the ventricle upstream from the obstruction 
to enlarge, producing obstructive hydrocephalus. In 
the cranial subarachnoid space, CSF circulates to the 
villous sites of absorption (spinal arachnoid villi) or 
caudally to the spinal subarachnoid space (Figure 
2.1.1): arachnoid villi are finger-like endothelium 
protrusions of the arachnoid outer-layer through the 
dura mater in the lumen of venous sinuses [10], that 
adsorb the CSF with a dynamic process which adapts 
the filtration rate to CSF pressure. Their absorption of 
CSF is described to be like a valve-like process, 
permitting the one-way flow of CSF from the 
subarachnoid spaces into the venous sinuses.  
CSF absorption does not occur until CSF pressure 
exceeds the pressure within the sinuses. Once this 
threshold is reached, the rate of absorption is 
proportional to the difference between CSF and sinus 
pressures. The interplay absorption by the arachnoid 
villi and the selective removal of molecules by the 
choroid plexus means that there can be a 
concentration gradient for molecules reaching the 
interstitial fluid of the brain to diffuse into the CSF. 
Regarding its biological function, for a long time the 
cerebrospinal fluid was considered only a “hydro-
mechanical damper” that protects the central 
nervous system from injuries. This function is true, 
but is not the only one: from the purely mechanical 
point of view, for example, being the skull a rigid 
structure, an increase in brain volume (such as those 
that occur from vasodilation) could cause marked 
rises in intracranial pressure; the fluid in the CSF 
system, whose volume can be modulated, limits such 
changes in pressure. Similarly, if the brain is 
dehydrated, the CSF acts as a source of fluid to 
rehydrate it. Early work on the CSF focused primarily 
on the importance of this pressure homeostasis in 
the developing brain [11]: too little pressure 
decreases brain size, while too much pressure leads 
to impaired neural stem cell division and 
hydrocephalus. Nowadays, molecular biology shown 
that CSF plays an essential role also in homeostasis of 
the interstitial fluid of the brain parenchyma and in 
the regulation  
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of the neuronal activity, and disorders of these CSF 
hydrodynamics and composition are responsible for 
the major alterations of cerebral physiology observed 
in hydrocephalus and dementia, reflecting the 
importance of exchanges between CSF and the 
neuronal environment. CSF role in these mechanisms 
comprise the regulation of electrolyte balance, 
circulation of active molecules, elimination of 
catabolites (wastes of brain metabolism, peroxidation 
products and glycosylated proteins) and transport of 
the choroidal plexus secretions (hormones, growth 
factors, inflammatory molecules) to their sites of 
action. This mode of distribution by CSF circulation 
modulates the activity of certain regions of the brain 
by impregnation [12]. Furthermore, the bulk flow of 
CSF along the optic and olfactory nerves drains 
through lymphatic 
tissue, letting the 
antigenic material in the 
CSF to produce a 
systemic immune 
reaction. 
As described above, the 
CSF system is the major 
source of entry into the 
brain for a number of 
substances, and several 
constituents are 
maintained at different 
concentrations in CSF 
from those in plasma: 
some substances enter 
the CSF via the blood-
CSF barrier and others 
enter via the blood-
brain barrier. Besides, 
neo-synthesized 
molecules are produced 
by specialized cells 
population of the CNS, 
like astrocytes, glial cells 
and epithelial cells of 
the choroid plexus.  
CSF is composed by 
99% water, provided 
primarily by Aquaporin-
1 channels located on 
the apical membrane of 
the epithelial cells in the 
ventricles, but it is also a 
rich source of proteins, 
ions, lipids, hormones, cholesterol, glucose, and 
many other molecules and metabolites. Recent works 
have turned to investigate the biological functions of 
known CSF-resident factors. Many of these CSF-
distributed factors, being the fluid in intimate contact 
with the thalamus, hypothalamus and pineal gland, 
have been speculated to influence a wide range of 
behaviors including sleep and appetite, circadian 
rhythms and loco motor activity. Many studies have 
taken advantage of advances in proteomic tools 
including mass spectrometry to better characterize 
these proteins that compose the CSF proteome [13]. 
These studies have demonstrated that the CSF 
proteome consists of hundreds of proteins of the 
extracellular matrix, ion carriers, regulators of osmotic 
pressure, hormone-binding proteins, growth-factors, 
Figure 2.1.1: The description of the CSF pathway. The CSF is produced by the choroid plexus (1) from where it moves 
from the lateral ventricles to the third and fourth ventricles (2). Then it flows across the surface of the brain and down 
the spinal canal (3). CSF is finally reabsorbed by the arachnoid granulations (4) back in to the blood stream. (Image 
adapted from [1]). 
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regulators of lipid metabolism and various enzymes 
and regulators. The CSF is home of hundreds of 
proteins and signaling activities, providing an 
elaborate range of biological functions for this 
complex fluid [14]. Although the factors responsible 
for the favorable effects of embryonic and adult CSF 
are only beginning to be uncovered, the range of 
factors already known to be active in CSF during 
embryonic brain development includes fibroblast 
growth factors (FGFs), insulin-like growth factors 
(IGFs), sonic hedgehog (Shh), retinoic acid, melatonin, 
bone morphogenic proteins (BMPs), Wingless-related 
integration site (Wnt), and others [15-17]. Melatonin, 
a hormone that regulates circadian rhythms, is 
released by the pineal gland into the CSF: melatonin 
is a potent free radical scavenger and antioxidant, 
and acts as a neuroprotective agent that decreases 
oxidative stress removing reactive oxygen species 
from the CNS [18].  
Igfs (Igf1 and Igf2) are a class of growth factors 
present prevalently in the embryonic CSF, regulating 
prenatal growth and body size and stimulating cell 
proliferation [19]. Depending on cellular context, Igf1 
can also regulate neuronal differentiation, glial 
development, and cell size [20]. The effects of CSF 
Igf2 are also age-dependent [3]: CSF-Igf2 levels in 
rodents are modest at the earliest stages of 
neurogenesis, peak near the end of neurogenesis, 
and decrease post-natally, suggesting that Igf2 may 
regulate specific aspects of neurogenesis. In 
adulthood, it is thought that Igf2 levels in the CNS 
remain relatively stable [21], but evidences suggests 
that Igf2 may be an important regulatory molecule 
released in a penetrating model of traumatic brain 
injury [22]. 
Retinoic acid, a hormone signal derived from vitamin 
A, is produced by the choroid plexus epithelial cells 
[23]  and by the meninges [24], providing long-range 
signaling activity for the developing brain [25]. 
Interestingly, while choroid plexus derived retinoic 
acid is secreted directly into ventricular CSF, 
meningeal sources of retinoic acid may reach the 
neuro-epithelial cells via the lateral ventricular CSF as 
well as by crossing the cerebral mantle.  
Last, Wnt signaling plays a key role in regulating early 
development of the CNS [26].  
The CSF has also attracted interest in the field of brain 
injury, possessing neurogenic and neuroprotective 
factors believed to have therapeutic effects following 
brain injury. The choroid plexus-CSF system can be 
disrupted in a wide range of CNS injuries, from 
hydrocephalus to age-associated neurologic diseases 
[23], and a plethora of growth factors are up-
regulated in the brain and CSF following injury; these 
include, together with the already mentioned Igf1 
and Igf2 [22, 27], FGF [28], nerve growth factor (NGF) 
[29] and transforming growth factor beta (TGF-β) 
[30]. 
Resuming, it appears that the key mechanism for 
promoting neural repair following brain injury is 
through the endogenous up-regulation of 
neurotropic factors important in neurogenesis and 
neuronal survival. The CSF may act as a vehicle for 
transmission and transport of important nutrients 
and growth factors to sites of brain injury and to the 
whole CNS to contributing to the mainteinance of 
the homeostasis, to promote neuroprotection and 
neurogenesis and to remove toxic products 
generated by injuries. 
This huge amount of features that characterize the 
CSF and the continue discoveries of its new functions 
open very large perspectives about the treatment of 
neurological diseases intervening directly via CSF. 
The possibility of administering a cocktail of 
neurogenic and neuro-protective factors to the CNS 
through this fluid provides an intriguing, non-
invasive method that is particularly exciting from the 
therapeutic point of view [31]. A recent study showed 
that media conditioned with choroid plexus 
secretome supports neural stem cell proliferation 
compared to media conditioned with cortical tissue 
[23]. Alternatively, suggested other ways for the 
treatment of neurological disorders have been made, 
manipulating endogenous choroid plexus or 
implanting it intra-ventricularly or at the site of brain 
damage, providing essential neurogenic growth 
factors and other proteins necessary to enhance CSF 
homeostasis.  
Concluding, CSF components, which can potentially 
be dispersed over large areas, may be more 
significant and pervasive regulators of brain 
development, neural stem cell renewal, disease, 
neurodegeneration, aging, behavior, and other states 
of consciousness than previously thought: in the 
mature brain, cells with access to the ventricles may 
respond to factors released into the CSF followed by 
all these both physiological and pathological 
processes. 
2.1.2   The Blood-CSF barrier 
The discovery of cellular barriers between the blood 
circulation and the CNS dates in the 1880s, when Paul 
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Ehrlich discovered that certain dyes, injected into the 
vascular system, were not taken up by the brain and 
spinal cord [32]. Ehrlich explained this phenomenon 
as a lack of affinity of the nervous system for these 
dyes, but Edwin E. Goldmann a few years later 
showed that the same dyes, injected into the 
cerebrospinal fluid, stained nervous tissue but not 
any other tissue [33], suggesting that differential 
staining was not due to a different affinity to these 
dyes, but to something within CNS that prevented 
their access to the blood circulation, and vice versa.  
Nowadays, researchers identified at least four 
different barriers that separate the brain from other 
organs: the blood-brain barrier (BBB) at the level of 
the cerebral blood vessels endothelium, the 
embryonic CSF-brain barrier, created by separation of 
the ventricular system from the extracellular fluid of 
the brain [34], the arachnoid mater in the 
subarachnoid space between the pia and the dura 
mater and the blood-CSF barrier, at the level of the 
choroid plexus epithelial cells (CPECs). 
Choroid plexus is a villous structure that floats on the 
ventricular surface into the lumen of the lateral, third 
and fourth ventricles (Figure 2.1.2), where it produces 
the CSF and form a unique interface between the 
peripheral blood and the liquor. CP plays key roles in 
many processes, maintaining the biochemical and 
cellular status of the central nervous system under 
both normal and pathological conditions. 
During mouse embryogenesis, the choroid plexus is 
clearly visible already at E12.5; in the human embryo, 
the choroid plexus begins to develop at 
approximately 44 days post-ovulation in the fourth 
and lateral ventricles and is easily visible already after 
9 weeks of gestation, filling a large part of the lateral 
ventricle and spanning the length of the fourth 
ventricle [35].  Albeit CPs of the lateral, third and 
fourth ventricles exhibit embryological, anatomical 
and functional differences [36], in adulthood these 
regions are almost similar: the adult CP structure is 
characterized by a monolayer of epithelial cells 
derived from the ependymal cells, interconnected by 
apical tight junctions that line the wall of the brain 
ventricles. Under this monolayer of epithelial cells 
lays a stroma perfused with an extensive capillary 
network (CP receives 10 times fold higher blood flow 
compared to the brain parenchyma [37]), fibroblasts 
and immune cells such as dendritic cells and 
macrophages (Figure 2.1.2). The glomerular-type 
capillaries [38] within the choroid plexus parenchyma 
differ from those of the brain, having an attenuated 
endothelium that allows free movement of molecules 
across the cells through fenestrations and 
intercellular gaps [39] similar to the endothelium of 
kidney and intestine. Is therefore evident that, within 
the CP, the barrier function is localized in the 
epithelium, where tight junctions between the 
epithelial cells, channels and active transporters 
confer to the tissue its permeability and secretory 
selectivity [40]. The CP epithelial cells are cuboidal-
shaped cells that display a polarized morphology, 
with a basolateral membrane facing the CP stoma, an 
apical surface in contact with the brain ventricles and 
lateral membranes between adjacent epithelial cells; 
their high secretory activity is reflected by the 
intracellular presence of a large central spherical 
nucleus, a big Golgi apparatus and an high density of 
ribosomes and mitochondria, that provide the 
necessary energy (ATP) to feed the CSF production 
and the neurochemical homeostasis functions [41, 
42]. The basal lamina of these cells shows a 
convoluted shape that increases the surface area 
between the epithelia and the interstitial fluid, so as 
to maximize the exchange of molecules between 
these two compartments. Their apical membrane 
instead expand its surface area sending out 
numerous finger-like villi and cilia [43]; so although, 
being the surface area apparently small referred to 
the whole CNS volume, it is not negligible [44]. On 
the apical membrane, a few macrophage-like cells 
(Kolmer cells) adhere tightly to the ciliated border of 
the CP epithelium [45]. Looking at the most apical 
portion of the lateral membranes, the presence of 
parallel strands of tight junctions (TJ) inhibits the 
para-cellular passage of blood derived cells and 
proteins [40]. The TJ composition between the 
epithelial cells of the CP are different from those 
connecting the endothelial cells of the blood–brain 
barrier: in addition to being on the apical part of the 
lateral membranes, CP tight junctions show a 
relatively short zonula occludens and a different 
composition, being formed by claudin-1 claudin-2, 
claudin-11, and occludin [46], causing the CP barrier 
to be leakier compared to the one forming the blood 
brain barrier.  
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Besides TJ restrict permeability across the choroid 
plexus epithelium, these cells also perform 
absorptive endocytosis and express a broad range of 
transporters for water molecules and ions, small 
peptides and polypeptides [47-50], allowing the 
passage of nutrients into the CSF and the removal of 
toxic agents out of the CNS. Together with these 
specific transport mechanisms, the capacity of these 
cells to synthetize and secrete a plethora of different 
proteins complete their CSF production process. In 
this view, the CP has an important autocrine, 
paracrine and endocrine effect on CNS by producing 
CSF and polypeptides and distributing them from the 
ventricles within the whole brain and the spinal cord:  
the expression of receptors (both in the apical and 
basolateral sides) for molecules such as 
neurotransmitters, cytokines and toxins that regulate 
the CP transcriptome and secretome [23, 51, 52] 
confirms that the modulation of these “active barrier 
functions” are essential for the health of the central 
nervous system.  
In addition to this primary function in secreting the 
CSF (that will be discussed in detail in chapter 2.1.3) 
choroid plexus epithelial cells cover many other roles: 
in the last years the interest has been directed to the 
understanding of CP function within the 
neuroimmune system [43]. T cell migration into the 
CNS via the choroid plexus was provided by a recent 
study demonstrating that Th17 cells may penetrate 
the BCSFB via binding to CCL20 receptor produced 
by choroid plexus epithelial but not endothelial cells 
in rodents and man, using then specifically the 
choroid plexus as CNS entry site [53]. Choroidal 
epithelial cells also constitutively express MHC class I 
and, in some species such as mice, MHC class II 
molecules that are inducible by infectious agents [54, 
55], making these cells also to be included in the 
family of the antigen-presenting cells. Secondly, Ling 
and colleagues described monocyte recruitment 
through the choroidal vessels and subsequent 
migration across the choroid plexus epithelium [56]. 
Interestingly, choroid plexus epithelial cells 
constitutively express at low levels the adhesion 
molecules ICAM-1 and VCAM-1 polarized to their 
apical surface [57], and both adhesion molecules can 
be up-regulated during inflammation, mediating 
adhesion of immune cells in vitro [58]; however, 
several studies failed to detect expression of E-/P-
selectin, ICAM-1 and VCAM-1 at the level of the 
basolateral membrane of the CP endothelial cells 
[58], making them to not be directly accessible for 
leukocytes migrating from the blood into the CSF 
compartment across the BCSFB. Nevertheless, a 
demonstrated enhanced leukocyte counts in the CSF 
Figure 2.1.2: influences the SVZ neuronal progenitor cells differentiation. Facing the SVZ, the CP and hence its secreted proteins, rapidly enter in contact 
with the cells of the SVZ; in particular, type B stem cells are in direct contact with CSF, projecting a cilium toward the ventricle. These cells, present in the 
adult SVZ, under differentiative stimuli generate type C cells that in turn give rise to neuroblasts (from [5]). 
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during inflammation and multiple sclerosis [57, 59] 
suggest an active recruitment into this compartment. 
The mechanism of immune cells extravasation across 
the CP is not clear: circulating immune cells would 
need to first migrate across the fenestrated choroid 
plexus capillaries, enter the parenchyma and then 
penetrate the layer of choroid plexus epithelial cells, 
either by passing through the parallel TJ strands or by 
passing through the choroid plexus epithelial cells at 
a trans-cellular level. All these data indicate that these 
cells may serve as an immune-surveillance barrier of 
the CNS, in synergy with other cells present in the 
parenchyma and on the apical surface of the CP, 
including the Kolmer cells, that normally act as 
phagocytic scavenger cells, displaying antigen 
inducible class I and II MHC molecules and 
proliferating when stimulated with toxins [56]. 
Choroid plexus then seems to have a crucial role in 
the intrinsic surveillance system defending against 
blood-born or CSF-generated antigens and 
pathogens. 
Lying within the central ventricular system, the CP is 
also in an ideal position for the monitoring of the 
CSF’s presence of toxic compounds or damaging 
cellular invasions; furthermore, it protects the brain 
against acute neurotoxic insults, using a complex 
detoxification system [60] that include a full set  of 
metabolizing enzymes  like glutathione and 
metallothioneins (that potently sequester toxic 
agents circulating in the CSF) protective enzymes 
such as superoxide dismutase, glutathione-s-
transferase, and glutathione peroxidase/reductase, 
providing a complete system which protects against 
free-radical oxidative stress [61]. 
Neurorprotection is, so, a trivial function that is 
paralleled with neurogenesis regulation [62], 
suggesting both a constitutive and an emergency 
role in cellular repair and replacement in the CNS: CP 
epithelial cells actively produce mitogens such as 
amphiregulin for regulating stem cell proliferation 
and neurogenesis [63, 64], and conditioned media 
from CP also enhanced neurite outgrowth and 
dopamine uptake on cultured neuroblastoma cells 
and on embryonic mesencephalic tissue, 
respectively. Yamamoto and colleagues showed that 
the CP modulates neurite outgrowth in the 
developing cerebellum [65]. The ability of CP 
epithelium to provide a scaffold for the extension of 
neurites is consistent with its known production of 
extracellular matrices including laminin and 
fibronectin [66]. The neurotrophic activity of CP acts 
also on the fast-proliferating cells (type A cells) of the 
sub-ventricular zone (SVZ), that are, in the ventricles, 
in direct contact with the CP secretion (Figure 2.1.2). 
These cells, migrating along the rostral migratory 
stream (RMS) anteriorly toward the olfactory bulbs, 
differentiate into GABAergic interneurons [67]; the 
SVZ also gives rise to oligodendrocyte progenitors, 
although in lower number [68].  Moreover, this 
proliferative function is accomplished also by CP–
resident stem cells, since proliferative markers clearly 
show their presence in the CP. These choroidal stem 
cells proliferate in response to trauma: Li and 
colleagues [62] demonstrated that CP cells proliferate 
and differentiate after stroke in adult rats, and 
transplant studies demonstrated that, when grafted 
into damaged regions of the CNS, CP cells have the 
ability to differentiate [69]. Additionally, CP stem cells 
isolated and maintained in vitro, exerts potent 
neuroprotective effects [70] and similar benefits have 
been observed in vivo too. 
The evidence that this small and complex organ play 
a primary role in the development and homeostasis 
of the CNS is demonstrated by the observation that 
its subtle physiological and pathological changes can 
have wide range consequences [71, 72]. The altered 
function of the CP may be implied in several diseases 
characterized by secretory cell dysfunction: in fact, 
since the CP epithelial cells are equipped with 
transporters for several proteins and metabolites, 
pathological damage to the CP itself will alter the CSF 
composition and the ventricular volume, as in the 
case of hydrocephalus [23]. For example, Miyan and 
colleagues [73] observed that hydrocephalus in rats 
impairs cortical development.  
In humans, the height of CP epithelial cells decreases 
by about 10% during aging [54], with decreased CSF 
production (about 45% in animal models [72]), 
diminished enzymatic and metabolic activity, 
reduced clearance of toxins and loss of polypeptide 
synthesis [74]. As said in the previous chapter, due to 
this decreased secretion and the simultaneously 
increased CSF volume caused by brain atrophy, CSF 
turnover takes significantly longer in elder people [9], 
causing an inadequate distribution of nutritive 
substance: these alterations may impact in all the 
cells in direct contact with the CSF, like the SVZ stem 
cells population. Degenerative pathologies, such as 
Alzheimer disease, manifest themselves as 
exacerbations of these changes: epithelial cell 
atrophy is greater, with cell height decreased up to 
22% compared to age-matched controls [54]. We can 
Introduction 
 
7 
 
then speculate that it’s possible that continued loss 
of normal choroidal function leads to additional 
cellular stress and contributes to the cognitive and 
motor decline in specific neurological disorders: 
indeed is proven that in AD, amyloid-beta clearance 
impairment contribute to the progress of the 
pathology [72, 75].  
2.1.3   The CSF production by choroid plexus 
epithelial cells 
In contrast to the CP’s relatively small volume, the 
rate of the CSF production is relatively high, 
suggesting the vital importance of a refreshing 
system and a flow of fresh fluid for the removal of the 
brain metabolism products. The structure of the CP is, 
indeed, very well adapted for the secretive activity 
[76]: its excellent blood supply, an extensive array of 
adrenergic, cholinergic, peptidergic and 
serotoninergic nerve fibers that modulate the CSF 
production by the epithelium [77, 78] and a complex 
set of transporters and ion channels, distributed 
unequally between apical and basolateral 
membrane, are essential features of this tissue [79]. 
The net force of fluid secretion across the epithelial 
monolayer is an active, unidirectional flux of ions 
from one side of the epithelial layer to the opposite 
side, which creates an osmotic gradient accompanied 
by the movement of water: this force cause the 
molecules secreted by the CP to be conveyed to the 
brain parenchyma via volume transmission, 
convective distribution and intra-parenchymal 
diffusion/receptor-mediated retrograde transport 
[80]. There are major differences between transport 
by the BCSFB and by the BBB: in terms of O2, CO2, 
glucose and amino acid entry into the brain, the BBB 
predominates, but for some other compounds like 
Ca2+ the BCSFB is the major site of entry. The first step 
of the cerebral fluid secretion consists of passive 
filtration of plasma from choroidal capillaries to the 
choroidal interstitial compartment, according to a 
pressure gradient; the second is the active transport 
from the interstitial compartment to the ventricular 
lumen across the choroidal epithelium, involving 
specific enzymes and membrane ion carrier proteins. 
Before discussing about the complex intra-cellular 
transport of ions and substances, a little mention has 
to be made about the paracellular passage of 
molecules: as discussed above, CP tight junctions are 
looser compared to those of other barriers, like the 
BBB. In fact, hydrophilic solutes like Na+ and small 
proteins can gain access to the ventricles by a slow 
leakage through these tight junctions: promoting this 
passage is the presence of Claudin 2, a TJ 
permeability enhancer, which specifically transfers 
solutes across the epithelium without entering the 
cells through the formation of channels [81].  
Numerous active transporters, together with ions and 
water channels, participate to the intra-cellular 
transport of molecules from blood to CSF (Figure 
2.1.3): starting with the baso-lateral membrane, 
plasma-derived Na+, Cl- and HCO3
- which are unable 
to diffuse through the cell membrane, enter the cells 
with a carrier-mediated transport: at the level of this 
membrane in fact, Na+/H+, Cl-/HCO3
- and sodium 
dependent Cl-/HCO3
- exchangers are expressed, aside 
from Na+-HCO3
- co-transporter. Na+ enters the cell 
prevalently down a chemical gradient in exchange 
for H+, while Cl− influx into the epithelium is via a 
Cl−/HCO3
− exchanger, favored by the exit from the 
cell of HCO3
− [82]. This ion exchange maintained by 
the presence, in the CP cells cytoplasm, of the 
carbonic anhydrase enzyme, which catalyzes the 
formation of H+ and HCO3
- from water and CO2, 
letting them to be available and exchanged for Cl- 
and Na+ [83]. In addition, a small amount of HCO3
− 
can leak out of the cell down the concentration 
gradient, through Na+-HCO3
− co-transporters located 
at the apical side. Overall, the net effect of the 
carbonic anhydrase is an intracellular accumulation 
of Na+ and Cl- which triggers the CSF secretion [84]. 
On the apical surface, since Cl- and HCO3
− levels 
inside the cells are above the electrochemical 
equilibrium, these ions diffuse down gradients 
through specific apical channels and through other 
carriers. The most important is the Na+/K+ ATPase 
pump that, on the contrary to others epithelia, is 
found on the apical brush membrane and not the 
basal membrane [83]. This enzyme uses the energy 
derived from the ATP hydrolysis to pump 2K+ in the 
cell and 3Na+ out of the cell in the CSF, against their 
concentration gradients. This action, which provides 
the electrochemical gradient for basolateral Na+ entry 
into the epithelium, leads to the accumulation of K+ 
within the cells, which is subsequently excreted from 
the apical membrane through the Na+-2Cl--K+ co-
transporter and the K+ channels [85] or, in minor 
amount, from the basolateral membrane via K+-Cl- co-
transporter [86]. Cl− efflux from the epithelium to the 
CSF is primarily via Cl- channel or co-transporters, 
which are either of the K+-Cl− or Na+-2Cl--K+ type [87]. 
The last one generates ion transport in both 
directions and has a crucial role in the regulation of 
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CSF secretion and composition. Summarizing, the net 
effect of all these ion movements is the unidirectional 
flux of Na+, HCO3
− and Cl- (NaCl and NaHCO3) from 
basolateral to apical space [76], generating an 
osmotic gradient that cause the diffusion of water, 
which can pass in the CSF trans-cellularly or also 
through the apical aquaporine-1 channel [83].  
CP is the main site of entry of Ca2+, being its influx 
rate ten-fold higher than the blood-brain barrier 
value: CP shows an active transport system, moving 
Ca2+ against unfavorable electrochemical gradients.  
Not only ions, but also nutrients and other molecules 
can be transported from blood to CSF by choroid 
epithelial cells, and their secretion is finely regulated: 
recent studies indeed shown that CP expresses 
different hormone receptors, mediating the secretive 
activity of the CP itself and affecting both the local 
metabolism and the CSF composition [61].  
Glucose and others sugars, that are necessary for the 
brain activity, are subjected to a powerful 
homeostatic mechanism, that maintain their 
concentration constant and different from that in the 
plasma, resulting in the equilibrium between influx 
and efflux: basolateral membrane of CP is very 
permeable to sugars, favoring the influx of glucose, 
but concentrative active transport  across the CP [88] 
is responsible of significant efflux from the CSF to the 
plasma, causing the concentration of glucose in the 
CSF to be steadily lower than in plasma [88]. Also the 
concentration of free amino acids in CSF is much 
lower than in plasma, with the CSF/plasma ratio 
between 0.29 and 0.38 [89]; in the brain interstitial 
space, the concentration of free amino acids is for 
more lower, almost 1/3 of the CSF concentration [90]. 
Except glutamate, aspartate, glycine and glutamine, 
that are synthesized by the brain, the low 
concentration of other amino acids in the CSF is 
again the result of active efflux from the CSF by the 
secondary active transport across the CP, like in the 
case of sugars.  
Finally, as said in paragraph 2.1.2, the choroid plexus 
also may be involved in the transport of hormones 
into the CSF or be the source of those hormones [91].  
Although the secretion of substances out of the CNS 
is carried out mainly by the arachnoid villi, also CP 
disposes of unneeded molecules by diffusion across 
pores or putative pinocytosis of large proteins [92], 
with diffusion to the basolateral membrane and then 
Figure 2.1.3: schematic representation of ions transport across choroid plexus epithelial cells (from [3]). 
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to the blood [93]. This mechanism, which works 
against an unfavorable CSF to blood gradient, is 
responsible of the removal of weak organic acids 
from the CSF.  
In conclusion, choroid plexus use the energy released 
by ATP hydrolysis to generate unidirectional flux of 
ions across the epithelial monolayer, which then 
drives trans-epithelial movement of water by 
osmosis. Moreover, regulating the passage of specific 
nutrients/hormones/molecules with dedicated 
inducible carriers, CP modulates and influences the 
osmosis and the activity of the whole central nervous 
system. 
2.1.4   Copper and iron metabolism in the CNS 
Copper and iron are essential cofactors for specific 
proteins, catalyzing electron transfer reactions and 
mediating inorganic ions binding used as substrates 
for these reactions [94]. Due to the loss of function of 
the iron- and copper-dependent proteins, an altered 
homeostasis of Cu and Fe results in metabolic 
abnormalities that can involve the whole organism, 
from the blood to the central nervous system [95].  
Copper homeostasis plays an important role in 
normal function and development of the central 
nervous system: in fact, copper concentration in the 
brain is one of the highest, second only to the liver, 
and is high in particular in the basal ganglia, 
cerebellum, cortex, lateral Amygdala and 
hippocampus. These copper concentrations most 
likely reflect the higher metabolic demands for 
copper in these regions. The metabolic demands for 
copper in the CNS change during brain development, 
and also copper concentration in the CNS increases 
with age [96] and in patients affected by several 
neurological disorders [97]. Copper, present in all 
major cell compartments in the CNS, take part in 
cellular respiration, defense from dangerous radicals 
and specialized processes such as production of 
peptides and hormones [98]. Moreover, copper is 
released at the synapse of some neurons [99] 
suppressing long-term potentiation in the 
hippocampus [100].  
This metal is readily available in the diet and, 
following absorption through the stomach and 
duodenum, is released from the enterocyte and 
travels, bound mainly to albumin, in the portal blood 
to the liver. Biliary excretion is the only physiological 
mechanism of copper elimination, and at steady state 
the amount of copper excreted into the bile is 
equivalent to that absorbed from the intestine [101]. 
Unlike Fe, there are no physiological intracellular 
storage systems of Cu, and body levels are therefore 
maintained by balancing dietary absorption, 
distribution and biliary excretion. Newly acquired Cu 
is rapidly addressed to a number of Cu-dependent 
enzymes through the action of several intracellular 
chaperone proteins [102]: in the liver a major 
proportion of the Cu is loaded onto Ceruloplasmin 
(Cp).  
Copper concentration in CSF was estimated to be 
approximately 20 mg/l, considerably lower than 
copper concentration in serum (more or less 1 g/l 
[103]), so the blood brain barrier effectively limits 
copper’s access to the brain. Comparison of the initial 
rates of copper transport, which demonstrated that 
the entry of copper into cells of the choroid plexus 
was faster than the copper entry into the brain 
parenchyma, suggest that copper efflux from the 
epithelial cells of the choroid plexus rather than its 
uptake from the blood is the limiting step for copper 
delivery to brain parenchyma. 
Key copper-metabolism proteins present in 
peripheral tissues are also detectable in the brain, 
and can be divided in three major groups: copper 
uptake transporters, which transfer copper into the 
cytosol, copper chaperones that facilitate copper 
distribution to intracellular protein targets and 
copper transporting ATPases, which translocate 
copper from the cytosol to the lumen of the secretory 
pathway and small vesicles, for the synthesis of 
copper-containing enzymes and their export into 
extracellular fluids (Figure 2.1.4A).  
Copper transporter 1 (Ctr1) belongs to the first group: 
CTR1 mRNA is uniformly expressed in the CNS, but is 
higher in the choroid plexus epithelial cells [104] and 
in endothelial cells of the BBB. Interestingly, the Ctr1 
level on the membrane in peripheral organs (like 
duodenum) is regulated in response to changes in 
the extracellular copper levels [105]. Similarly, the 
expression of Ctr1 in the choroid plexus can be up-
regulated after dietary copper deficiency while 
increased copper facilitates endocytosis of Ctr1 by 
intracellular vesicles [106], suggesting that Ctr1 is the 
first pathway for copper entry into cells.  The 
mechanism of copper transport by CTR1 is not yet 
fully understood: its structure suggests that it may act 
as a channel in which copper binding to the 
extracellular surface triggers the opening of the 
cytosolic gate, which allows copper to be released 
inside the cell and to be bound to cytosolic 
chaperones, that delivers copper to different 
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intracellular compartments. These chaperones 
include Ccs (Copper Chaperone for Superoxide 
dismutase 1), Cox17 (Cyclooxygenase 17) and Atox1 
(antioxidant protein 1 homolog). Ccs, in the cytosol, 
delivers copper to the catalytic site of protein 
superoxide dismutase 1 (Sod1) [107]; in addition, a 
small fraction of Ccs is found in mitochondria, where 
Sod1 can enter after hypoxia or oxidative stress. Ccs is 
thought to incorporate copper into Sod1 that enters 
mitochondria, thus increasing its concentration in the 
inter-membrane space and protecting from oxygen 
reactive species also these organelles, mostly under 
stressful conditions. Cox17 instead, together with 
Sco1/2, deliver specifically copper to mitochondrial 
cytochrome c oxidase (Cco) [108], a terminal enzyme 
of the mitochondria respiratory chain, that catalyzes 
electron transfer to molecular oxygen and 
contributes to the electrochemical potential 
formation used for the synthesis of ATP. Lastly the 
small cytosolic protein Atox1, in addition to play an 
antioxidant role [109], mediates copper movement 
from the Ctr1 intra-cellular domain to the late trans-
Golgi network, where it can bind copper-transporting 
ATPases (Atp7a and Atp7b) [110]. ATPases use the 
energy of ATP hydrolysis to transport copper from 
the cytosol into the lumen of the secretory pathway 
and to incorporate the metal into various copper-
proteins, including blood clotting factors V and VIII, 
tyrosinase and, as mentioned before, ceruloplasmin. 
The evidence that genetic mutations in ATP7A or 
ATP7B are associated with severe neurological, 
developmental and psychiatric problems lead to the 
hypothesis that these membrane ATPases play a 
particularly important role in CNS physiology: 
although Atp7a and Atp7b are often co-expressed in 
same cells, Atp7a and Atp7b exhibit distinct 
expression patterns in the CNS, and they do not fully 
compensate for each other’s function when one is 
lost [111]. In adult brain, Atp7a levels are greatest in 
the choroid plexus cells of the lateral and third 
ventricles [111] where it facilitates copper movement 
across the basolateral membrane into the intra-
ventricular space of the brain. This indicates again the 
central role of this region in the homeostasis of 
copper. Atp7b instead is mainly expressed in 
hepatocytes and is required for copper excretion 
from these cells into the bile and the copper 
incorporation on Cp. Intracellular trafficking of 
copper finally requires other metallo-chaperones 
proteins like metallothionein, a cysteine-rich protein 
that chelates copper protecting against the toxicity 
caused by cytoplasmic excess of this ion [112].   
Many diseases result from an altered copper 
metabolism due to genetic defects resulting in 
unpaired copper absorption and abnormal copper 
distribution, or abnormal absorption due to a wrong 
diet. Severe copper deprivation is associated with 
marked neurological defects, since inactivation of 
copper-dependent enzymes can result in altered cell 
morphology [113], increased inflammation [114], 
motor neuron disease [115] and embryonic death; 
either genetic or acquired copper deficiency 
moreover leads to demyelination of the neurons in 
the white matter of the spinal cord and brainstem 
[116], but the specific role of copper in myelination is 
not well understood.  
Being essential for several metabolic processes like 
oxygen transport, electron transport and citric acid 
cycle [117], also iron is vital for all organisms. The 
most important biologic function of iron is the 
coordination of oxygen in erythrocytes, in fact in 
hepatocytes or mainly in erythroblasts, the 65% of 
the total systemic iron can be delivered to 
mitochondria for the synthesis, as Fe2+, of the heme 
group. Like copper, iron is acquired from the diet and 
transported across the intestinal mucosa, as either 
inorganic iron or heme iron. The major mechanism of 
iron absorption in the intestine involves mucin, that 
chelates Fe3+ in the luminal space of the duodenum 
[118], the membrane-bound reductase Dcytb, that 
reduces Fe3+ to Fe2+ [119], and the divalent metal 
transporter known as Dmt1 [120] which imports Fe2+ 
into enterocytes. In enterocytes, iron can be 
incorporated in ferritin for its intracellular storage or 
can cross the polarized enterocytes up to the iron 
exporter ferroportin (FPN), the only identified 
mammalian iron exporter, which allow Fe2+ export 
from the enterocytes into the circulation [121]. On 
the extracellular side of the enterocytes a membrane 
bound ferroxidase, hephaestin, oxidizes the iron 
transported by Fpn to Fe3+, which is accepted by 
transferrin (Tf) in the circulation [122]. This 
ferroxidase role in the other body compartments is 
covered also by hephaestin together Ceruloplasmin. 
The ferroxidase activity contributes to the rate of 
plasma iron oxidation and to the regulation of the 
release of this metal from the storage sites [123] 
through the Fpn exporter. The functioning of the Fpn 
channel is also regulated by hepcidin, a protein 
secreted by the liver that binds to fpn and induce the 
endocytosis and the turnover of this plasma iron 
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exporter [124] in 
response to 
inflammation, 
erythropoietic needs 
and iron availability 
[125]. Acting at the 
level of the Fpn 
expressed by 
enterocytes, hepcidin 
can also block the 
iron uptake from the 
lumen of the intestine 
in response to 
systemic iron 
overload.  
Under normal 
physiological 
conditions there is 
almost no free iron in 
circulation, because a 
majority of it is bound 
to Tf, an abundant 
circulating protein 
that delivers iron to 
cells throughout the 
systemic circulation: 
Tf can bind to Tf 
receptors (TfRs) on the surface of cells that express 
this receptor, causing the Tf-TfR complex to be 
internalized in a vesicle; then, due to the slightly acid 
pH of the endosome, iron is released from Tf, reduced 
to the transportable ferrous form Fe2+ by the vesicular 
reductase Steap3 [126] and transported across the 
endosomal membrane into cytosol by Dmt1 present 
on the vesicular membrane, ready for the storage or 
for the incorporation in various proteins. The Tf-TfRs 
uptake of iron is the predominant mechanism of iron 
uptake of non-intestinal cells[127], but all nucleated 
cells also possess the capability to transport free 
inorganic iron [128] using the Dmt1 pathway for Fe2+, 
or the integrin-mobilferrin pathway (IMP) for the Fe3+ 
[129]. Being iron requirements higher than the 
gastrointestinal absorption capacity, all of the iron 
utilized each day is continuously recycled from 
internal stores [130]: the majority of iron turnover in 
the body is thus accounted by the continual 
synthesis and destruction of erythrocytes. This 
recycled iron can be either reused for new 
erythrocyte production or delivered to the liver long-
term storage system. About the Iron excretion out of 
the organism, several studies showed that this 
process is limited to the passive loss of cells lining the 
gastro-intestinal/urinary tracts, and skin. Anyhow, to 
maintain normal homeostatic iron balance dietary 
absorption must match endogenous losses and 
disequilibrium in these processes can lead to several 
metabolic disorders; in fact, nutritional iron 
deficiency has a significant impact on infant and child 
health in many developing countries, where it is one 
of the major public health problems [131]. All tissues 
in the body share a common system of iron delivery, 
except two regions that are separated from the 
systemic circulation by epithelial or endothelial 
barriers: the central nervous system, and testicles 
[132].  
In the CNS iron is essential as a cofactor of several 
enzymes involved in phosphorylation, 
neurotransmitters production, nitric oxide 
metabolism, myelination and oxygen transport [133]; 
the concentration of iron in the brain is therefore very 
high compared to other organs, and is higher in the 
basal ganglia, where it’s comparable to the one 
found in liver [134]. Iron is also widely distributed in 
all cell types within the CNS but is abundant 
especially in astrocytes, suggesting the idea that 
Figure 2.1.4: representation of cellular Copper (panel A) and iron (panel B) homeostasis. Adapted from [7]. 
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these cells function as iron storage site for the whole 
brain.  
CNS iron uptake is high in infants, when the brain is 
growing and developing, but measurable iron uptake 
is present also in adult [48]: iron is taken up through 
two different ways: through the brain capillary 
endothelial cells (BCECs) of the BBB or through the 
epithelial cells of the choroid plexus, which both 
express high levels of Dmt1 transporter and TfRs. 
Since the hydrophilic nature of iron bound to 
transferrin prevents its passage into the brain as it is, 
the TfRs mediated uptake is the major pathway for 
iron uptake by the brain: failure of the transferrin 
receptor expression in mice results indeed in lethal 
outcomes during development with severe defects in 
the CNS. As said above, the transferrin receptor is 
continuously expressed by BCECs and CPECs [135], 
but the expression pattern can change with age and 
in pathological conditions. The up-regulation of the 
TfRs synthesis in iron deficiency conditions increases 
the transport of iron into the brain, compared to 
standard conditions with normal available levels of 
iron [136]. This regulation is mediated by the five iron 
responsive elements (IRE) present in the un-
translated region of the TfRs mRNA [137] that interact 
with iron regulatory proteins to protect mRNA from 
cleavage and degradation, thereby increasing protein 
synthesis  if the cellular iron levels are low.  
Like in other cells, binding of iron-transferrin complex 
to the TfRs is followed by docking and formation of 
an endosome that enters in the cytoplasm (Figure 
2.1.4B): the slightly acid endosomal pH causes the 
iron to be detached from transferrin and the 
presence of Dmt1 transporter (in the CPECs) allows 
the passage of divalent cations out of the endosome 
and into the cytosol [137]. Dmt1 interestingly could 
not be detected in BCECs endosomes, suggesting 
that iron is transported from the luminal to the 
abluminal surface of these cells inside vesicles 
without any intermediate step, fusing with the CSF-
faced membrane and leading to the exposure of the 
iron from the endosome into the interstitial fluid, 
where it can be loaded on different molecules and 
ready transported into the brain. The transferrin 
would mainly remain bound to its receptor which has 
a high affinity for apo-Transferrin at acidic pH [138] 
and would be recycled to the plasma-side of the 
BCECs. The BCECs are so likely to release ferric iron, 
whereas ferrous iron release occurs by secretion of 
iron from CPECs, neurons and oligodendrocytes 
through Fpn transporter [139]. In the last case, 
extracellular ceruloplasmin (the major ferroxidase 
present in the CNS) secreted by CPECs or GPI-bound 
on the membrane of astrocytes, mediates Fpn-
mediated iron release from cells and its loading on Tf 
[140]. 
Being the concentration of transferrin low in the CSF 
and in the brain interstitial fluid, astrocytic end-feet 
that form intimate contacts with the abluminal side 
of BCECs [141], play an important role in the 
regulation of solutes transported through these cells, 
producing several alternative iron carriers (hydrogen 
ions, ATP, and primarily citrate [142]) that can 
circulate throughout the brain interstitium, supplying 
iron to cells within the CNS [4]. The rate of release of 
iron is in fact directly proportional to these molecules 
concentration [143]. Another interesting protein who 
can act as an extracellular iron carrier in the brain is 
lactoferrin, which is secreted in the brain by CPECs 
and is structurally related to transferrin but with an 
higher affinity for ferric iron. Lactoferrin, present in 
CSF, shows increased concentrations after 
inflammatory reaction [144], suggesting its role in the 
scavenging of iron released from damaged cells. 
Scavenging is necessary to reduce the toxic effects of 
free iron, that can be non-enzymatically oxidized 
from Fe2+ to Fe3+, triggering the Fenton and Haber 
Weiss reaction (Fe2+ + H2O2 +H
+ → Fe3+ + HO• + H2O) 
which in turn produce toxic hydroxyl radical, a very 
reactive molecule that have deleterious effects 
reacting with and altering the structure of several 
molecules including proteins, nucleic acids and lipids. 
All the different cell types present in the CNS differ 
apart from each other by mechanism of 
uptake/export of iron, depending on the transport 
molecules they express. Neurons, containing both 
TfRs and Dmt1, take up both transferrin-bounded 
iron [135] as well as free iron: interestingly, these cells 
up-regulate the expression of transferrin receptors in 
response to iron deficiency [135], while the 
expression of DMT1 are unaffected by the iron 
interstitial concentration [145]. Moreover neurons 
constantly express FPN and in some regions of CNS 
ferritin, showing that they are able to store iron [146]. 
Astrocytes instead do not express TfRs, suggesting 
that they take up iron by different mechanisms [147], 
and their iron export involve Fpn and the membrane-
bound form of ceruloplasmin [148]. 
Oligodendrocytes, not expressing TfRs too, seem to 
acquire iron by a mechanism that could involve 
uptake of iron-citrate. Also these cells use Fpn as iron 
export mechanism [149].   
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Iron leaves CNS through its uptake by the arachnoid 
villi in the subarachnoid space; alternatively, if the 
CNS iron requirements are high, iron can be stored by 
the ependymal cells of the choroid plexus. The dis-
regulation of the brain iron equilibrium can be a 
primary cause of neurodegeneration, suggested by 
disorders like aceruloplasminemia and 
neuroferritinopathy [95]:  in fact concentration of iron 
in the brain, increased also with aging, is higher in 
subjects with neurodegenerative diseases such as 
Parkinson’s disease and Alzheimer’s disease [150, 
151], indicating a pivotal role of this metal in the 
development of several diseases. Moreover, being 
the BBB and the BCSFB the major sites of iron uptake 
and secretion of regulatory proteins, diseases (or also 
aging) that cause their secretion/barrier-functions 
dis-regulation could have adverse effects on brain 
iron homeostasis.  
2.1.5   The cupro-ferroxidase Ceruloplasmin 
Among all the proteins implicated in iron and copper 
homeostasis, Cp seems to cover a key role, being at 
the intersection point of the metabolisms of these 
two metals. Cp (EC 1.16.3.1) is a blue colored 
glycoprotein composed of a  single chain 
polypeptide of 1046 amino acids, with a molecular 
weight of about 130 KDa, which may vary depending 
on the carbohydrate attachments diversity [152]: this 
glycosylation heterogeneity may have implications in 
protein half-life and enzymatic activity. The Cp gene 
is found on chromosome 3q25–q24 and encodes 20 
exons encompassing 65 Kb of DNA: Serum Cp (300 
mg/l) is expressed by the liver, but extra hepatic gene 
expression has been documented in the brain, lung, 
spleen and testis. Furthermore, Cp’s gene 
transcription in the liver is mediated by inflammatory 
cytokines, and increased plasma concentrations were 
found in inflammation and trauma, making the 
protein an acute phase reactant [153]. In the CNS, Cp 
is expressed in retina as well in the epithelial cells of 
the choroid plexus and astrocytes [154]. The isoform 
expressed by astrocytes, due to an alternative 
splicing of exons 19 and 20 in Cp gene, which replace 
the final five amino acids of the secreted protein with 
an alternative 30 amino acids that constitute an 
hydrophobic stretch, is anchored to the cell 
membrane trough a glycosylphosphatidylinositol 
(GPI) anchor [148, 155]. Choroid plexus epithelial cells 
instead express the Cp soluble form, secreting it in 
the cerebrospinal fluid (2 mg/l). 
From the structural point of view the molecule is 
composed of three consecutive homology units 
further subdivided into six compact cupredoxin-type 
sub-domains [156], with large loop insertions (Figure 
2.1.5); this high degree of internal homology has led 
to the proposal that Cp arose by tandem triplication 
of a primordial gene that coded for a primitive two-
domain oxidase.  Inserted in its structure, six tightly 
bound copper atoms are fundamental for the 
structure organization and the enzymatic activity of 
the protein. Due to the presence of these copper 
atoms, characterized by different spectroscopic 
properties and reactivity, Cp falls in the multi-copper 
oxidases family; these enzymes, also called blue 
oxidases, commonly present at least one blue or type 
1 (T1) site, able to bind a copper atom in a unique 
tetrahedron structure. Interestingly, these sites are 
the responsible of the typical blue color of this 
proteins family. In addition to the blue copper 
centers, these proteins share three other copper 
atoms with a common site of binding, which is thus 
called the tri-nuclear cluster. On the basis of their 
spectroscopic properties, the three copper ions can 
be formally distinguished in one mononuclear type 2 
(T2) copper site, with a normal electron paramagnetic 
resonance (EPR) signal and nearly undetectable 
absorptions in the optical spectrum, and a pair of 
anti-ferromagnetically coupled copper ions, or type 3 
(T3) copper site, with strong absorption at 330 nm in 
the oxidized state and no EPR signal, but they in fact 
functionally behave as a single multi-metallic unit. 
Figure 2.1.5: 3D representation of the Cp structure (EC 1.16.3.1): each 
different color represents a different domain of the protein. In green, the 
copper trinuclear cluster, in blue, the two mononuclear copper centers.  
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The role of the Cp’s T1 site in the domain 6 is the 
sequential uptake and transfer of single electrons 
from substrate to the trinuclear cluster that uses the 
acquired electrons to reduce oxygen to water [157, 
158]. This unique structure for a copper site is 
exclusive to blue oxidases and enables these  
enzymes to catalyze the four-electron reduction of di-
oxygen to two  water molecules by one electron 
oxidations of substrates [159]. Additionally to the 
four atoms of the catalytic center, the remaining two 
copper atoms (that do not participate to the 
oxidation reaction) are mononuclear centers held by 
intra-domain sites: one located on domain 4 that has 
a typical T1 copper environment with a set of four 
ligands (two histidine, one methionine and one 
cysteine), and one located in domain 2 that has a 
different structure since it lacks the methionine 
which is replaced by a leucine residue [160]. 
Ceruloplasmin is synthesized in hepatocytes (and by 
the other specialized cells in brain, retina and lung) 
and secreted into the plasma as holo-protein, with 
the six integral copper atoms already incorporated 
during biosynthesis immediately before secretion (or 
before membrane anchoring in the case of the 
glycosylphosphatidylinositol (GPI)-linked form [161]). 
This process is performed by the P-type ATPase 
Atp7b [162], and a failure to incorporate copper 
during synthesis results in secretion of an unstable 
apo-ceruloplasmin, which has no enzymatic activity 
and has an half-life of approximately 5 hours [163] 
compared to the 5.5 days for the holo-ceruloplasmin. 
This rapid degradation of the apo- form is due to its 
different conformation respect to the active 
ceruloplasmin, that makes it even more susceptible 
to proteolytic cleavage by plasma proteases [164].  
Free copper concentration is physiologically 
maintained low by binding proteins that delivers it to 
specific cells, molecules or subcellular compartments 
[165, 166]; as we will see later in detail, this free pool 
of Cu can be toxic in particular pathological 
conditions, catalyzing the formation of hydroxyl 
radicals from H2O2 and, in the CNS, the oxidation of 
dopamine to aminochrome, which is suggested to be 
involved in the degeneration of dopaminergic 
neurons of Parkinson’s disease patients [167]. Still in 
the CNS, copper plays a role in the assembly of the β -
amyloid and prion protein aggregates [168]; 
ceruloplasmin, binding up to 95% of circulating 
copper, should have a major role in copper 
homeostasis and in the delivery of this metal to 
recipient systems. In contrast, the discovery that 
copper metabolism is normal in patients with 
aceruloplasminaemia [169] seems to refute this 
hypothesis, maybe because Cp’s  activity is 
compensated by the redundancy of the copper 
transport systems which can also easily cope with its 
absence.   
On the contrary to the majority of multi-copper 
oxidases, which act only on organic substrates, Cp 
oxidizes both inorganic ferrous iron and different 
organic substrates (described below), sharing this 
property with only a few other enzymes of unicellular 
organisms. In particular, the oxidation of iron is 
considered as the most important antioxidant activity 
of Cp, because iron is particularly prone to engage 
redox reactions with oxygen, resulting in a flux of 
ROS against many molecules and cell structures 
[170]. However, as outlined in the review of Floris et 
al [171], because Fe2+ is readily oxidized to Fe3+ 
through a non enzymatical reaction, it would seems 
that there is no need for a specific catalyst. As said in 
the 2.1.4 chapter, non-enzymatic oxidation of Fe2+ to 
Fe3+ is believed to trigger Fenton/Haber-Weiss 
reaction with the production of deleterious oxygen 
radicals: the hydrogen peroxide, in the presence of 
ferrous iron, serves as a source of the strongly toxic 
hydroxyl radicals, and oxidation of Fe2+ by Cp with 
production of molecular oxygen and water prevents 
further dangerous reactions (Figure 2.1.6).  
So, the role of Cp might be an efficient control of the 
level of ferrous iron oxidation, without the 
production of toxic hydroxyl radicals [172]. 
Subsequently to this enzymatic reaction, the ferric 
iron is loaded on transferrin [2, 148, 173], the protein 
responsible of the transport of the ferric iron in the 
plasma and in the cerebrospinal fluid. This 
Figure 2.1.6: schematic representation of ceruloplasmin ferroxidase 
activity (from [2]). 
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mechanism is required in order to maintain the iron 
efflux outside the cells through the iron exporter 
Ferroportin, that exports iron from cells as Fe2+; a 
failure in the extracellular conversion of Fe2+ to Fe3+ 
leads the ferrous iron to be accumulated inside the 
cells. Moreover, the un-converted ferrous iron, 
blocking the Fpn channel, induces Fpn 
internalization, ubiquination and degradation (Figure 
2.1.7). Thus, removal of Fpn-bound iron is an essential 
function of Cp [8], jointly with the direct oxidation of 
Fe2+ outside the cells. An important indication of this 
fundamental function of Cp is that  humans with 
mutations of the Cp gene show iron accumulation in 
various organs including the retina, liver and brain 
[174].  
Beside ferrous iron, Cp is able to oxidize an extensive 
group of other organic compounds: these include p-
phenylenediamines, amino-phenols, catechols and 5-
hydroxyindoles [175]. Interest in Ceruloplasmin 
catalyzed oxidation of arylamines and phenols has 
been the object of a long and detailed investigation, 
stimulated by the presence of catecholamines and 5-
hydroxytryptamine neurotransmitters among those 
substrates that could relate Ceruloplasmin to 
neurologic diseases. The possibility that 
ceruloplasmin is a regulator of biogenic amine levels 
in the plasma and eventually in the brain, is currently 
controversial [171]. The main problems that hinder 
the resolution of the question are related to the in 
vitro conditions of the assays that cannot mimic in 
vivo conditions for the 
action of Ceruloplasmin, 
the extreme reactivity of 
the intermediates and 
the involvement of 
oxygen radicals in these 
reactions. This is 
particularly true for the 
metabolism of 6-
hydroxydopamine, a 
neurotoxin involved in 
Parkinson’s disease, 
which is oxidized in vitro 
by Ceruloplasmin [176, 
177]. 
As said before, a role for 
Ceruloplasmin in this 
and other metabolic 
processes is justified by 
the ability to oxidize 
substrates at the 
expense of oxygen without ROS release that would 
otherwise be formed if substrates are engaged in 
direct redox reactions with oxygen. Finally, another 
significant activity of Cp is the one mediated by its 
catalytic site which involves Cys699, that performs a 
copper-independent glutathione peroxidase activity, 
with both hydrogen peroxide and/or organic 
peroxides [178]. This site enables ceruloplasmin to 
remove reactive intermediates that, in the case of 
hydrogen peroxide, could lead to an altered 
intracellular redox state. Also nitric oxide (NO) has 
been recently described as a substrate of 
ceruloplasmin: Cp has been shown to favor formation 
of S-nitrosoglutathione (GS-NO) when added to 
cultured monocytes expressing inducible NO 
synthase (iNOS) [179]: the role of Cp would be the 
oxidation of NO released by cells to nitrosonium, 
(NO+), a species more reactive than NO in the 
reaction with thiols. The mechanism exploits the 
property of NO to act as a ligand for copper and to 
engage a redox reaction with the metal once bound 
to it. NO appears unique among substrates of 
ceruloplasmin since it can reach and directly bind to 
blue copper sites, although with low affinity [180].  
A very interesting observation is that Ceruloplasmin 
seems to be, in turn, a target of oxidative damage; in 
fact oxidative modifications by peroxylradicals and 
by hydrogen peroxide, during ageing, can result in 
the release of bound copper [181-183], with 
Figure 2.1.7: Cp extracellular ferrosidase activity is essential for the maintenance of the FPN exporter on the cell 
membrane (From [8]). 
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consequent dramatic change of its EPR spectrum 
[184]. 
An elevation of plasma Cp concentration commonly 
accompanies a lot of pathological states and 
malignancies, in particular metastatic cancers [185, 
186]; Cp seems to be involved in angiogenesis, an 
event common to a variety of physiological and 
pathological processes and, since it’s known that this 
is copper-dependent process, it possibly be 
supported by a high level of Ceruloplasmin at a 
proper angiogenic site. The capability to take part in 
the angiogenic process and in antioxidant defense, 
which are two activities of Ceruloplasmin that could 
benefit the organism under some pathophysiological 
conditions, such as neovascularization of injured 
tissues, in the case of tumorigenesis would facilitate, 
rather than counter, cancer progression [187].  
In conclusion, with all its functions, Cp can be 
included in the family of multifunctional proteins 
recently defined “moonlighting proteins” which are 
able to change their function switching between 
different capacity in response to changes in 
concentration of their ligand/substrate, their 
differential localization and/or differential expression 
[188]. A new function can be the result of a different 
use of a pre-existing site or of a modification of 
unused regions of protein surfaces, especially in the 
case of large molecules; in the Cp structure indeed, 
the presence of particularly reactive groups on the 
lateral chains of amino acid residues can lead to a 
gain of function that further expands ceruloplasmin 
modes of action.    
Introduction 
 
17 
 
2.2  Neurodegenerative diseases: 
metals matter  
2.2.1   Alzheimer’s disease 
Described for the first time in 1907 by Alois 
Alzheimer, Alzheimer disease (AD), a progressive 
neurodegenerative pathology, is the most common 
form of dementia all over the world covering from 50 
to 80% of the cases and affecting 2/1.000 individuals 
between 65 and 69 years, 9/1.000 between 75 and 79 
years and 40/1.000 between 85 and 89 years. The 
pathology initially manifests itself with symptoms like 
memory loss, disorientation, personality and humoral 
and intellective changes, leading the individual 
incapable of make various simple daily activities. 
Afterwards, all these symptoms get worse, causing in 
the patient amnesia, aphasia, agnosia and apraxia 
and making, in the terminal phase of the disease, the 
patient to be completely not self-sufficient and 
helpless; death (that can take place from 3 to 20 years 
after first diagnosis) will occur by collateral 
pathologies, like opportunistic infections. Like most 
of other dementias, AD is mostly a sporadic disorder 
and the major risk factor is the aging; however, 
genetic autosomal dominant variants of the 
pathology are also known, and can be divided in 
early onset familiar forms (rare, age of onset under 60 
years) and late onset familiar forms (much more 
frequent, with an age of onset above 65 years). Most 
of the times anyhow AD, described as a complex 
multifactorial pathology, is the result of the 
interaction of different predisposing factors, either 
genetic or environmental.  
The etio-pathogenesis of AD is still controversial, but 
the most diffused hypothesis is the amyloid cascade 
theory: according to it, the formation of β-amyloid 
(Aβ) oligomers or mature fibrils is the first step of the 
pathology. β-amyloid (which accumulation impairs 
synapsis activity, proteasome function and cause 
neuronal death, correlating with the clinical stage), is 
derived from the proteolytic cleavage of the amyloid 
precursor (App), a membrane protein which, being a 
ferroxidase, is involved in the metabolism of iron in 
the central nervous system [189]; moreover, App 
seems to play a role in the formation and function of 
synapses [190]. Cleavage of App can follow two 
different ways: the first one involves both α-secretase 
and the γ -secretase, that cleave the App at the N-
terminal and at the C-terminal respectively producing 
a non-amyloidogenic peptide; the second, 
amyloidogenic, produces the Aβ1-42 and the Aβ1-40 
peptides, is mediated by β-secretase and γ-secretase 
[191].  At the level of amyloid plaques, both Aβ1-
40/Aβ1-42 are found, but Aβ1-42 is known to be more 
prone to aggregate. Moreover, under physiological 
conditions 90% of Aβ produced is of the Aβ1-40 form, 
which is soluble and promptly degraded; on the 
contrary during aging, the ratio of Aβ1-40/Aβ1-42 
production is overturned, which in turn results in Aβ1-
42 accumulation, oligomerization and formation of 
fibrils. Why Aβ aggregates into fibrils is not yet 
explained, but Aβ aggregation seems to cover an 
antioxidant role in the early phase of the pathology: 
as Aβ increases in the AD cortex, there is in fact a 
decrease in neuronal levels of oxidized nucleic acids, 
decreased oxidative damage [192] and decreased 
toxic free metals, being iron ions [193] sequestered 
within the plaques. Aβ sequence and Aβ 
concentration [194] are thought to be key factors in 
the set off of the amyloido-genic process: due to 
dominant mutations of three genes coding for App 
(APP) or Presenilin 1 and 2 (PSEN-1/PSEN-2), two 
proteins that are part of the γ-secretase complex, the 
senile augmented production of Aβ1-42 is anticipated 
and enhanced, causing most common cause of early 
onset familiar AD (5% of the cases) [195]. Another 
hallmark of Alzheimer pathology, aside from 
extracellular amyloid plaques, is the presence of 
intracellular neurofibrillary tangles (NFT) composed 
prevalently by a hyper-phosphorylated form of Tau 
protein. Tau, associated to microtubules of neurons, 
is essential for cytoskeleton organization and for the 
transport of nutritive molecules inside the cell; hyper-
phosphorylation (probably caused by toxic 
concentrations of Aβ) causes Tau to be less affine to 
microtubules [196], letting it to form oligomers which 
can aggregate into an extremely insoluble β-sheet 
structure that compose then the neurofibrillary 
tangles. The mechanism of this hyper-
phosphorylation is not explained yet: many 
phosphokinases, including GSK3β, CDK5, and ERK2, 
have been investigated as potential player in this 
process, making them also possible treatments 
targets to reduce tau phosphorylation [197].  
Oxidative stress plays a pivotal role in AD, because 
age-related accumulation of reactive oxygen species 
(ROS), which results in damage to major components 
of cells, is enhanced in AD patients: oxidized nucleic 
acid, lipids and proteins are indeed found in AD 
patients CNS [198, 199]. Free radicals are potent 
damaging agents responsible of cell death or other 
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irreversible modifications [200], and neurons appear 
to be particularly vulnerable to attack by these free 
radicals due to their low glutathione content [201], 
the polyunsaturated fatty acids of their membranes 
[202] and the high quantities of oxygen required by 
the their metabolism. Much is the attention spent in 
the last years on the study of the correlation between 
metals and AD, as it’s known that several metals play 
a major catalytic role in the production of free toxic 
radicals, and high concentrations of metals like iron, 
aluminum, copper and zinc are found in AD patient’s 
brain. The concentration of iron (which, as said in the 
paragraph 2.1.4, can induce oxidative environment 
through the Fenton Haber Weiss reaction [203]) in 
the brains of AD patients is elevated and transferrin, 
ferritin and iron have also been found localized in 
senile plaques [204] and NFT.  Furthermore, the 
ability of α-secretase to cleave App can be modulated 
by iron [205]. Copper instead have the potential to 
produce oxidative damage by altering ceruloplasmin 
function [206] and interacting with App [207]. The 
involvement of copper in neurodegeneration is also 
suggested by the fact that this metal is essential for 
many enzymatic activities, including cytochrome-c 
oxidase and Cu/Zn superoxide dismutase [208]; 
furthermore, copper concentrations are also highly 
concentrated within Aβ plaques. Zinc localizes into 
Aβ plaques too, and binds modulating its functional 
properties [189].  
Oxidative stress can be generated in numerous ways, 
and can impair various mechanisms like 
mitochondrial metabolism and protein degradation. 
Free radicals, for example, are involved in glycation 
processes and can foster the formation of advanced 
glycation end products (AGEs) [209]: AGEs, a class of 
posttranslational modifications, are generated by the 
non-enzymatic reaction of a sugar ketone or 
aldehyde group with the free amino groups of a 
protein or amino acid [210], and in the presence of 
transition metals these AGEs can also undergo redox 
cycling with consequent ROS production. 
Accumulation of AGEs in the brain is a feature of 
aging [211], and since their production is accelerated 
by, and result in formation of, oxygen-derived free 
radicals, they represent an important source of the 
oxidative stress in AD; in addition, AGEs were 
detected in association with β-amyloid [212] and NFT 
[213]. 
The secretion of ROS/reactive nitrogen species (RNS) 
by immune cells is the major mechanism for 
attacking target cells, and activated microglia have 
the potential to produce large amounts of ROS/RNS 
by various mechanisms: both activated microglia and 
astrocytes localize at sites of Aβ deposition [214], 
producing hydrogen peroxide [215] and various 
cytokines, chemokines and complement components 
[216]. Activated microglia and astrocytes can produce 
also large amounts of nitric oxide (NO), which in turn 
can react with superoxide to form the peroxynitrite 
radical, increasing the amounts of nitrotyrosine-
modified proteins [217] and enhancing the oxidative 
environment. 
The degradation of non-functional, oxidized proteins 
is an essential part of the antioxidant defenses of 
cells: proteasomal activity declines with age, and 
further studies demonstrate disease-specific 
alterations in the level and distribution of 
proteasomal subunits and decreased proteasome 
activity in the AD brain [218]; chronic proteasome 
inhibition, in addition to increased protein 
insolubility, induces elevated levels of protein 
oxidation and significantly inhibits the activity of 
mitochondrial complex. Moreover, disruption of 
membrane lysosomes [219] cause the release of 
lysosomal contents including redox-active iron that 
directly participate to oxidative stress also inducing 
mitochondrial damage with enhanced production of 
ROS [220]. Reduced energy production and increased 
oxidative stress, as well as damaged mitochondria, 
are also characteristics of AD [221]. The defect in the 
electron transport chain within the mitochondria is a 
factor that can contribute to the production of free 
radicals, being damaged mitochondria less efficient 
to produce of ATP and more efficient to produce 
(ROS): a reduced rate of brain metabolism is one of 
the best-documented abnormalities in AD [222], 
having the AD patients CNS an higher percentage of 
completely damaged mitochondria compared to 
aged-matched controls. The most consistent defects 
in mitochondria in AD are deficiencies in several key 
enzymes of oxidative metabolism: Mutisaya et al 
[223] showed, for example, that albeit normal 
amounts of cytochrome-c oxidase are found in the 
brains of AD patients, its oxidase activity was about 
25–30% lower than normal in the cerebral cortex, 
suggesting that it’s only the enzyme activity that is 
affected [224]: cytochrome-c oxidase defect can 
produce increasing amounts of free radicals, and 
interesting, mutations in cytochrome-c oxidase genes 
segregate with late-onset AD [225].  
Summarizing, we can describe Alzheimer neuro-
pathological disorder as a combination of two 
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different factors: a genetic defect related to a 
particular molecule and the age-related abnormal 
production of free radicals, but the exact contribution 
of each source of oxidative stress above described is 
complicated, as these sources of oxidative stress 
interact with each other, establishing a positive 
feedback. Furthermore, what may be the initiating 
factor and how this whole process is set off is still 
unclear. 
The amount of risk of Alzheimer’s disease that is 
attributable to genetics is estimated to be around 
70%, but Identification of specific risk genes is 
problematic because, being AD a multifactorial 
pathology, the overall increase in risk conferred by a 
single gene is small and because the pathological 
changes in AD are highly heterogeneous. In addition 
to the genes related to App metabolism listed above, 
several other potential risk genes for AD have also 
been identified: the most important gene linked to 
an high risk to develop AD, both in familiar and 
sporadic forms, is the APOE gene, that encodes for 
apolipoprotein E (ApoE). ApoE is a protein localized in 
the plasma, involved in the transport of cholesterol 
through both the vascular system and the neurons, 
and known to bind Aβ protein. Three forms of apoE 
are known: ε2, ε3 and ε4. E4 allele is more frequent in 
AD subjects, and its presence determines a 4-fold 
increased chance to develop the pathology [226]. 
Apo ε2 instead seems to have a protective role. ApoE 
is a protein sensitive to attacks by free radicals, but 
the E4 isoform is more sensitive, suggesting that this 
feature of the E4 allele contribute to the pathology. 
Moreover, the level of peroxidation in the brains of 
AD patients is inversely proportional to the 
concentration of ApoE, which suggests the 
hypothesis that apoE has a beneficial effect against 
lipids peroxidation, and that the effect is more 
pronounced when the patient has the ε2 allele. 
Alzheimer’s disease can only be definitively 
diagnosed post mortem (observing the atrophy of 
parietal cortex, temporal cortex and hippocampus 
and a reduced brain volume of about 1/3 compared 
to healthy subjects), although earlier “probable” 
diagnosis may be possible with improved diagnostic 
techniques and criteria, that include a detailed 
history of the type and course of symptoms, 
computational tomography CT or  (magnetic 
resonance imaging) MRI detection of intracranial 
lesions or diseases that might cause or contribute to 
dementia syndromes (tumors, cerebrovascular 
disease) [227] or detection of atrophy in 
hippocampus, cortex and amygdala. PET (positron 
emission tomography)-glucose brain metabolism 
analysis and Aβ neuroimaging in vivo are innovative 
diagnostic procedures, whose can put forward the 
diagnosis of the disease. AD can be also 
differentiated from other dementias by the combined 
detection of lower concentrations of CSF’s Aβ1–42 and 
increased concentrations of total Tau or hyper-
phosphorylated Tau at threonine 231 and 181 than 
age-matched control individuals [228]. From the 
therapeutic point of view, AD is still incurable, and 
the therapy tries only to lighten its symptoms: 
cholinesterase inhibitors are used to improve 
patients’ behavior, but the effect on cognition is 
moderate. Memantine improve cognitive 
performance [229] and might also be beneficial in the 
prevention and treatment of agitation and 
aggression [230], while antipsychotic drugs are 
commonly used to treat agitation, aggression, and 
psychosis in patients with dementia [231]. Simple 
non-pharmacological treatments, such as social 
interaction and care training, can be effective 
alternatives to drug. Innovative therapies include 
active immunotherapy with fragments of the Aβ 
protein, that was effective at clearing Aβ and 
improving conditions in transgenic mice [232], but 
raised skepticism about how this approach works, 
because only a small proportion of antibody crosses 
the brain barriers. Several potential therapies either 
inhibit β-secretase or modulate γ-secretase, with the 
goal of reduce Aβ1–42 concentration. Nowadays, 
reduction of the risk of developing Alzheimer’s 
disease depends mostly upon lifestyle changes and 
improved treatment or prevention of medical 
conditions that confer additional risk.  
2.2.2   Parkinson’s disease 
Described for the first time by James Parkinson, 
Parkinson disease (PD) is a chronic progressive 
pathology, and, after AD, is the second predominant 
form of dementia. Although genetic familiar forms 
are also described, Parkinson's disease, like AD is 
prevalently a sporadic disorder (90-95% of the cases) 
and aging is the major risk factor [233], rising the 
incidence from 20/100000 persons between 50 and 
59 years of age to 120/100000 persons after 70 years 
of age [234]; only 10% of people with the disease are 
younger than 45 years, and men are about 1.5 times 
more likely than women at risk to develop PD. 
The diagnosis of the pathology is very difficult, being 
its onset gradual and the earliest symptoms that 
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include depression, anxiety, smell impairment and 
sleep disorders are non-specific, unnoticeable and 
linked to the normal aging process. When the disease 
progress and the neuronal loss is significant however, 
more specific and evident symptoms appear, like 
impairment of dexterity, resting tremor, muscular 
rigidity, bradykinesia, monotonous speech and 
postural imbalance. All these PD characteristics are 
the result of the degeneration of specific regions of 
the patients’ brain, in particular of the dopaminergic 
neurons in the midbrain area called substantia nigra 
pars compacta (SN), but as well as with more 
widespread neuronal changes. 
From the pathological point of view, the hallmark of 
PD is the presence of intra-cytoplasmic inclusions 
called Lewy bodies (LBs), a dense granular structures 
localized principally in the dopaminergic neurons of 
the caudal and ventro-lateral regions of the SN but 
also in the hypothalamus, basal ganglia, cortex and 
olfactory bulb. LBs are composed mainly by α-
synuclein (α-syn) and other proteins like Ubiquitin 
and Parkin. LBs, that are continuously forming and 
disappearing in the SN, are often accompanied by 
the presence large eosinophilic structures thought to 
be the predecessor of LBs called pale bodies [235], 
and by Alzheimer characteristic β-amyloid 
aggregates in patients with severe memory loss [236, 
237]. Interestingly, LBs are also present in 10% of the 
people older than 60 years who died without 
neurological evidences: this condition, called 
incidental LBs pathology, might be the early pre-
symptomatic phase of PD [238]. Braak et al. [239] 
proposed a PD progression theory divided in 6 
stages, based on LBs diffusion through the different 
CNS regions: first, these α -syn immune-reactive 
inclusions are found within the olfactory system, 
causing olfactory deficits; in stage 2, the LBs are more 
widespread within the medulla oblongata and also 
during these first stages, the individuals do not 
present any perceptible motor symptoms. Stage 3 is 
characterized by the progression of LBs in the 
midbrain, basal forebrain, and later into SN. In stage 4 
cell loss in the SN is evident, as well as α-syn immune-
reactivity in the cerebral cortex: at this time, patients 
may display the first PD symptoms. Finally, in stages 5 
and 6, α -syn pathology begins to invade the neo 
cortex: at this phase, motor symptoms are clearly 
diagnosable, and cognitive dysfunction becomes 
evident. 
The physiological function of α-syn protein in the 
healthy brain is not well understood: expressed 
prevalently in the neo-cortex, hippocampus, SN, 
thalamus, and cerebellum [240], this 140 KDa protein 
is present in the cytoplasm as a monomer, and high 
concentrations are present in the pre-synaptic space 
of neurons where it coordinates the neurotransmitter 
vesicular recycling (fundamental for the correct 
functioning of the synapse [241]). Characterized by a 
highly amyloido-genic domain (which presents a 
high propensity to aggregate and to form oligomeric 
structures and insoluble fibers under particular 
conditions such as elevated concentrations) α-syn 
can aggregate in β -sheet proto-fibrils which trigger 
the LBs formation. The mechanism of α-syn 
oligomers formation is not clear: mutations of the 
SNCA gene (which encodes for the α -syn) increase 
the tendency of the protein to oligomerize [242, 243], 
and many studies suggested that this aggregates, 
sequestering toxic α-syn, are made to prevent its 
cellular toxicity.  
Oxidative stress, characterized by an imbalance 
between the generation of free radicals and 
antioxidant defenses, may be related to the impaired 
mis-folded protein clearance as well as to 
mitochondrial function [244]: DAergic neurons of the 
SN are the most oxidative-sensible cells because the 
dopamine (DA) metabolism, which generates highly 
toxic molecules, can contribute to mitochondrial dis-
function increasing the oxidative damage. DA, 
synthesized from tyrosine by tyrosine hydroxylase, is 
stored in millimolar concentrations in synaptic 
vesicles: impairment in the storage of DA, which may 
be due to α -syn fibrils (which are shown to be 
responsible of the leakage of the neurotransmitter 
from the presynaptic vesicles [245]), can increase DA 
levels in the cytoplasm. In this condition DA can auto-
oxidize its catechol ring with the production of DA-
quinone, superoxide radical (•O2) and hydrogen 
peroxide (Figure 2.2.1) [246]. Alternatively, DA can be 
degraded by monoamino-oxidases A and B (Mao-
A/B) with the production of hydrogen peroxide. DA-
quinone is a very reactive molecule, and it has been 
shown to interact with α-syn inducing its aggregation 
[247], impair brain mitochondrial function [248] 
causing ROS production, induce proteasomal 
inhibition leading the cells to undergo apoptosis 
[249] and cyclize to become the highly reactive 
aminochrome, who leads the generation of 
superoxide and depletion of cellular NADPH. 
Moreover, hydrogen peroxide generated during DA 
metabolism, as described in the chapter 2.1.5, can be 
subsequently converted into the highly reactive 
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hydroxyl radical in the 
presence of high 
transition metal ions 
[250] contributing to 
oxidative stress (Figure 
2.2.1). Interestingly, 
DAergic neurons 
physiologically show 
high concentration of 
iron and ferritin that are 
increased in PD [251], 
and iron deposits were 
found in microglia, 
olygodendrocytes, 
astrocytes located close 
to neurons and in the 
rim of Lewy bodies in 
the SN of PD patients 
[252]. It is so conceivable 
that oxidative stress is 
a common mechanism 
that leads to cellular 
dysfunction and death, causing the cellular and 
molecular modifications present in PD, like α-syn 
olygomerization; this hypothesis is supported by 
various evidences, like decreased intracellular 
reduced glutathione (GSH) [253, 254] found in the 
damaged cells of the SN, their increased levels of 
oxidized lipids [255], proteins and DNA [255]. 
Neuromelanin, the final product of DA oxidation, is 
furthermore accumulated in the nigral region of the 
human brain [256] and it can sequester free iron, 
acting as a neuroprotective factor [257].  
Mitochondrial dis-function can also be provoked by 
α-syn: indeed α-syn aggregates induce mitochondrial 
release of cytochrome c (triggering apoptosis), 
increase mitochondrial calcium, nitric oxide, and 
oxidative modification of mitochondrial components. 
In addition, α-syn, although mostly cytosolic, seems 
to interact with mitochondrial membranes to inhibit 
Complex I [258]: higher number of respiratory chain 
deficient DAergic neurons have been found, in fact, 
in PD patients compared to age-matched controls 
[259]. At this point it’s clear that all the pathways 
above mentioned are thus interconnected in a 
positive-feedback mechanism, because 
mitochondrial dysfunction itself leads to increased 
free radical generation, which further provokes α-syn 
aggregation; the net result of this “pathologic loop” is 
an increased cell dysfunction and a lowered 
threshold to apoptosis.  
The theory of the mitochondrial dysfunction and 
oxidative stress [260] role in PD is supported today by 
the study of its genetics forms, either recessive or 
dominant and which involve several genes that often 
code for mitochondrial proteins. “Loss of function” 
mutations in four genes (PINK1, PARK7, PARK2 and 
PARK5) cause recessive early parkinsonism with an 
age of onset under 40 years: all these mutations lead 
to a disease that has a more benign course than 
Parkinson's disease and responds well to 
dopaminergic drugs. Pink1, localized to the 
mitochondrial inter-membrane space and bound to 
mitochondrial membranes, is thought to 
phosphorylate mitochondrial proteins in response to 
cellular stress and to protect against mitochondrial 
dysfunction. Interestingly, LBs localization of Pink1 
was observed in patients with sporadic PD [261]. 
PARK7 gene encodes for a cytoplasmic protein (Dj-1) 
that appears to exert an antioxidant function [262]  in 
physiological conditions, but under stress 
environment can also translocate into the 
mitochondria and nucleus [263]; deletions and point 
mutations in the PARK7 gene cause a loss of its 
protective role. Mutations in the gene PARK2 (that 
encodes for Parkin) and PARK5 (which encodes for 
Uchl1) underline the importance of the protein 
degradation system in the disease, being Parkin [264] 
and Uchl1 included in the ubiquitin-proteasome 
pathway, responsible of the removal of oxidative mis-
Figure 2.2.1: Iron and oxidative stress hypothesis in PD. This figure summarizes the pathological mechanism in PD, 
explaining the possible cell-death mechanisms. From [4]. 
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folded proteins from the cytosol. Mutations of this 
two genes cause an impairment of the mis-folded α-
syn degradation, causing its accumulation in LBs.  
Looking at the autosomal dominant genes, SNCA 
(coding for α -syn and described previously) and 
LRRK2 instead have been shown to cause with a 
mutation frequency of 5% [265], the majority of the 
cases of autosomal dominant PD; LRRK2 gene 
represent the most common known cause of familial 
PD, encoding a large multi-domain protein able to 
undergo phosphorylation and to phosphorylate 
generic substrates. Although Lrrk2 protein is mainly 
localized to the cytoplasm, consistent levels of the 
protein are associated with the outer mitochondrial 
membrane [266], raising an important question of 
whether mutant Lrrk2 kinase increased activity might 
directly affect mitochondrial function.  
The final evidence of the key role of oxidation in PD is 
provided by the treatments of animal models in 
which PD is provoked: MPTP (1-metil-4-fenil1,2,3,6-
tetraidropiridine) treatment, which block the 
mitochondrial respiratory chain complex I and induce 
DA dependent oxidative stress, induces in the animal 
a PD-similar phenotype. Rotenone (which acts as an 
inhibitor of the mitochondrial respiratory chain 
complex too) and Paraquat, two pesticides, cause a 
loss of dopaminergic neurons in rodents and increase 
the incidence of Parkinson disease in human 
professions in direct contact with them.  
Neuronal loss in PD is finally associated with also 
chronic neuro-inflammation, which is mediated 
primarily by microglia, the main resident immune 
responsive cells in the central nervous system. 
Microglial reaction has been found in the SN of 
sporadic PD patients [267] as well as familial PD 
patients [268]: microglia, activated in response to 
injury or toxic insult as a self-defensive mechanism to 
remove cell debris and pathogens, release free 
radicals such as NO and superoxide, which can in turn 
contribute to oxidative stress in the 
microenvironment. Over-activated or chronically 
activated microglia causes an excessive and 
uncontrolled neuro-inflammatory response, leading 
to an increased cell apoptosis with consequent 
neurodegeneration [269]. The oxidized or ROS-
damaged molecules released from suffering nigral 
DAergic neurons that trigger microglial activation 
include neuromelanin and α-synuclein, as 
demonstrated by strong microglia activation caused 
by intra-cerebral injection of neuromelanin, and by 
that a fraction of α-syn fibril released from neurons 
[270] is found in the cerebrospinal fluid of PD 
patients [270] and causes activation of microglial 
cells; moreover, α-syn stimulates astrocytes to 
produce inflammatory modulators that augment 
microglial chemotaxis, activation and proliferation 
[271]. Concluding, the understanding of the patho-
physiology of the disease at cellular and molecular 
levels and finding the molecular targets for an 
efficacious neuro-protective therapy is a crucial issue 
in the field of Parkinson disease research.  
2.2.3   Cp in in neurodegenerative diseases 
Being ceruloplasmin a crucial protein in the 
metabolism of both iron and copper, seems quite 
clear that an alteration of its function at the level of 
CNS can result in an impairment of the homeostasis 
of these two metals, possibly leading to the iron and 
copper disequilibrium described in the previous 
chapters for AD and PD patients. An important 
evidence of this fundamental role of Cp is provided 
by three human genetic disorders: 
Aceruloplasminemia, Menkes disease and Wilson 
disease, which are characterized by the absence of 
the protein or at least by its presence in an inactive 
form in the whole body. 
Aceruloplasminemia is an autosomal recessive 
disorder [272, 273] caused by 40 distinct loss-of-
function mutations in the Cp’s gene [274], which lead 
to the formation of a premature stop codon causing 
the formation of an inactive apo-form of the protein, 
that lacks the copper cluster sites critical for its 
enzymatic function. The rapid degradation of the 
apo-Cp in this way produced leads the patients to 
have absent serum ceruloplasmin, albeit particular 
mutations where patients present the clinical 
features of aceruloplasminemia [275] while having 
detectable levels of serum ceruloplasmin have also 
been reported; despite symptomatic heterozygous 
patients exist, usually these heterozygous individuals 
have normal iron metabolism and no clinical 
symptoms. 
The absence of Cp in the body leads patients to have 
also decreased serum iron, elevated serum ferritin 
and iron accumulation within hepatocytes, 
pancreatic endocrine cells, basal ganglia and 
astrocytes [276]. This accumulation causes hepatic 
iron overload, anemia, retinal degeneration, diabetes 
mellitus and adult-onset neurological symptoms, 
which reflect the CNS sites of iron accumulation [2, 
277, 278]. Despite the fact that the truncated Cp 
molecule loses all its coordinated copper ions, no 
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serious disorders of copper metabolism have been 
reported in aceruloplasminemic patients (and also in 
Cp knockout mice) [2], and none of the clinical 
symptoms associated with the disease is 
consequence of copper deficiency or toxicity. 
Neurological symptoms, which often occur when 
patients are older than 40 years [279], are usually 
progressive and are caused by cerebellum and basal 
ganglia neuronal cell loss, abnormal astrocytes 
morphology and deposition of ferrous iron in glia 
[280, 281], neurons and reticulo-endothelial cells, 
where in physiological conditions this metal is stored 
and then mobilized for recycling [282]. This increased 
brain iron, hallmark of aceruloplasminemia, has been 
detected by MRI or autopsy [283], and seems to be 
the responsible of the neuronal cell death through 
two different mechanisms:  via iron-mediated radical 
stress (high levels of lipid peroxidation in 
aceruloplasminemia have been evidenced in various 
organs, including the brain) and via iron deficiency in 
regions where iron accumulated in astrocytes is not 
able to be exported for uptake, like neurons: The 
latter mechanism is due to the absence on the 
astrocytes of their GPI-anchored form of Cp, required 
for the cellular iron efflux; it’s known that astrocytes 
GPI-Cp is essential for the stability on the cell surface 
of the iron exporter Fpn [8], and in vitro biological 
analyses demonstrated in fact that the 
ceruloplasmin-mutants astrocytes have impaired 
ferroportin stability on the cell surface, resulting in 
exacerbated iron accumulation within the cell [284]. 
Menkes (MD) and Wilson disease (WD) instead are 
not characterized by mutations of the Cp gene, but 
by mutations in the genes encoding copper-
transporting ATPases ATP7A and ATP7B, responsible 
the first of the copper transport through the 
intestinal and brain barriers, and the second of the 
incorporation of copper into fully developed holo-
ceruloplasmin. 
MD is an X-linked fatal loss-of function disease [285], 
characterized by an impaired copper metabolism and 
delivery in the whole body  including the brain, with 
marked metabolic and developmental changes 
(growth failure, hypo-pigmentation, arterial 
tortuosity), progressive neuro-degeneration and 
death of the majority of patients in early childhood. 
The various features of this disease are the result of 
abolished activity of several cupro-enzymes 
(including Cp) due to the lack of systemic Cu caused 
by the Atp7a dis-function at the level of the intestinal 
barrier. Neurologic features develop in early infancy, 
due to loss of neurons and extensive atrophy in 
cerebellum and cortex [286], with focal degeneration 
of the gray matter and de-myelination [287]; systemic 
copper treatment clearly is not effective in MD, as 
copper transport into the brain is dependent on 
Atp7a.  
Wilson Disease is also characterized by copper 
deposition in the liver, brain, kidneys and cornea, 
with an increased copper concentration in the CSF 
too; symptoms of the disorder reflect the copper 
accumulation sites, and are the onset of hepatic 
cirrhosis, neurological symptoms and Kayser-
Fleischer corneal rings. WD is characterized by more 
than 200 different loss-of function mutations 
(deletion, insertions and missense/nonsense 
mutations) of ATP7B [288, 289], whose gene is 
located on chromosome 13 [290]; some mutations 
are associated with a severe impairment of copper 
transport, resulting in severe liver disease, while 
other mutations appear to be less severe, depending 
on the site of mutation in the ATP7B sequence. Loss 
of function of Atp7b results in synthesis of an apo-
ceruloplasmin that is rapidly degraded in the plasma 
[291], as Atp7b function is to load copper on the apo-
form of ceruloplasmin; moreover, another Atp7b 
function is to mediate the excretion of excess copper 
into bile [292]. These two distinct functions require 
the protein to localize at different subcellular 
compartments: at the trans-Golgi network, where 
Atp7b incorporate copper into apo-ceruloplasmin, 
and to post-Golgi vesicles in proximity to the 
canalicular membrane, where Atp7b translocate 
when intracellular copper levels are increased to 
facilitate biliary copper excretion.  
Due to the copper imbalance in the CNS, a large 
proportion of WD patients display neurological and 
psychiatric symptoms; in the brain of patients copper 
is accumulated in selected structures, such as nucleus 
lenticularis, substantia nigra, globus pallidum and 
corpus striatum, affecting in particular mitochondrial 
respiration and triggering activation of cell-death 
pathways [293]. This accumulation leads to early 
symptoms like hyperkinesia with typical flapping 
tremor, dysarthria and dementia, which consequently 
progress to severe Parkinsonian symptoms [294] and 
neuro-psychiatric illness [295] when other CNS 
regions are affected, including the thalamus, 
subthalamic nuclei, brainstem, and frontal cortex. On 
the contrary of MD, improvement in these symptoms 
can be observed upon treatment, in this case with 
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oral chelating agents able to restore copper 
homeostasis. 
Aside from being involved primarily in these focused 
diseases, Ceruloplasmin seems to play an important 
role also in AD and PD patients, characterized by iron 
and copper anomalous homeostasis and oxidative 
stress [296]. In fact, Cp concentrations are often 
increased in AD and PD patients in particular regions 
characterized by extensive pathology (for example in 
AD hippocampus and frontal cortex and in PD 
substantia nigra) but not in others. However, the 
relationship between this regional brain Cp content 
and neuronal loss is unclear: probably, elevated 
regional Cp levels are induced by the suffering brain 
in order to enhance the anti-oxidant capacity of the 
system increasing the regional iron-oxidative activity 
of Cp [297]. 
Furthermore, although being an oxidation-protective 
enzyme, Cp seems to be subjected to oxidative 
modifications itself: in fact, besides Cp concentration 
in serum is the same for example in control and AD 
subjects, its ferroxidase activity is significantly lower 
[298] and free copper in serum is increased in 
patients, correlating with the MMSE (Mini Mental 
State Examination) score [299]. These observations 
suggest an alteration in the structure of the protein 
which, although being present, loses its enzymatic 
activity and its ability to transport copper. Also in the 
cerebrospinal fluid of patients Cp oxidative activity 
was significantly lower while its concentration is not 
generally affected; on the contrary, in the brain of AD 
patients copper has been found to be not increased 
[297, 298] or even significantly lowered, due to its 
sequestration within Aβ plaques [300]. 
This decreased Cp activity (and of others cupro-
enzymes) in AD can be thus the result of a defect in 
the incorporation of copper in the protein (due to the 
specific copper accumulation and sequestering in Aβ 
plaques) or of a release of copper from the oxidation-
damaged protein. Cp ferroxidase activity impairment 
can finally influence also iron homeostasis: in fact 
iron, despite is, in general, not increased in AD [300], 
accumulates specifically in NFT, neuritic plaques and 
intra-cellularly in neurons and astrocytes, indicating 
again a dysfunctional status in its metabolism in the 
brain, inducing tissue damage, axonal dysfunction 
and cell death.  
In the case of Parkinson disease, the issue is more 
complicated, being described several variants of PD: 
one, the most common, with increased iron in the 
substantia nigra and low Cp concentration in serum 
[301], the second with normal iron in the substantia 
nigra and normal Cp concentration in serum, and the 
last with additional increased serum copper 
matching an increased Cp [302]. Anyhow, the 
common feature of these different variants of PD is 
again the lack of Cp ferroxidase activity, suggesting 
that also in PD this enzymatic activity is necessary for 
the correct metabolism of iron in the brain. In the 
second variant of PD described above in fact, albeit 
Cp serum concentration is not modified, its oxidative 
activity in serum negatively correlates with the iron 
content of the substantia nigra, and in the last variant 
(that shows biological markers similar to the Down 
syndrome) Cp concentration increasing might 
indicate that the impaired copper incorporation into 
the Cp molecule and the deficiency of its ferroxidase 
activity triggers a compensatory mechanism of the 
brain that synthetize high amounts of Cp [303]. 
Looking at these different variants of PD phenotypes, 
seems clear that accumulation of iron in the 
substantia nigra, although common in PD (and, 
interesting, associated with Cp gene mutations 
[304]), is not enough to produce the clinical 
symptoms of the pathology: the oxidative activity of 
Ceruloplasmin is indeed not only addressed to Fe 
oxidation, but it’s also involved in the oxidation of 
catecholamines (like DA) in neurons where these 
amines function as neurotransmitter molecules, it is 
so reasonable that Cp oxidative activity participate 
also in this process to avoid the occurrence of PD. As 
said before, Cp is in effect able to enhance the 
oxidation of 6-hydroxydopamine [177], an 
intermediate product on the way to the formation of 
dopamine-melanin, and oxidation of 6-
hydroxydopamine by Cp avoid H2O2 production 
[177], unlike the case of its oxidation in the absence 
of Cp when toxic oxygen species are generated. 
In PD, a negative correlation has indeed been found 
between the Cp concentration and its oxidative 
activity in serum and iron deposits in the substantia 
nigra in the brain [302]; furthermore, Kyung-hee Lee 
at al discovered that pathological amounts of Cp in 
the brain induce gene expression and activate 
signaling molecules implicated in microglial 
activation [305], causing an aberrant inflammatory 
response inducing nitric oxide production and 
exacerbating the oxidative environment and cell 
death. The difference in sensitivity to rotenone of rats 
and mice, which seems to correlate with the levels of 
Cp in animals is, again, another evidence that suggest 
an involvement of Cp in the pathology [306].  
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2.3  Asparagine spontaneous 
deamidation and NGR-motif-
dependent gain of function 
2.3.1   Molecular timing of asparagine 
deamidation 
Proteins and peptides are susceptible to a variety of 
post translational modifications (acetylation, 
phosphorylation, methylation and glycosylation) that 
can affect their structure and their biological 
functions. These aminoacidic modifications can 
occour spontaneously during the normal aging of 
proteins, but the normal turnover/neosyntesys keep 
the rate of modified proteins under control. During 
the ageing of an individual, due to the unbalance 
between deleterious vs. repairing systems, these 
modifications take over causing an accumulation of 
these modificated proteins. This process can be 
accelerated also under pathological coditions: it’s 
very well reported in literature for example that the 
oxidative environment present in several 
neurodegenerative diseases (like AD and PD, as 
described before) cause an increase in this 
deleterious modifications of a variety of proteins, 
which become often unactive or even capable to 
trigger pathological effects. Among these 
modifications, the formation of isoaspartic acid 
(isoAsp), result both of the isomerization of aspartic 
acid (Asp) and the deamidation of asparagine (Asn) 
[307], occurs spontaneously in proteins and peptides 
either in vitro (for example in the storage and 
purification of calmodulin [308]) and in vivo during 
development and aging of cells [309]. Deamidation 
of Asn is a hydrolytic reaction that brings to an 
anomalous β-linkage formation and to the 
introduction of a negative charge that may cause a 
change in the protein primary structure, which may 
in turn affect the secondary, tertiary structure and its 
biological activity. The deamidation of the asparagine 
residue is a ubiquitous non-enzymatic process that is 
initiated by a nucleophilic attack of the peptide bond 
amino group on the asparagine side-chain carbonyl 
group, with release of NH3 (Figure 2.3.1). The cyclic 
succinimide-ring-intermediate thus resulting rapidly 
hydrolyzes to a mixture of aspartate or isoaspartate, 
with a preference of 1:3 [310] for the formation of the 
latter because of the asymmetry of the succinimide 
structure [311]. Asparagine is not the only amino acid 
able to deamidate: also glutamine, the other amino 
acid with an amide side chain, can undergo 
spontaneous deamidation, but with a slower rate 
[312]. Isoaspartate can result also from the 
spontaneous isomerization of Aspartate, but this 
reaction occurs at a slower rate compared to Asp 
deamidation. IsoAsp formation is influenced by 
several factors like pH, temperature, oxidation [313], 
tertiary, secondary and primary structure of the 
protein: Robinson et al. [307] demonstrated indeed 
that the rate of asparagine deamidation can be 
determined by the surrounding amino acid 
sequence, being the Asn deamidation affected by 
Ser, Thr and Lys located at the N-terminal side [314] 
and favored when the side chain of the carboxyl-
flanking amino acid is relatively small and hydrophilic 
(in particular Glycine and Serine). By contrast, 
branched hydrophobic amino acids, such as Valine, 
protect Asn and Gly from possible deamidation. Also 
the degree of local polypeptide flexibility influences 
the kinetic of this reaction: isoAsp formation 
generally occurs within flexible protein sequences 
and is less likely to be found within secondary 
structures such as α-helics or β-sheets [315].  
Asn deamidation was considered nothing more than 
a purification artifact until the 1960s, when Flatmark 
and colleagues demonstrated that Cytochrome C 
becomes deamidated in vivo [316] spontaneously 
and under physiologic conditions. They thus 
proposed Asn deamidation as a form of protein 
damage and a consequence of aging, and for the 
majority of the proteins it is still thought to be the 
case: organism can use this reaction has a timer of 
biological events and protein survival that can be 
genetically programmed to regulate biological 
events of various durations, simply by varying the 
amino acids that surround asparagine residues within 
proteins [307].  Interestingly, a comparison of the 
total number of amide-containing amino acids in 
long-lived and short-lived proteins demonstrated an 
inverse correlation between this number and the 
half-life of a protein [317], confirming again the 
“molecular clock function” of asparagine 
deamidation [318]. But how does this “aging signal” 
works? It is assumed that deamidation destabilizes 
the proteins by making them more susceptible to 
proteolytic degradation [319], and this susceptibility 
could be determined by a change in the protein 
structure, cellular location, or state of aggregation. 
Anyhow, although this function is well-founded, the 
observation that such an unstable amino acid as 
asparagine would not be so widely distributed in 
nature unless its deamidation had a beneficial role 
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[307] induced to think that certain proteins evolution 
may have chosen susceptible sequences in order to 
produce a remodeling of protein structure that serves 
a useful function: this is the case of Fibronectin, an 
extracellular matrix protein that has important roles 
in cell adhesion, migration, growth, and 
differentiation, which contains two highly conserved 
Asn-Gly-Arg (NGR) loops. Asn deamidation at the 
level of these NGR loops is capable to promote an 
integrin-mediated cell adhesion [320, 321], 
suggesting the NGR role as a molecular switch for the 
activation of latent integrin-binding sites. 
Protein-l-isoaspartyl/d-aspartyl methyltransferase 
(PIMT), an ubiquitous cytosolic enzyme, partially 
repair deamidated and isomerized proteins 
catalyzing the conversion of isoAspartate to 
Aspartate [312] in this way: enzymatic methylation of 
isoAsp sites by PIMT facilitates reformation of the 
cyclic succinimide intermediate, which immediately 
hydrolyzes spontaneously to a mixture of isoAsp and 
Asp again in a ratio of 3:1 (Figure 2.3.1). Although 
each cycle across this repair pathway is only 30% 
efficient, recycling of the generated isoAsp sites 
through the PIMT reaction results in an overall high 
repair efficiency; albeit repairing the isomerized Asp 
sites, in the case of Asn deamidation the repair is 
incomplete, since PIMT restores the normal peptide 
backbone but not the normal Asn side chain. Repair 
of isoAsp, which can restore the loss of biological 
function and require less energy compared to 
degradation and resynthesis of a new protein, has 
been demonstrated in vitro with synthetic isoAsp-
containing peptides [322, 323] as well as with aged 
proteins [323]. PIMT is expressed in every organism 
from bacteria to humans, and in mammals PIMT 
levels are higher in brain and testes [324]: the 
findings suggest a key role of PIMT in these two 
organs, being both neurons and mature spermatozoa 
highly differentiated cells that may have special 
needs for damaged proteins repair. The same isoAsp-
sensitivity of brain may play a pathological role also 
in human neurological diseases, ranging from 
childhood neurological disorders to age-related 
dementias: recent studies have indeed reported the 
formation of isoaspartate in age-associated 
neurodegenerative diseases, for example in brains of 
mice affected by prion disease [325]. Moreover, 
isoAsp have been found in Aβ peptide of senile 
plaques and Tau in NFT of AD [326], and expression 
of PIMT is up-regulated in AD brains compared to 
healthy brains. PIMT co-localize with NFT but not 
with senile plaques: an explanation of this different 
co-localization is that NFT localize intracellularly 
(where PIMT is present) while amyloid deposits 
accumulate in the extra cellular space where PIMT 
does not exist.  Interestingly, it is observed that the 
site-specific deamidation/isomerization observed in 
the microtubule-binding domain of Tau (Asn381 and 
Asp387) induces a conformational change, by which 
the Tau protein can aggregate into NFT with an 
exceptional stability in vivo [326]. 
2.3.2   The NGR motif 
Asparagine-Glycine-Arginine motif (NGR) confer to 
proteins and peptides a tumor targeting property, 
specifically binding aminopeptidase N (CD13) [327], a 
membrane-bound metallopeptidase that plays 
multiple functions in the regulation of various 
hormones and cytokines, protein degradation, 
antigen presentation, cell proliferation, cell 
migration, and angiogenesis [328]. Many cell types 
express CD13, including the endothelium of 
angiogenic blood vessels, tumor cells, pericytes, 
myeloid cells, antigen-presenting cells, keratinocytes 
and, in some cases, fibroblasts [329-331]. 
Noteworthy, CD13 is up-regulated in angiogenic 
blood vessels [327] but expressed at a very low level 
by the endothelium of normal blood vessels: NGR-
containing peptides can hence target activated 
Figure 2.3.1: mechanism of spontaneous isoDGR formation by Asn 
deamidation or Asp isomerization. See the text for the detailed 
description of the reactions (From [6]). 
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endothelial cells in tumors and in other physiologic 
or pathologic conditions as for example 
inflammation. Differentially immunoreactive forms of 
CD13 are expressed in tumor-associated blood 
vessels, myeloid cells and epithelia [330], and it’s 
possible that the selectivity of NGR peptides for 
endothelial CD13 is related to differential 
glycosylation or conformational changes caused by 
complex formation with unknown compounds. The 
tumor-targeting property of NGR suggest its use as a 
carrier for the targeting of molecules to the 
neovasculature of tumors: various compounds and 
particles have been coupled or added synthetically to 
NGR peptides [332, 333] in order to increase their 
neovasculature-homing attributes, including 
cytotoxic drugs, cytokines and antiangiogenic 
compounds. Coupling CNGRC to the N-terminus of 
tumor necrosis factor (TNF), a cytokine endowed with 
potent vascular damaging properties and antitumor 
activity, for example led to the generation of a new 
compound, named NGR-TNF, with improved 
antitumoral activity [332, 334].  
In addition to this tumor-targeting function, NGR 
motif has another very important property, being 
able to rapidly convert to isoDGR by asparagine 
deamidation: this motif (that mimic the specular 
structure of the integrin-binding motif RGD) can 
recognize members of the RGD-dependent integrin 
family, such as αvβ3, αvβ5, αvβ6, αvβ8 and α5β1 
integrins [335] (Figure 2.3.2). Considering the known 
effects of structural protein elements on the 
deamidation rate of 
Asn residues discussed 
in the previous chapter 
(that range Asn 
deamidation kinetics 
ranging from hours to 
years), only certain 
NGR sites with suitable 
accessibility, flexibility 
and side chain 
orientation are likely to 
undergo deamidation 
under physiological 
conditions and 
subsequently bind 
integrins, while others 
need a protein 
reorganization in order 
to undergo this 
reaction.  
Interestingly, it has been shown that also DGR has a 
role in integrin recognition and cell adhesion [336]: 
fibroblast growth factor 2 (FGF2), a pro-angiogenic 
heparin-binding cytokine that contains two DGR 
sites, can bind to αvβ3 integrin promoting 
endothelial cell adhesion [337] after DGR’s Asp 
isomerization.  
The search for exact matches of vertebrate proteins 
with NGR in the SWISS-PROT database showed that 
5.02% of proteins contain this motif, and although it 
is likely that most of these sites are not properly 
folded and sufficiently exposed for receptor 
interaction, it is tempting to speculate that at least 
some of them might play a role in cell adhesion: in 
effects, approximately 17% of proteins that are 
classified by the keyword ‘adhesion’ in vertebrate 
protein databanks contain NGR sites [338]. Frequency 
of the DGR motif in proteins classified as having a role 
in cell adhesion is also high [338] suggesting that 
DGR too can function as a latent integrin-binding site 
that is differentially activated dependent on its 
molecular context and the conditions.  
Like for NGR, also DGR flanking residues and its 
microenvironment can affect the kinetics of Asp 
isomerization into isoDGR. Anyhow, the rate of Asp 
isomerization is generally slower than that of Asn 
deamidation in similar peptides [310].  
Competitive binding experiments showed that 
isoDGR can inhibit the binding of RGD-containing 
ligands to both αvβ3 and α5β1, suggesting that the 
binding site is located within the same RGD binding 
Figure 2.3.2: schematic representation of an isoDGR dependent molecular switch for integrin recognition. IsoDGR, 
derived from NGR’s Asn deamidation, is able to interact with integrin RGD-binding pocket. IsoDGR can also be 
converted into DGR by PIMT enzyme, abolishing the acquired adhesive function (From [6]). 
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pocket: NMR studies and docking experiments 
showed subsequently that cyclic isoDGR peptides 
favorably interacts with the RGD-binding site of αvβ3 
in an inverted orientation. Asn/Asp flanking residues 
not only influence isoAsp formation, but, like RGD 
scaffold, determine the affinity and specificity of the 
interaction between the resulting isoDGR and 
different integrins [335]. IsoDGR, being a natural fit 
for the RGD-binding pocket of αvβ3 integrin, 
supports the hypothesis that both NGR and DGR can 
work as “molecular timers” for generating integrin-
binding sites in proteins. The rapid transition of NGR 
to isoDGR could have important implications in the 
biological properties of NGR-displaying phages and 
NGR-conjugates, but also for the physiologic or 
pathologic effect of NGR containing proteins, like 
fibronectin (Fn) and fibronectin fragments. 
Four Fn modules, the first type II (Fn-II1), the fifth type 
I (Fn-I5), the seventh type I (Fn-I7) and the ninth type 
III (Fn-III9) repeats, contain NGR sequences. Full-
length plasma fibronectin was shown to be 
considerably more resistant to Asn deamidation than 
short Fn fragments or peptides [339], suggesting that 
rapid deamidation of NGR in fibronectin requires 
proteolytic processing and/or conformational 
changes. On the contrary, NGR deamidation in the 
Fn-I5 fragment is very rapid (probably because Asn is 
followed by a Gly residue), with a half-life of the NGR 
site in cell culture medium of only ~4 hours [321].  
The isoDGR-integrin interaction could exert different 
functions also in physiopathological mechansims: 
isoDGR peptides recognize αvβ3-integrin-positive 
endothelial cells in tumor vessels, inhibiting tumor 
growth when systemically administered to tumor-
bearing mice [321, 335]. Given evidence that 
implicates αvβ3 integrin in angiogenesis [340], it is 
possible that the interaction of the isoDGR site in 
fibronectin fragments with αvβ3 integrin could have 
an important role in cancer and in other diseases that 
involve angiogenesis. 
Clearly, all the possible functions described for Fn 
may be translated to other NGR-containing proteins 
which can activate latent integrin-recognition-sites in 
physiological or pathological condition, contributing 
to beneficial or unwanted/deleterious processes in 
various biological phenomena. Interestingly, 
ceruloplasmin sequence contains two NGR motifs: 
the first one (568NGR) is exposed on the surface of the 
protein while the second (962NGR motif), being buried 
inside the 3D structure of the protein, is less exposed 
and therefore less accessible to the solvent. 
Considered the rate of NGR frequency in vertebrate 
proteins seems plausible that, in Cp, a regulation of 
the deamidation of these two sites can be a 
mechanism able to give to the protein new 
properties that might participate to patho-
physiological phenomena. 
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3.1.1 Ceruloplasmin shows differing isoform 
patterns in PD 
Cp expression was analyzed by SDS-PAGE and WB on 
CSF proteins. Immunoblots indicated that, once 
normalized for total proteins, the PD Cp expression 
level did not vary from that of control subjects (CN) 
(Figure 3.1.1) and thus confirmed data already 
reported [341]. As examined under 2DE, CSF Cp 
showed several isoforms with distinct isoelectric 
points (pI) and a relative molecular mass of 150 kDa; 
the distribution of said points differed between PD 
and CN (Figure 3.1.2A).  
To analyze Cp patterns, we used a constant pI 
threshold (pH 5.6) to divide the profile into two 
distinct areas: region A and region B (Figure 3.1.2A). 
Analysis of the respective distribution of the signal to 
the two regions, each distribution being evaluated as 
a percentage of the total Cp signal, showed 
significantly higher values (t test, p< 0.0001) in the 
acidic region A for PD than for CN patients (Figure 
3.1.2B). This represents the fraction of total Cp that is 
modified in the CSF of PD patients. The distribution 
of Cp signal in the two regions was investigated by 
means of ROC curve analysis, which showed a PD 
versus CN area under the curve of 0.919 (p= 0.00012) 
(Figure 3.1.2A). Application of a signal cutoff value in 
region A>46.02% enabled discrimination of PD from 
CN patients with a sensitivity of 71.4% and a 
specificity of 93.3% (likelihood ratio, 10.7). 
Interestingly, PD patients’ clinical status (as UPDRS 
score, Table 5.1) and Cp acidification (signal in region 
A as percentage of total WB Cp signal) were found to 
correlate (Pearson’s correlation coefficient r=0.745; 
p= 0.0022) (Figure 3.1.3B). To understand whether Cp 
isoform acidification is a feature shared by other 
neurological pathologies, we analyzed the Cp pattern 
in CSF from patients affected by AD, ALS, and PN. Cp 
signal distribution enabled us to discriminate PD 
from the other neurological pathologies (t test: PD vs 
AD, p=0.0310; PD vs ALS, p=0.0119; PD vs PN, 
p=0.0022) (Figure 3.1.2A,B). The analysis also showed 
a difference between CN and, respectively, AD 
(p=0.0060) and ALS (p=0.0253), while no differences 
between CN and PN were observed (p>0.05) (Figure 
3.1.2A,B). A statistically significant result was 
obtained even when the five independent groups 
were evaluated together by ANOVA test (p=0.0001). 
Postanalysis test was significant for PD versus CN 
(p<0.001) and PD versus PN (p<0.01) comparisons 
(Figure 3.1.2B). Collectively, these results suggest that 
the Cp present in PD CSF is affected by modifications 
that induce protein acidification, which in turn is 
Figure 3.1.1: A) Cp expression levels in the CSF of control (CN) or 
Parkinson disease patients (PD) analyzed in western blot; B) 
quantification of Cp signal in panel A. 
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underlined by signal accumulation in the acidic 
region A. 
3.1.2 Unsupervised analysis uncovers a 
discriminative pattern for Cp in PD 
patients 
We applied a fully unsupervised automatic 
computational classification method; by means of 
unsupervised machine learning applied to the image 
pixels, this classification offers dimensionality 
reduction, feature selection, and clustering of the 
2DE anti-Cp WB map data set. Dimensionality 
reduction allowed the display of images in a new 
two-dimensional projection space, within which 
cluster analysis identified two groups, one 
corresponding to CN and the other to PD (Figure 
3.1.2Ca, dark gray and light gray clusters, 
respectively). This identification confirms that Cp 
pattern is able to distinguish PD from CN (accuracy, 
96%), with the single exception of CN13. Moreover, 
MCAP clustering revealed two respectively 
representative exemplars (CN9 and PD13) for the 
given clusters (Figure 3.1.2Ca). The WB map for the 
cluster exemplars provides an explanatory 
comparison between prototypes of the two states 
(Figure 3.1.2Ca). Similarly, Cp pattern is able to 
distinguish the PD cluster from the cluster comprised 
of those CN, PN, and ALS subjects who proved to be 
homogeneous (Figure 3.1.2Cb); accuracy was 91%, 
with 5 of 58 subjects misclassified (ALS 5, 7, 10, and 
PN4, 6). When analyzed together with other  groups, 
AD patients failed to be homogeneously distributed 
in a single cluster and thus obstructed unsupervised 
analysis. Interestingly, when directly compared, AD 
and PD groups were 86% accurately recognized by 
unsupervised Cp pattern analysis (Figure 3.1.2Cc) (4 
of 28 subjects misclassified; AD 8 and PD 11, 13, 14). 
Comparison of the WB maps corresponding to the 
Figure 3.1.2: CSF Cp 2DE profile discriminates PD from AD, ALS, PN, and CN. A, Representative results for WB analysis performed with anti-Cp on 2DE-
resolved proteins. On the basis of pI threshold value, Cp signal distribution was divided into two distinct areas, regions A and B. B, Analysis of WB signal 
optical density value distribution in region A, evaluated as a percentage of the total Cp signal. Data were analyzed both by Student’s t test and by ANOVA. 
Single patient distributions as well as means and SE are shown (PD, n=14; CN, n=15; AD, n=14; ALS, n=16; PN, n=13) (*p<0.05; **p<0.005; ***p<0.001). 
C, Unsupervised cluster identification discriminates Cp pattern of PD patients from other groups. Dimensionality reduction of the anti-Cp WB images data set 
executed by principal component analysis (the first two principal components, PC1 and PC2, are shown), and clusters of homogeneous subjects were 
identified by unsupervised minimum curvilinear affinity propagation clustering analysis. Red clusters are for PD attribution, and blue and black clusters for 
non-PD attribution. Markers associated with sample names indicate the exemplars for the respective cluster. An original 2DE-WB image is displayed for each 
exemplar. a, Clustering of PD and CN. Sample cn13 proved to be misclassified. b, Clustering of PD, CN, PN, and ALS subjects. Five of 58 samples were 
misclassified, from left to right, als7, als5, pn4, als10, pn6. c, Clustering of PD and AD patients. Four of 28 samples proved to be misclassified (from left to 
right, ad8, pd13, pd14, pd11). 
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cluster exemplars (Figure 3.1.2Cc, PD 10 and AD 17) 
shows that, of the two prototypal states, AD Cp 
undergoes lesser modification. 
 
3.1.3 In vitro oxidative stress induces Cp 
interconversion to acidic isoforms and 
an increase in CSF total protein 
carbonylation 
It has been shown that, because of its interaction 
with metal cofactors, Cp is sensitive to oxidative 
stress [182]. We accordingly hypothesized that the 
oxidative stress affecting CNS in PD patients might 
induce sufficient protein modifications to change pI. 
Given the hypothesis that Cp is a protein with a 5.5 
days half-life [342], chronic exposure even to mild 
oxidative conditions may result in extensive oxidative 
modifications. To confirm this hypothesis, we 
induced in vitro oxidative stress on CN CSF, and we 
analyzed the resulting Cp pattern. It is known that, in 
in vivo experiments, an increase in H2O2 
concentration correlates with an increase in ROS 
concentration [343]; we accordingly used a high H2O2 
concentration treatment to mimic the prolonged 
exposure of the Cp to an oxidative environment. We 
observed that increased H2O2 concentration led to 
proportional shifts in Cp isoforms to the acid region 
(Figure 3.1.4A). Oxidation also induced the 
progressive generation of two Cp products, 
amounting to ~120 and 80–100 kDa, respectively 
(Figure 3.1.4A, indicated by arrows). These products 
were probably degradation fragments, as previously 
reported [181]. Interestingly, the 120 kDa product 
was detectable in most (10 out 14) PD patients 
(Figure 3.1.2A). The CSF Cp pattern obtained by 
oxidative treatment was similar to that observed in 
PD patients, a finding that suggests that changes 
might be due to oxidative 
modifications. Among several 
modifications induced by 
oxidative stress, one of the 
most common is protein 
carbonylation [344], and we 
accordingly analyzed this 
modification in CSF. Metal-
catalyzed oxidation induced 
by treatments with high 
concentration of ascorbate, 
both with and without FeCl3, 
produced mild and strong 
carbonylation, respectively 
[see OxyBlot assay 
manufacturer indications and 
the study by Musci et al. 
[184]], and resulted in a 
proportional increase in 
OxyBlot reactivity (Figure 
3.1.4B). Subsequently to these 
treatments, the Cp 2DE 
pattern showed a shift to 
Figure 3.1.3: Cp pattern acidification discriminates healthy subjects and 
correlates with Parkinson’s disease grading. A, The ROC curve was used 
to define the ability of the assay to discriminate between PD and CN 
groups, and to define the threshold value at which OD gave the best ratio 
between sensitivity and specificity. PD versus CN showed an area under 
the curve (AUC) of 0.919 with p=0.00012. A signal cutoff value in region 
A>46.02% enabled discrimination of PD from CN patients with a 
sensitivity of 71.4% and a specificity of 93.3%. B, Correlation analysis 
was evaluated as Pearson’s coefficient (r) between Cp signal in region A 
(as a percentage of total WB Cp signal) and PD clinical status (as UPDRS 
score) for each patient. UPDRS and Cp signal in region A values passed 
the normality test for Gaussian distribution as assessed by Kolmogorov–
Smirnov test. Correlation showed a coefficient r=0.745 with p=0.0022. 
 
Figure 3.1.4: In vitro oxidative stress induces Cp to convert to acidic isoforms and total CSF protein 
carbonylation to increase. A,WB analysis of Cp profile in the CSF from a representative CN subject resolved by 
2DE under resting conditions or after treatment with increasing amounts of H2O2 (1, 5, 10 mM); percentages 
indicate the amount of total Cp signal present in regions A and B (Figure 3.1.1); the arrows indicate low-
molecular-weight products generated by protein oxidation. B, Detection of protein carbonylation by OxyBlot 
assay on total CSF proteins resolved by SDS-PAGE and stained for carbonyl groups, under resting conditions or 
after oxidation obtained by treatment with Asc with or without ferrous chloride (FeCl3). C,WB analysis of  2DE 
Cp profile in the CSF under resting conditions or after oxidation treatments as in B; percentages indicate total 
Cp signal present in regions A and B (Figure 3.1.2). 
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region A that was proportional to the degree of 
carbonylation (Figure 3.1.4B, C). Albeit at different 
levels, these changes were similar to those obtained 
with H2O2 treatment (Figure 3.1.4A, C) and hence 
suggest that protein oxidation contributes to Cp 
isoform changes.  
 
3.1.4 CSF total protein carbonylation increase 
in PD patients 
Analysis of total protein carbonylation in the CSF 
obtained from PD patients showed a significantly 
greater level than that of control subjects (p=0.0015) 
(Figure 3.1.5A, C). This suggests that CSF proteins 
undergo oxidative modifications during the course of 
PD pathological events. However, in contrast with Cp 
2DE shift, no correlations were observed between 
severity of disease and CSF total protein 
carbonylation levels. This finding is plausible, given 
the diversity of the parameters that we tracked: on 
the one hand, 
electrophoretic mobility 
changes in single/individual 
Cp proteins, as possibly 
induced by several, differing 
forms of modification; on 
the other hand, specific 
changes in carbonylation 
levels as evaluated in total 
CSF proteins as a collective 
whole. 
3.1.5 Cp carbonylation 
occurs in PD patients, and 
modified Cp corresponds 
to acidic isoforms 
OxyBlot analysis, performed 
on 2DE-resolved CSF 
proteins from both the 
pool of PD patients and 
the pool of CN subjects, 
followed by staining on 
the same nitrocellulose for 
Cp expression, showed 
that the Cp present in PD 
CSF was carbonylated 
(Figure 3.1.5D). Moreover, 
the carbonylation signal 
was found to correspond 
mainly with more acidic Cp 
isoform, a feature that did 
not appear in the CN subjects (Figure 3.1.5D, see 
arrows). This analysis was restricted to the pooled 
samples due to the limited amount of samples 
available. However, the same analysis performed on a 
single PD patient (PD2), from whom we had by 
chance collected a larger amount of CSF, showed the 
same results (Figure 3.1.5E). Carbonylation converts 
side chains of many amino acids to reactive aldehyde 
and ketone groups, and thus may causes loss of 
positive charges, which in turn results in protein 
acidification. For this reason, it is conceivable that 
oxidative stress-induced Cp carbonylation might 
contribute to the isoform switch observed both in 
vitro and in PD patients. However, the complexity of 
the Cp 2DE pattern observed indicates that the 
oxidation-induced changes involved multiple target 
sites and varying events (e.g., methionine and 
cysteine oxidation, asparagine deamidation, glucidic 
moiety modifications, etc.). In particular, the shift to 
acidic pI values may have resulted from the formation 
Figure 3.1.5: CSF total protein carbonylation is increased in PD patients and Cp is a carbonylation target. A, 
Representative gel of OxyBlot assay for carbonyl group detection. CSF total proteins from PD patients and healthy 
subjects (CN) were resolved by SDS-PAGE either after derivatization with DNPH (+) or without derivatization (-), 
and analyzed by WB with anti-DNPH for carbonylation detection. B, Ponceau red staining of the nitrocellulose used 
for OxyBlot assay shows that proteins were loaded in equal amounts. C, Evaluation of total protein carbonylation 
detected in the CSF of PD patients (n=14) and CN subjects (n=15): the y-axis indicates OxyBlot signal OD values (in 
arbitrary units) normalized by total protein loading. Data were analyzed by Student’s t test; means with SE are 
indicated (**p<0.005). D, CSF proteins from both the PD patient pool and the CN subject pool were resolved by 
2DE after derivatization with DNPH. Carbonylation was revealed with anti-DNPH antibody, and the same 
nitrocellulose membrane was further stained with anti-Cp to detect signal colocalization. E, The same analysis as in 
D, performed on a single PD patient (PD2), from whom greater amounts of CSF had by chance been collected 
showed identical results. The arrows indicate the colocalization of carbonylated spots with Cp acidic spots. 
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of sulfinic acid on some of the 15 cysteine residues 
present in Cp. These alterations are now under 
investigation. Moreover, the oxidative modifications 
that triggered Cp acidification in PD patients were 
irreversible, since neither antioxidant (200 μM 
ascorbate) nor catalase treatment reverted the 
isoform switch (Figure 3.1.6). 
3.1.6 Oxidation decreases Cp ferroxidase 
activity 
The literature reports a reduced level of ferroxidase 
activity in PD CSF [345, 346], and it is noteworthy that 
CSF ferroxidase activity mainly corresponds to Cp 
activity [7, 347]. To investigate the connection 
between oxidative modifications and Cp function, we 
analyzed the ferroxidase activity of purified Cp. We 
observed that a reduction in ferroxidase activity 
correlated with increases in H2O2 concentrations 
(Figure 3.1.7A). Apparently, ferroxidase activity 
inhibition was not complete (Figure 3.1.7A), as a 
result of the interference of the copper (Cu) atoms 
released by Cp during denaturation by oxidative 
treatment with the Btp assay [348]. As already 
reported, Cp heat denaturation leads to Cu release 
[182], and under this condition we obtained 
ferroxidase activity profiles that closely resemble 
those obtained with strong protein oxidation (Figure 
3.1.7B). A similar decrease in iron detection was 
observed in an assay that used a mere 20 nM Cu, a 
concentration that equates to the Cu concentration 
releasable after denaturation of the total amount of 
Cp used in our assay (Figure 3.1.7B). These results 
indicate that Cp oxidation impairs ferroxidase 
activity; as reported [184], this impairment induces 
structural changes that lead in turn to the release of 
Cp coordinated Cu atoms, which are necessary for 
enzymatic activity. 
3.1.7 Extracellular oxidized Cp favors 
intracellular iron accumulation 
Impairment of the extracellular ferroxidase activity of 
GPI-bound membrane 
Cp has been reported to 
block iron efflux from 
cells by 
downmodulation of 
Fpn, a membrane 
ferrous iron transporter 
[8, 174], with the 
ensuing increase of 
intracellular iron 
accumulation. We 
investigated whether 
similar iron retention 
might be induced by 
nonfunctional soluble 
Cp in dopamine 
hydroxylase-positive 
cells that do not 
express membrane 
GPI-Cp. 
Figure 3.1.6: The oxidative modifications that triggered Cp 
acidification in PD patients were irreversible. CSF from PD (15 μg of 
total proteins) was separately incubated with the antioxidant 200 μM 
ascorbate (2 hrs at 25°C under shaking conditions, 600 rpm) or the 
catalase enzyme (Sigma C30, 65 units; 16 min at 25°C under shaking 
conditions, 600 rpm). (-): untreated condition. 
 
Figure 3.1.7: Oxidation decreases Cp ferroxidase activity. A, Ferroxidase activity was analyzed by Btp assay. Purified Cp 
(1.25 μg) was incubated with 60μM FeCl3 (ferrous form) and analyzed at five different times (0, 15, 30, 45, 60 min) with a 
solution of 1 mM Btp. The decrease in absorbance at 535 nm of Btp-Fe2+ complex is due to ferrous iron oxidation into ferric 
form (Fe3+). Ferroxidase activity was also analyzed after oxidation by H2O2 treatments (1, 5, 10 mM). By way of control, the 
assay was performed in the presence of buffer alone (No Cp). Means with SE are indicated (n=5). The inset shows linear 
regression of the Btp- Fe2+ complex optical density at 535 nm with different Fe2+ micromolar concentrations.B, Btp assay 
performed with Cp after 50 mM H2O2 treatments, with heat-denatured Cp (Den Cp), and with buffer alone containing 20 nM 
Cu2+, the concentration reached by the Cu released from 1.25 μg of denatured Cp. 
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The SH-SY5Y neuroblastoma cell line was iron loaded 
by treatment with ferrous ammonium citrate (FAC) 
and with Asc in the presence of serum, and duly 
demonstrated the upregulation of the Fe storage 
protein ferritin (Figure 3.1.8A, B); extracellular iron 
was subsequently removed, and cells were further 
incubated in the medium alone (without serum), or in 
the presence either of functional Cp, or of oxidized 
Cp. In the presence of functional Cp, we observed a 
decrease of ferritin expression (Figure 3.1.8A, B), 
which, in turn, indicates functional Fe2+ exportation 
from cells. In contrast, the absence of extracellular 
ferroxidase activity (absence of Cp or presence of Ox-
Cp) witnessed high ferritin levels (p=0.0040 and 
p=0.0173, respectively), which suggests a impairment 
in iron efflux from cells (Figure 3.1.8A, B). A similar 
conclusion was inferred from the direct evaluation of 
the radioactive Fe released into the medium or 
retained in the cells. Both in the absence of Cp and in 
the presence of Ox-Cp, cells showed, in comparison 
with functional Cp, a 13–23% increase in iron 
retention (Figure 3.1.8C), and a corresponding 
reduction in Fe2+ export that ranged from 26.5 to 
46.9% (Figure 3.1.8D) (Cp vs No Cp, p=0.0325; Cp vs 
Ox-Cp, p=0.0112; Student’s t test). The reduced iron 
efflux was not paralleled by a statistically significant 
down modulation in Fpn expression level as assessed 
by WB, even though a trend of expression decrease 
was observed in the absence of extracellular 
ferroxidase activity (Figure 3.1.8A, No Cp and Ox-Cp). 
To evaluate whether Cp contribution to pathological 
mechanism is effective in primary cells, which proved 
to be more sensitive to intracellular iron 
accumulation than did the cell line model [349], we 
also tested Cp functionality on iron homeostasis in rat 
primary neuronal culture. This culture produced 
ferritin expression results that resemble those 
acquired with the dopaminergic cell line, a finding 
that in turn implies intracellular iron retention. The 
iron load, induced by treatment with FAC and Asc, 
promoted an upregulation of ferritin (Figure 3.1.7A, 
B). After iron removal, the neurons were maintained 
for 24 h in medium with low serum (1.25% derived 
from the presence of neuron culture conditioned 
medium) in the absence (No Cp) or in the presence of 
functional (Cp) or oxidized (Ox-Cp) ceruloplasmin. A 
significant reduction of ferritin expression was 
observed only in the presence of extracellular 
functional Cp (p=0.0303, Mann–Whitney test), while 
neither Ox-Cp nor No-Cp conditions were able to 
promote iron export (Figure 3.1.9A, B). The decrease 
in ferritin expression in the presence of extracellular 
functional Cp was significant compared with neuron 
invariability observed in the presence of Ox-Cp 
Figure 3.1.8: Extracellular oxidized Cp favors intracellular iron accumulation. A, SH-SY5Y neuroblastoma cells maintained in medium supplemented with 
10% FBS (CTR) were iron loaded by treatment (20 h) with FAC (100 μM) and Asc (200 μM). Extracellular iron and ascorbate were subseque ntly removed (w/o 
FAC+Asc) and cells further incubated (24 h) in the medium alone without serum (No Cp) or in the presence either of functional Cp (5  μg/ml) or of inactive 
oxidized Cp (Ox-Cp). Cell lysates resolved by SDS-PAGE were used for WB performed with anti-Ferritin (Frt) and anti-Ferroportin (Fpn); reactivity of anti-β-
tubulin (Tub) was used for signal normalization. B, Analysis of Ferritin OD normalized signals (in arbitrary units) in treated SH-SY5Y. C, Evaluation of Fe 
retained in the cells. SH-SY5Y cells were iron loaded as previously described but with 95 μM FAC supplemented with 55Fe citrate (5 μM) as a tracer. After 20 h  
incubation, the cells were washed, and one aliquot (2x10 5 cells/well, in triplicate) was kept for 100% iron-loading evaluation (FAC), while other aliquots 
were further incubated (24 h) in serum-free medium alone (No Cp), or in the presence either of functional Cp or of inactive oxidized Cp (Ox-Cp). Cells were 
then washed, lysed, and counted. Radioactive counts per minute in each well (in triplicate for each condition) were normalized on the basis of total protein 
contents and used to evaluate the differences in percentages of total intracellular iron contents. D, Evaluation of Fe released by the cells. Spent media after 24 
h incubation in serum-free medium alone (No Cp), or in the presence either of functional Cp or of inactive oxidized Cp (Ox-Cp), were collected and counted. 
Radioactive counts per minute of medium from each well (in triplicate for each condition) were used for the calculation of percentages of iron released from 
total intracellular iron loading. Data in B–D were analyzed by both unpaired ANOVA and Student’s t test; respective means with SE of five (B) and three (C, D) 
independent experiments are indicated (p values: *p<0.05; **p<0.005; ***p<0.0001). 
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(p=0.0041, Mann–Whitney test) (Figure 3.1.9A, B). The 
high variability observed with primary culture in 
multiple experiments (n=5) might be due to the 
residual ferroxidase activity in the serum. Similar 
results, albeit with lower differences, were obtained 
when primary cultures after FAC loading were kept 
only 6 h under treatment conditions in the presence 
of low serum to exclude a putative role of neuronal 
suffering during the treatment.  
We ruled out the hypothesis that astrocyte expressed 
GPI-Cp plays a role in the cocultures because 
astrocyte levels in the cultures were very low, as 
evaluated by anti-GFPA/ anti-βIII-tubulin reactivity 
ratio (range, 0.013-0.011). This estimation excludes 
also a contribution of astrocytes in the ferritin signal 
obtained in hippocampal cultures. Moreover, in pure 
hippocampal astrocyte cultures, subjected to the 
same treatments, the ferritin levels and variations 
were almost undetectable. Since GPI-anchored Cp as 
expressed by astrocytes plays a major role in brain 
iron homeostasis, we investigated whether this Cp 
isoform might also be the target of pathological 
oxidative conditions. Pure primary rat astrocytes 
exposed to oxidative conditions compatible with cell 
survival (0.6mM H2O2) showed that the GPI-Cp 2DE 
pattern profile (which differs from its soluble Cp 
equivalent [350] had shifted to a more acidic pH 
(Figure 3.1.9C). This finding indicates that astrocyte-
expressed membrane GPI-Cp undergoes oxidative 
modifications too. 
  
Figure 3.1.9: Extracellular oxidized Cp favors intracellular iron accumulation in primary neuron. A, Rat primary hippocampal neurons maintained in medium 
supplemented with 5% FBS (CTR) were iron loaded by treatment (20 h) with FAC (100 μM ) and Asc (200 μM ). Extracellular iron and ascorbate were 
subsequently removed (w/o FAC+Asc) and cells further incubated (24 h) in the medium with low serum (1.25% derived from the presence of neuronal 
culture conditioned medium) in the absence (No Cp) or in the presence either of functional Cp (5μg/ml) or of inactive oxidized Cp (Ox-Cp). Cell lysates resolved 
by SDS-PAGE were used for WB performed with anti-Ferritin (Frt); reactivity of anti-βIII-tubulin (Tub) was used for signal normalization. B, Analysis of Ferritin 
OD normalized signals (in arbitrary units) in rat primary hippocampal neuron culture. C, Membrane anchored GPI-Cp expressed by astrocytes undergo 
oxidative modifications. Pure primary rat astrocytes (Atx) were exposed to oxidation (1 h at 0.6 mM H2O2) (Atx ox), and GPI-Cp 2DE pattern profile was 
analyzed by 2DE and by WB performed with anti-Cp. Percentages indicate the amount of total Cp signal present in the regions defined by the threshold line. 
The data in B were analyzed by Mann–Whitney test; means with SE of five independent experiments are indicated (p values: *p<0.05; **p<0.005; 
***p<0.0001). 
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3.2.1 Accelerated aging of Cp under oxidative 
conditions causes deamidation of NGR 
sites 
Sequence analysis of purified Cp by tandem mass 
spectrometry (MS) showed that both 568NGR and  
 
962NGR motifs were not deamidated (Figure 3.2.1A 
and B, Untreated) and that protein oxidation by 
incubation in 10 mM H2O2 at 37°C cannot convert 
NGR to DGR/isoDGR (Figure 3.2.1A and B, ox). In 
contrast, protein incubation in 
100 mM ammonium 
bicarbonate (AmBic) or Ambic 
plus 10 mM H2O2, i.e., solutions 
that respectively mimic 
accelerated asparagine aging 
conditions (AmBic) [321] and 
accelerated asparagine aging 
under oxidative conditions 
(ox/AmBic), the 568NGR motif 
was partially deamidated 
(Figure 3.2.1A). Interestingly, 
the 962NGR motif was partially 
deamidated exclusively 
following Cp aging under 
oxidative conditions (Figure 
3.2.1B, ox/AmBic). The presence 
of Asp (D) in place of Asn (N) in 
the AmBic-treated Cp indicate 
that a deamidation reaction 
occurred at the two NGR sites of 
Cp, although MS did not 
ascertain whether DGR or 
isoDGR isoform were present.  
A possible explanation for the 
different behaviour of the 
568NGR and 962NGR motifs may 
arise from analysis of the 
crystallographic Cp structure 
(PDB 2j5W) [351], which reveals 
that the 568NGR motif is exposed 
Figure 3.2.1: Mass spectrometry analysis show that the NGR motifs are deamidated during Cp aging under 
oxidative conditions.  A) zoomed annotated ESI-MS/MS spectra of the peptide 563-570 derived from trypsin 
digestion of Cp upon different treatments: Untreated, resting conditions; ox, oxidation by Cp incubation in 
the presence of H2O2; AmBic, accelerated Asn aging by Cp incubation in the presence of Ammonium 
Bicarbonate buffer; ox/AmBic, mimicking accelerated Asn aging under oxidative conditions by Cp incubation 
in the presence of AmBic and H2O2. B) zoomed annotated ESI-MS/MS spectra of the peptide 948-964 
derived from trypsin digestion of Cp upon different treatments as in A. Only principal fragmentation series (b 
and y) are indicated. The MW, the charge state and the error of the peptides are reported. Deamidation was 
inferred by sequencing the D amino acid corresponding to N+1Da increased molecular mass. 
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on the surface of the protein, while the 962NGR motif 
is less exposed and therefore less accessible to the 
solvent (Figure 3.2.2A and B). The two sequences 
display differing tertiary contexts (Figure 3.2.2C and 
D) that might in turn influence deamidation rates 
differentially. We then attempted to clarify the 
structural differences between the two sequences by 
a computational approach. Molecular dynamics 
simulations on wild type Cp (PDB 2j5w) showed a 
relatively stable structure with large fluctuations of 
loop regions (Figure 3.2.2E). Notably, the root means 
square fluctuations, as calculated throughout the 
simulation, suggest that the two NGR sequences are 
more rigid than the other residues (Figure 3.2.2F). 
Importantly, the 568NGR sequence is steadily 
accessible to the solvent throughout the simulation, 
while 962NGR is buried inside the protein and is 
blocked in a stable conformation by polar 
interactions with neighbouring aminoacids (Figure 
3.2.2C and D). Accordingly, we hypothesized that 
oxidation might affect the Cp-structure and promote 
the exposure of the 962NGR motif, which in turn 
adopts a favorable conformation for deamidation. 
Indeed, it has been previously inferred that Cp 
structure is affected by oxidation [182, 184, 352, 353]. 
 
3.2.2 Cp oxidation induces secondary 
structure changes 
Circular dichroism (CD) spectra obtained for purified 
Cp indicated that the secondary structure of Cp, 
which is principally composed of β-strands (45,5%, as 
evaluated by Uniprot tool, 
www.uniprot.org/uniprot/P00450), was partially 
affected by Cp-Ambic treatment (Figure 3.2.2G, black 
vs. blue lines); notably, large spectra changes 
occurred upon Cp-ox and -ox/AmBic treatment, 
suggesting structural alterations (Figure 3.2.2G, black 
vs. Green vs. orange lines). Interestingly, the spectra 
profile obtained with heat-denatured Cp (Figure 
3.2.2G, red line), which showed a pronounced 
minimum towards random coil structure (~200 nm), 
differed from that of Cp obtained in -ox/AmBic 
conditions. These data suggest that Cp oxidation or 
accelerated Asn deamidation under oxidative 
conditions induce secondary structure changes but 
do not unfold the protein. Comparison of the protein 
melting temperatures (Tm) before and after the 
Figure 3.2.2: NGR-motifs structural analysis, Cp molecular dynamics modelling 
and circular dichroism analysis indicate that 962NGR is buried inside Cp structure 
and that secondary structure changes induced by oxidative conditions might 
allow its surface exposure. A and B) Surface representation of Cp, in red are 
highlighted the 568NGR and 962NGR sequences, respectively, as calculated by the 
GROMACS g_sas tool on crystallographic Cp structure (PDB 2j5W). The higher 
solvent accessible surface of 568NGR is represented by the larger size of the red 
coloured region. C and D) Cartoon representation of 568NGR and 962NGR sequences 
in Cp. The NGR aminoacids are shown in orange sticks. The hydrogen bonds are 
shown in red dashed lines. 568NGR is engaged in short range polar interactions 
between GLY and ASN, whereas 962NGR sequence is mostly involved in strong 
interactions with the rest of the protein. E) Cα root-mean square deviations 
(RMSD) from the initial Cp structure. The three different trajectories calculated by 
molecular dynamics modelling, shown in red, black and green, respectively, 
indicate a relatively stable structure. F) Cα root-mean square fluctuations (RMSF) 
of the concatenated molecular dynamics simulations (3x50 ns, 150 ns total 
simulation time). 568NGR and 962NGR are indicated with red circles. The plot shows 
large fluctuations localized in the loop regions, notably the two NGR sequences 
show a rigid behaviour, with low RMSF values along the whole simulation. G) 
Circular dichroism spectra of Cp after different treatments: resting conditions 
(Untreated, black line); accelerated Asn aging (AmBic, blue line); oxidation (ox, 
green line); accelerated Asn aging under oxidative conditions (ox/AmBic, orange 
line); and heat-denaturation (red line). Each spectrum was averaged using four 
accumulations collected in 0.1 nm wavelength intervals with an average time of 
0.5 sec. The observed ellipticity (mdeg) was converted into molar residue 
ellipticity [θ] (deg cm2 dmol-1). For each treatment the melting temperature 
(Tm) is also indicated. 
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different treatments shows that oxidation induces 
the strongest destabilizing effect, as assessed by the 
decreased Tm after oxidation (Cp= 54.2°C; Cp-
ox/AmBic= 46.5°C; Cp-ox= 40.4°C); in contrast, the 
AmBic treatment did not change the Cp 
thermostability (Cp-AmBic= 53.3°C) (Figure 3.2.2G). 
 
3.2.3 Cp aged under oxidative conditions 
binds integrins 
We investigated whether Cp’s Asn accelerated aging 
under oxidative conditions, i.e. the condition that 
may occur in some neurodegenerative diseases, can 
induce integrin binding via isoDGR formation. In vitro 
binding assays to purified integrins showed 
negligible binding of untreated Cp, while after 
accelerated Asn aging in AmBic alone or in the 
presence of oxidative conditions (-ox/AmBic), Cp 
acquired clear binding properties to αvβ5, αvβ6, 
αvβ3 and αvβ8, albeit to differing degrees (Figure 
3.2.3A). Of note, oxidation alone was ineffective. In 
the light of the observed additional increase in 
binding to αvβ6 of Cp aged under oxidative 
conditions, in comparison with Cp aged alone, and 
being the αvβ6 integrin expressed by the epithelial 
cells, this integrin was used for the further analysis. 
Interestingly, the -ox/AmBic treatment increased the 
binding to αvβ6 (Figure 3.2.3A), in a dose-dependent 
manner (Figure 3.2.3B). Competitive binding 
experiments, performed either with the isoDGR-
peptide capable to bind the RGD binding pocket of 
integrins [335] or with the control ARA-peptide, 
showed that the isoDGR-peptide is able to abolish 
the binding of oxidized-aged Cp to the αvβ6 integrin 
(student’s t-test, p<0.0001) (Figure 3.2.3C) supporting 
the role of Cp NGR-deamidation in the acquisition of 
binding activity after aging. The effect of Cp 
accelerated aging under oxidative conditions was 
also investigated by Western blot (WB) analysis. 
Untreated Cp showed a principal band of 150 kDa, as 
expected for a full-length protein (Figure 3.2.3D), 
whereas the treatment caused the appearance of an 
additional band >250 kDa. This data suggests that 
treatment may cause partial protein aggregation 
likely due to reactive succinimide intermediate 
reaction with amino-group present in neighboring 
Cp molecules [354]. Remarkably, both products, full-
length Cp and aggregates, bind αvβ6 integrin (Figure 
3.2.3D). Taken together, these results indicate that 
accelerated Asn aging under oxidative conditions 
promotes the Cp ability to bind integrins’ RGD-
binding pocket, presumably via NGR-to-isoDGR 
conversion. 
 
3.2.4 Molecular dynamics simulations and 
docking calculations indicate that 
568isoDGR-Cp can interact with αvβ6 
integrin 
Our results indicated that the accelerated Asn aging 
under oxidative conditions leads to the deamidation 
of both 568NGR and 962NGR motifs in the Cp sequence. 
Computational approaches have been exploited to 
evaluate the possibility for deamidated Cp to bind 
αvβ6 integrin. However, the experimental evidences 
reported in Figure 3.2.2, suggest that the 
deamidation of 962NGR in oxidative conditions causes 
a considerable structural re-arrangement, that cannot 
be predicted by computational methods. Thus, we 
decided to perform molecular dynamics simulation 
Figure 3.2.3: Cp aged under oxidative conditions is able to bind integrins via isoDGR-motifs. A) Screening by ELISA of the binding to several integrins of Cp 
under resting conditions (Untreated), after Asn accelerated aging (AmBic) or after Asn accelerated aging under oxidative conditions (ox/AmBic). B) Analysis 
of the dose-dependent binding to αvβ6 of untreated Cp or aged/oxidized-Cp (ox/AmBic). C) Competitive binding of aged/oxidized-Cp (Cp-ox/AmBic) to αvβ6 
with the isoDGR-peptide and control ARA-peptide. D) Western blot analysis of the Cp-ox/AmBic compared to the untreated Cp (Controls) and of the Cp-
ox/AmBic eluted from the ELISA microplate either coated (+) or non-coated (-) with αvβ6. All the assays were performed in triplicate for 3 independent 
experiments (n= 3). Statistical significance reported as p values was evaluated by student’s t-test. ****=p<0.0001, ***=p<0.001, **=p<0.01, *=p<0.05. 
 
Results 
 
39 
 
only on 568isoDGR-Cp protein in order to generate a 
set of reliable structures to be docked onto αvβ6.  
Cluster analysis on the 568isoDGR-Cp molecular 
dynamics allowed to extract a number of 
representative structures of the simulations.  A 
bundle of 27 isoDGR structures, corresponding to the 
center of the clusters, were docked onto a bundle of 
10 αvβ6 structures, which are the center of the 
clusters obtained from 10ns of molecular dynamics of 
the free αvβ6. To restrict the number of possible 
docked solutions, we defined a set of restrains (Cp-
568IAS: αvβ6-150D, 218D, 143A, 184P, 185F, 238T; Cp-569G: 
αvβ6-150D, 218D, 143A, 184P, 185F, 238T; Cp-570R: αvβ6-150D, 
218D, 143A, 184P, 185F, 238T) corresponding to canonical 
RGD- or isoDGR-integrin binding site [355] as 
suggested from competition experiments. The 
docking calculations lead to different solutions 
(Figure 3.2.4A) whereby the cluster 3, representing 
the best solution, showed that the 568isoDGR-Cp 
docked onto αvβ6 integrin recapitulates the classical 
RGD/isoDGR receptor interactions [355] and creates 
some additional interactions (αvβ6/Cp: 199S β6/ 427E, 
1.7 ± 0.1Å; 178Y αv /570R, 2.1 ± 0.1Å; 146D β6 /378K, 1.9 ± 
0.3Å; 238T β6/568IAS, 1.9 ± 0.2Å; 150D αv/570R, 1.8 ± 0.2Å; 
147D β6/562K, 1.9 ± 0.3Å)  (Figure 3.2.4B). 
3.2.5 Deamidated Cp mediates cellular 
adhesion and spreading 
The binding to integrins observed in vitro might not 
reflect the real binding properties of deamidated Cp, 
given the possibility that adsorption of purified 
integrins on microtiter plates might alter their 
conformation. Furthermore, it has been previously 
shown that the isoDGR site of fibronectin but not its 
corresponding NGR site can promote cell adhesion 
[6, 321, 335, 355]. To assess whether Cp can generate 
an isoDGR motif able to recognize integrins in 
physiological conformations, we analyzed the effect 
of Cp aged under oxidative conditions on the 
adhesion of human epithelial (HaCaT), endothelial 
(E.A.hy926) and glioblastoma (T98G) cell lines. 
Preliminary flow cytometry analysis showed αvβ6-
expression by HaCaT, αvβ3- and αvβ5- expression by 
EA.hy926 and αvβ8-expression by TG98. 
Figure 3.2.4: Molecular docking model of isoDGR-Cp/αvβ6 integrin binding site. A) HADDOCK scores versus RMSD from the lowest energy complex 
structure for docking run performed of Cp-αvβ6. Different Clusters are shown (circles) represented in different colors. They were obtained fitting the models 
on the backbone of the αvβ6-binding site and then calculating the RMSD values from the lowest energy solutions over the heavy atoms of the Cp protein. 
Structures belong to the same cluster if they differ by less than 2 Å in the pairwise RMSD matrix. The HADDOCK score corresponds to the weighted sum of 
different energy terms (van der Waals, electrostatic, and restraint energies). The cluster 3 is the best solution which is represented in panel B. B) HADDOCK 
model of isoDGR-Cp/αvβ6 integrin binding site. Surface representation of αvβ6 binding pocket (green) in complex with isoDGR-Cp (cyan cartoon). The side-
chains of the residues forming stable interactions (as reported in text) are shown in licorice. Orange spheres correspond to Cu2+ ions; magenta sphere 
corresponds to Ca2+ cation; green spheres correspond to Na+ ions. Red dotted lines denote the hydrogen bonds of the Cp with αv and β6-subunits. In 
magenta licorice is shown the 962NGR motif.  The arginine of 568isoDGR predominantly interacts with D150 of αv domain, whereas the same arginine can 
transiently interact with D218. The isoaspartyl residue of isoDGR interacts with Ca2+ MIDAS ion located in the β6 domain (see zoomed area). Other 
interactions between 568isoDGR-Cp and αvβ6 have been highlighted, in particular we noticed a strong and stable  network of salt bridges between K562 and 
K369 of isoDGR-Cp and D146 and D147 of β6 domain of αvβ6 integrin (interaction reported in text). 
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Plates coated with ox/AmBic-Cp increased in a dose-
dependent manner the adhesion and spreading of 
HaCaT cells, while untreated Cp induced little cell 
adhesion (Figure 3.2.5A and B). Cells spreading 
showed a cell’s area significant increase (p=0.0087) of 
about 20% in HaCat cells adhering to ox/ambic-Cp 
coated plates compared to cells adhering to Cp 
(Figure 3.2.5C). Similar pro-adhesive effects were 
observed with glioblastoma (Figure 3.2.5D and E) and 
endothelial cell lines (Figure 3.2.6).  To assess whether 
cell adhesion was mediated by isoDGR, we incubated 
ox/AmBic-treated Cp with PIMT (Protein-l-
isoaspartyl/d-aspartyl methyltransferase), an enzyme 
that converts L-isoAsp residues to L-Asp [321, 356]. 
PIMT treatment almost completely inhibited the pro-
adhesive activity of ox/AmBic-treated Cp and of 
isoDGR-peptide, the latter serving as a control 
(student’s t-test, p<0.0001) (Figure 3.2.5D and E). 
These results suggest that isoAsp formation, 
presumably at NGR site(s) of Cp, is associated with a 
“gain of function” in cell adhesion assays. 
 
3.2.6 Cp aged under oxidative conditions 
transduces intracellular signal through 
integrin engagement 
Having observed that Cp after accelerated Asn aging 
under oxidative conditions was able to bind integrins 
expressed on the cell surface, we investigated 
whether this binding could also induce intracellular 
signalling. Signal transduction pathway analysis, as 
performed by reverse-phase protein arrays on 
epithelial cells, indicated that cells incubation with 
ox/AmBic-treated Cp can induce coordinated 
phosphorylation events that recapitulate many of the 
steps of classical integrin-mediated signal 
transduction. Hierarchical clustering analysis of the 
comparison of treatment with either ox/AmBic-Cp or 
untreated Cp revealed that after 30 minutes: 1) there 
was an increase in the phosphorylation of the 
Figure 3.2.5: Cp deamidation mediate cells adhesion and spreading via isoDGR-
integrins interaction. A) Adhesion of epithelial HaCat cells to plates coated with 
different concentrations of either Cp (Untreated) or aged/oxidized-Cp (ox/AmBic). 
Adhesion was evaluated as adsorbance at 570nm of the crystal violet stained cells. 
B) Microscopy images of stained cells adherent to Cp-ox/AmBic, untreated Cp or 
BSA-coated plates (None). Cell spreading is visible at higher magnification showed 
in the boxes. C) Cells spreading was evaluated as pixel area automatically detected 
by image software analysis. Statistical significance was evaluated on cells 
measurement in 3 different microscopy fields for each conditions (Cp, n= 112; Cp-
ox/AmBic n=208), **p=0.0087. D) Adhesion of glioblastoma T98G cells to plastic 
coated either with BSA (None), aged/oxidized-Cp (ox/AmBic) or the isoDGR-
peptide. Inhibition of cells adhesion occurred after treatment of coating proteins 
with PIMT (+) compared to the untreated wells (-). E) Microscopy images of 
stained cells adherent to ox/AmBic-Cp treated with (+) or without (-) PIMT 
enzyme. All the adhesion assays were performed in triplicate for 3 independent 
experiments (n= 3). Statistical significance reported as p values was evaluated by 
student’s t-test; ***=p<0.0001. 
 
Figure 3.2.6 Deamidated Cp mediates cellular adhesion and spreading. Adhesion of 
human endothelial cells (EA.hy926) to plates coated with different concentrations of 
either Cp (Untreated) or Cp after accelerated aging under oxidative conditions (ox/AmBic). 
Adhesion was evaluated as wells adsorbance at 570nm of the crystal violet stained cells. 
Statistical significance is evaluated by student’s t test. 
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activation residues of several molecules e.g. p-
Tyr397FAK1, p-Thr514PKCγ, p-Ser217/221MEK1, p-
Thr185/202Tyr204ERK1/2, p-Ser241PDK1, p-Ser473Akt, and 
2) the phosphorylation of inhibitory residues e.g p-
Ser9/21GSK3β which in turn maintain β-catenin activity 
by preventing its phosphorylation (Figure 3.2.7A and 
B). Several other proteins were unaffected (such as 
CrKl, SAPK/JNK, c-Jun and Raf1) or slightly inhibited 
(PTEN and PKCα) (Figure 3.2.7A and B). These results 
suggest that early signals mediated by deamidated-
Cp mostly addressed gene activation regulation, cell 
cycle and MAPK signaling pathway (Figure 3.2.8). In 
contrast late signals (i.e. immediately after 120 
minutes of treatment) seemed to sustain actin 
cytoskeleton rearrangement rather than cell survival, 
proliferation and MAPK pathway activation (Figure 
3.2.8). Src and CrkL were activated, and the 
phosphorylation of FAK1 was inhibited, 
concomitantly with the slight phosphorylation of 
PTEN and Raf1 inhibitory molecules, which block 
MEK1 and ERK1/2 activation (Figure 3.2.7A and B; 
Figure 3.2.8). Similarly, Akt inactivation results in β-
catenin inhibition by Ser33/37/45Thr41-phosphorylation, 
as mediated by GSK3β activation (Figure 3.2.7A and 
B; Figure 3.2.8). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.7: Phosphorylation rate analysis of proteins belonging to the integrins signalling pathway as consequence of epithelial cells treatment with 
aged/oxidized-Cp. A) Hierarchical clustering analysis of the reactivity of specific antibodies assessed by reverse phase protein arrays; the columns represent 
the rate of ox/AmBic-Cp vs. Cp at two different treatment time [(Cp-ox/AmBic)/Cp 30 and 120 minutes)], while the rows represent individual protein 
residue/s phosphorylation; the up- and down-regulated residue phosphorylation rate are respectively indicated in red and green. The intensity of colour 
increases as the rate differences increase, as shown in the bar. B) Expression profiles of clustered proteins. Y axes indicate the specific residue/s 
phosphorylation rate as normalized with the total protein expression and compared with the phosphorylation level of control conditions (Cp) at 30 minutes 
treatment; X axes indicate the two different time (30 and 120 minutes) of Cp (blue) and ox/AmBic-Cp (red) treatments. 
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3.2.7 Pathological CSF from Alzheimer 
disease fosters integrin binding of 
spiked purified Cp and inhibits its 
ferroxidase activity 
To investigate whether Cp deamidation might occur 
also in vivo, in particular in pro-oxidant pathological 
CSF environment, we added purified Cp to CSF from 
healthy subjects or CSF from Alzheimer disease (AD) 
patients, and incubated the mixture for 0, 3, 6, 9 and 
12 days at 37oC. Cp was added in large amounts due 
to the presence of other integrin-binding molecules 
in CSF (e.g. fibronectin, tenascin) that can compete 
the binding of Cp. Aging in a pathological milieu was 
able to induce a time-dependent Cp significant 
binding to αvβ6 (p<0.0001) (Figure 3.2.9A, CSF/AD), 
while binding was absent or very weak when aging 
occurred in normal CSF (Figure 3.2.9A, CSF). Thus, Cp 
deamidation showed a faster kinetic in the CSF from 
AD patients then from healthy subjects. By 
comparison with the binding ability of the same 
amount of in vitro chemically aged Cp (Cp-ox/AmBic), 
we ascertained that about 40% of the added Cp was 
converted to pro-adhesive Cp after 12 days of aging 
in AD patients CSF (Figure 3.2.9B). Also in the case of 
purified Cp aging in the CSF, the gain in integrin-
binding properties was mediated by Cp deamidated 
NGR motifs, as demonstrated by competition with an 
isoDGR-peptide, which abolished binding to αvβ6 
(p= 0.0004) (Figure 3.2.9C, grey bars). To investigate 
whether the Cp aged in pathological conditions was 
also able to recognize integrins in their physiological 
conformation, we performed cell adhesion 
experiments. HaCat cells were seeded on plates 
coated with Cp immunoprecipitated from either AD 
CSF (black bars) or control CSF (white bars) at time 
Figure 3.2.8: Schematic representation of the signalling transduction throughout integrin engagement by Cp aged under oxidative conditions. Changes in 
molecules’ phosphorylation after 30 and 120 minutes of treatment with deamidated Cp suggest that early signal is address to gene activation, cell cycle 
induction and MAPK signalling pathway activation, while late signal sustains actin cytoskeleton rearrangement, and cell cycle and proliferation arrest. The 
schematic evaluation is based on the results obtained by activation signal analysis performed with reverse phase protein arrays Figure 3.2.7 and reports the 
rate of phospohrylation compared to control conditions consisting in cells treated with non-modified Cp. 
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zero or after 9 days of aging. The Cp aged in 
pathological CSF was able to promote the HaCat cells 
adhesion, whereas little or no adhesion was observed 
on Cp aged in control CSF (Figure 3.2.9D). 
Additionally to the gain of integrin binding function, 
Cp aged in AD’s CSF showed a complete loss of 
ferroxidase activity (p<0.0001), while the Cp aged in 
healthy CSF showed a reduction of about 40% (Figure 
3.2.9E, 9 days). 
  
Figure 3.2.9: Cerebrospinal fluid from Alzheimer’s diseases foster NGR-
motif deamidation and binding to αvβ6 -integrin of spiked purified Cp. A) 
Binding to αvβ6 of purified Cp added to CSF from healthy subjects (CSF, 
white squares) or AD patients (CSF/AD, Black squares) aged for 0, 3, 6, 9, 12 
days at 37°C. B) Quantitation of the Cp bound to αvβ6 integrin after ex vivo 
aging in CSF evaluated by the comparison with binding of chemically in 
vitro aged Cp (Cp-ox/AmBic, 100%). Aging from 0 to 9 days at 37°C of 
purified Cp in the CSF from AD patients (CSF/AD) showed about 40% of the 
protein binding ability to αvβ6, while the same aging conditions in th e CSF 
from healthy subjects showed negligible binding ability (3-4%). C) 
Competition with isoDGR-peptide (grey bars) of the binding to αvβ6 of Cp 
aged in CSF from healthy subjects (CSF, white bars) or AD patients (CSF/AD, 
black bars). D) HaCat cell adhesion to plates coated with 
immunoprecipitated purified Cp (5 μg/ml) after ex vivo aging (0 or 9 days) 
in CSF from healthy subjects (CSF) or AD patients (CSF/AD). Adhesion was 
evaluated as adsorbance (570 nm) of the crystal violet stained cells and 
expressed as % of control (cells in adhesion on BSA-coated wells). E) Cp 
ferroxidase activity after incubation in CSF from healthy subjects (CSF, 
white bars) or AD patients (CSF/AD, black bars). Ferroxidase activity of 
immunoprecipitated Cp (1.25 μg) was evaluated by the decrease in Btp-
Fe2+ complex absorbance at 535 nm. Values are expressed as % of total 
ferroxidase activity measured for 1.25 μg of untreated Cp. 
All the assays were performed in triplicate for 2 independent experiments, 
by using CSF from n=8 different subjects each group (see Table 5.2). 
Statistical p value was evaluated by student’s t test. ****=p<0.0001, 
***=p<0.001, **=p<0.01. 
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3.3 Cerebrospinal fluid from Parkinson’s disease promote 
oxidation, deamidation and integrin binding of spiked 
ceruloplasmin 
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In preparation
3.3.1 CSF from PD 
induces structural 
changes to spiked 
purified Cp’s 
fostering 968NGR-
motif deamidation, 
gain of integrin 
binding function, 
and ferroxidase 
activity inhibition. 
To investigate whether 
pathological PD-CSF may 
promote Cp modifications, we 
added ex-vivo the purified Cp 
to the CSF either from healthy 
subjects, peripheral 
neuropathies (PN) or PD 
patients. Cp aging from 0 to 12 
days in the CSF from PD was 
able to induce a time-
dependent Cp binding to 
αvβ6-integrin (at 9 and 12 
days, p=0.0091 and p=0.0083, 
respectively) indicating Cp-
deamidation [357], while 
binding was negligible when 
aging occurred in healthy or PN 
CSFs (Figure 3.3.1A). The gain 
in integrin-binding properties 
of purified Cp aged in PD’s CSF 
was mediated by deamidated 
NGR-motifs, as demonstrated  
 
 
 
Figure 3.3.1: Aging of purified Cp in CSF from PD patients induces changes in Cp structure and biological 
function. A) Binding to αvβ6 of purified Cp added to CSF from healthy subjects (CSF, white circles), PN patients 
(CSF/PN, gray circles) or PD patients (CSF/PD, black circles) aged for 0, 3, 6, 9, 12 days at 37°C. B) Competitive 
binding of Cp aged in CSF either from healthy (CSF) or PD (CSF/PD) for 0 or 9 days at 37°C to αvβ6 with the 
isoDGR-peptide (striped bars) and control ARA-peptide (gray bars). C) Rate of NGR-motifs deamidation. Semi-
quantitative label free protein evaluation based on the intensities of precursors performed with MaxQuant 
software on the peptides observed by mass spectrometry containing either 568NGR- or 962NGR-motif as they are 
or deamidated. Analysis was performed on resting purified Cp (CSF-0) and on purified Cp immunoprecipitated 
after 9 days of aging at 37°C either in CSF from healthy subjects (CSF-9), or PD patients (CSF/PD-9). Data are 
reported as ratio of DGR/NGR quantitation. D) Evaluation of Cp ferroxidase activity after incubation in CSF from 
healthy subjects (CSF, white bars), PN patients (CSF/PN gray bars), or PD patients (CSF/PD, black bars). Values 
are expressed as % of total ferroxidase activity measured for 1.25 μg of untreated Cp. E) Western blot analysis 
after limited trypsin proteolysis (+) of the Cp aged for 9 days at 37°C in CSF from PD patients (CSF/PD) compared 
to Cp aged in healthy subjects CSF (CSF) or in CSF from PN patients (CSF/PN). All the assays were performed in 
triplicate for 2 independent experiments, by using CSF from n=8 different subjects each group (see Table 5.4); 
in the MS-analysis experiments n=6. Data were analyzed by student’s t test; means with standard error are 
indicated (***=p<0.001, **=p<0.01). 
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by binding-competition observed using an isoDGR-
peptide (p= 0.0009), but not using a control ARA-
peptide (Figure 3.3.1B, striped and gray bars, 
respectively). Semiquantitative mass spectrometry 
(MS) analysis of spiked Cp immunoprecipited after 9 
days of aging in normal and PD CSF environments 
showed that a partial deamidation occurred at the 
568NGR-motif in the CSF from healthy subjects (Figure 
3.3.1C), likely reflecting the spontaneous 
deamidation rate of the surface exposed 568NGR-
motif; strangely, 568NGR-motif of Cp aged in PD’s CSF 
showed a very low deamidation rate. 
Interestingly, even though not significant, in PD the 
deamidation rate of 962NGR-motif, normally hidden 
inside the Cp structure [357], showed a trend of 
increase in comparison to healthy subjects (Figure 
3.3.1C,CSF/PD vs. CSF respectively), a finding which 
suggests (although MS did not ascertain whether the 
pro-adhesive isoDGR isoform was present) that Cp-
structural changes occurred in PD CSF and that the 
962NGR-motif plays a major role in the acquisition of 
the integrin binding properties (Figure 3.3.1 A and B). 
Additionally, Cp aged in PD’s CSF showed a great 
significant reduction of ferroxidase activity 
(p=0.0011), while the Cp aged in healthy or PN CSFs 
didn’t (Figure 3.3.1D, 9 days). Similarly, Cp aged in PD 
CSF showed higher sensitivity to limited trypsin 
proteolysis compared to Cp aged in healthy or PN 
CSF (Figure 3.3.1E) confirming the occurrence of Cp-
structural changes. Together these findings indicated 
that purified-Cp was modified by the pathological PD 
CSF environment. 
3.3.2 Oxidative stress contributes to 
ceruloplasmin structural changes 
Increased carbonylation of total CSF’s proteins and 
carbonylation of oxidized/acidic-Cp isoforms have 
been reported in PD (3.1.3) suggesting that oxidative 
modifications may occur during PD pathological 
events. Also the ex-vivo aging in PD CSF of spiked Cp 
showed an increase in Cp carbonylation, such 
increase was not observed if aging occurred in PN 
CSF even though a weak basal carbonylation was 
detectable in comparison to the incubation in 
healthy subjects CSF (Figure 3.3.2A, 0 vs. 9 days). 
Noteworthy, CSF of PD patients showed a significant 
higher concentration (48 µM) of H2O2 compared to 
healthy (p<0.0001) or PN (p=0.0001) CSFs (25 and 26 
µM, respectively) (Figure 3.3.2B). Finally, the 
abolishment of the gain of integrin-binding ability of 
Cp after 9 days of aging in the pathological PD CSF 
supplemented with catalase (p=0.009) indicate that 
the H2O2 present in the CSF contributed to the Cp 
gain of function (Figure 3.3.2C). As control, the 
binding ability of the already in vitro oxidized-Cp (Cp-
ox/AmBic) added to healthy subjects CSF wasn’t 
affected by the presence of catalase (Figure 3.3.2D).  
Figure 3.3.2: Cp’s modifications fostered by incubation in PD CSF are 
generated by oxidative stress. A) Detection of Cp carbonylation after 
aging in CSF from either healthy controls (CSF), PN patients (CSF/PN) or 
PD patients (CSF/PD). Carbonylation was assessed by using OxyBlot 
assay on DNPH-derivatized proteins from Cp-spiked CSF at time 0 or 
after 9 days incubation at 37°C. Western blot, performed on proteins 
resolved by SDS-PAGE, were done using either an anti DNPH or anti-Cp 
antibodies. B)  Evaluation of the hydrogen peroxide concentration in 
the CSF of healthy subjects (CSF, n=8), of PN patients (CSF/PN, n=9) 
and PD patients (CSF/PD, n=12) performed using AmplexRed®. C) 
Binding to αvβ6 of purified Cp after incubation 9 days at 37°C in the CSF 
from healthy subjects (CSF, n=8) or in the CSF of PD patients (CSF/PD, 
n=8) either in the presence (black bars) or in the absence (white bars) 
of catalase (60 μg/ml). D) Binding to αvβ6 of the in vitro oxidized Cp 
(Cp-ox/AmBic) added in healthy subjects CSF either in the presence 
(black bars) or in the absence (white bars) of catalase (60 μg/ml ). 
Statistical p value was evaluated by student’s t test, means with 
standard error are indicated (****=p<0,0001 ***=p<0.001, 
**=p<0.01). 
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3.4 The effects of deamidated ceruloplasmin on cellular 
patho/physiology 
 
3.4.1 Integrin signaling induced by 
deamidated-Cp interaction produces 
proliferation arrest in both epithelial 
and neural stem cells. 
Epithelial HaCat cells treated with Cp-ox/AmBic 
showed a proliferation reduction in the first 24 h and 
a proliferation arrest in the subsequent 24 h (Figure 
3.4.1A). The proliferation inhibition was dose-
dependent and was not observable when cells were 
incubated with untreated Cp or with control -
ox/AmBic-treated BSA (Figure 3.4.1B). Flow cytometry 
analysis assessed whether the proliferation inhibition 
was the result of apoptosis induction or of cell cycle 
blockage. In contrast with untreated cells or cells 
treated either with non-modified Cp or with 
ox/AmBic-treated BSA, epithelial cells incubated with 
aged/oxidized-Cp started to accumulate after 48 h, 
i.e. in the late-S/G2-entry phase of the cell cycle 
(Figure 3.4.2); this result suggests that cell arrest 
occurred and that it took place in the G0/G1 phase. 
The effect was more dramatic at 72 h, when very few 
cells treated with Cp-ox/AmBic were in the S phase, 
and an accumulation was observable in the G2/M 
phase (Figure 3.4.2). It is noteworthy both that the 
rate of EdU incorporation 
had already reduced in 
Cp-ox/AmBic treated 
cells at 24 h, thus 
indicating an early effect 
(Figure 3.4.2), and that a 
similar reduction was 
observed for the control 
treatments (Cp and BSA-
ox/AmBic) at 72 h (Figure 
3.4.2). In contrast with 
cell cycle, apoptosis 
induction, as assessed by 
AnnexinV staining, 
proved to be negligible 
at 24 and 48 h for all 
treatments (0.5-4.5 % of 
the cells), and started to 
be substantial at 72 h 
and exclusively for the ox/AmBic-Cp-treated cells 
(14.5% positive cells). These data confirmed the 
hypothesis derived from signaling analysis, namely 
that signaling elicited by deamidated-Cp/integrin 
interaction modulates the effect of cell proliferation 
by acting on the cell cycle. Interestingly, the blockage 
in cell proliferation upon exposure to deamidated-Cp 
was cell-specific, as it was not observed in the SH-
SY5Y neuronal cell line, whereas it was dose-
dependently evident in mouse adult subventricular 
zone neural stem cells cultured as neurospheres 
(Figure 3.4.3C) (p=0.0068). To investigate whether cell 
proliferation inhibition may be mediated also by Cp 
aged ex-vivo in pro-oxidant pathological CSF 
environment, we incubated HaCat cells for 24, 48 and 
72 h in the presence of the immunoprecipitated Cp 
aged in CSF from healthy subjects or CSF from 
Alzheimer disease (AD) patients for 0 days (w/o 
aging) or for 9 days. Growing HaCat cells with Cp 
derived from aging in AD CSF was able to reduce 
their proliferative activity (Figure 3.4.3, CSF/AD 9) 
(p=0.0091), while inhibition was absent when Cp 
from aging in normal CSF was added (Figure 3.4.3, 
CSF 9). Incubation of cells with Cp not subjected to 
Figure 3.4.1: Integrin signaling induced by deamidated-Cp interaction results in a reduction of epithelial and 
neural stem cell proliferation. A and B) Proliferation was measured by MTT assay on HaCaT, after starvation in 0.1% 
FBS containing medium. Cells were incubated for 24 or 48 h with different concentration (1, 5, 20 μg/ml ) of 
untreated Cp, aged/oxidized-Cp (Cpox/ AmBic) or aged/oxidized-BSA (BSA-ox/AmBic). Cells number was reported 
as percentages of the seeded cells. Statistical significance, reported as p value, was evaluated by student’s t test (3 
experiments with 6 replicates each). C) Short-term proliferation assay of neural stem cells (NSCs) isolated from the 
subventircular zone of postnatal day 40 FVB mice. NSCs, cells were plated (8x103 cells/cm2) in mitogen containing 
medium in the presence of either Cp, aged/oxidized-Cp or aged/oxidized-BSA (5 and 20 μg/ml). Formed 
neurospheres were collected 96 h later and total number of viable cells was assessed by Trypan Blue exclusion. 
Statistical significance, reported as p value, was evaluated by student’s t test. **= p<0.01; ***= p<0.001. 
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aging treatment (Figure 3.4.3, CSF 0; CSF/AD 0) was 
also not effective to reduce their proliferative ability. 
3.4.2 Human Choroid Plexus epithelial Cells 
characterization 
Being the epithelial cells of the choroid plexus layer 
the cells that regulate the synthesis and the 
composition of the CSF, aside from being in direct 
contact with it, we focused our attention on the study 
of the possible effects that deamidated-Cp can 
induce on their biology. The shape of the 
commercially available HCPEpiC’s is quite different 
compared to the typical polygonal epithelial shape 
(Figure 3.4.4A), and so we analysed the expression of 
epithelial cells-specific markers in order to rule out 
that the cells that we used were un-differentiated 
precursors or contaminated 
by fibroblasts. 
Immunofluorescence 
analysis showed the 
expression of choroid 
plexus-specific protein 
transthyretin (Figure 3.4.4B) 
and the Western blot 
analysis showed the 
expression of cytokeratin-19 
(an epithelial marker) and 
the absence of Vimentin 
expression (epithelial-to-
mesenchimal transition 
marker) (Figure 3.4.4C). As a 
control, HaCat epithelial cell 
line expresses the same 
markers of HCPEpiC, while 
primary fibroblasts showed 
an inverted protein 
expression (Figure 3.4.4C). 
These results suggest that, 
albeit with an altered shape, 
HCPEpi cells can be 
considered as epithelial cells 
and can be used in our 
experiments with the 
exception of cell-layer 
permeability assays, being 
reported that these cells 
were not adapt for this kind 
of experiments [358]. Furthermore, these cells 
express and secrete ceruloplasmin (Figure 3.4.4D), a 
feature exclusive (at least in the CNS) of the choroid 
plexus tissue.  
 
Figure 3.4.3 Cell cycle flow cytometry analysis of Cp-stimulated HaCat cells. After starvation, HaCaT cells were 
treated for 24, 48 and 72 h either with untreated Cp, aged/oxidized-Cp (Cp-ox/AmBic) or aged/oxidized-BSA 
(BSA-ox/AmBic) (5 μg/ml). Cells were stained with thymidine analog (EdU) in order to separate cells in S phase 
from those in G0/G1 and G2+M (y axes) and with Vybrant®DyeCycle™Violet (Invitrogen) for total DNA, 
discriminating between G0/G1 and G2 phase (x axes). Percentages of gated cells are reported: G0/G1 magenta, S 
orange, G2+M blue. 
 
Figure 3.4.2: Proliferation of HaCat cells incubating cells in 0.1% FBS DMEM with 2 μg/ml 
of purified Cp immunoprecipitated after aging (0 or 9 days at 37°C) in healthy or Alzheimer’s 
disease CSF (CSF and CSF/AD respectively). Statistical significance, reported as p value, was 
evaluated by student’s t test. **= p<0.01. 
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3.4.3 Deamidated Cp mediates HCPEpiC 
adhesion and spreading 
To assess whether Cp aged under oxidative 
conditions can bind membrane integrins expressed 
by HCPEpi cells, similarly to what we observed for the 
HaCat cell (seen in chapter 3.2.5), we analyzed the 
adhesion of the choroid plexus-
derived cells to plates coated with 
ox/AmBic-Cp. Flow cytometry analysis 
showed that HCPEpiC express αvβ3, 
αvβ5 and α5β1 integrins on surface 
membrane. The adhesion and 
spreading of HCPEpi cells on plates 
coated with ox/AmBic-Cp increased in 
a dose-dependent manner, while 
coating with untreated Cp did not 
induce cell adhesion (Figure 3.4.5A).  
Subsequently, to assess whether cell adhesion was 
mediated by isoDGR, we incubated ox/AmBic-treated 
Cp with PIMT, which converts L-isoAsp residues to L-
Asp which is not able to bind integrins: PIMT 
treatment inhibited the pro-adhesive activity of 
ox/AmBic-treated Cp (Figure 3.4.5B) (p=0.0061), 
indicating that deamidated Cp can interact also with 
the integrins present on the surface of HCPEpi cells, 
presumably through its isoDGR motifs.  
 
3.4.4 Cp aged under oxidative conditions 
transduces intracellular signal through 
integrin engagement 
In order to investigate whether the binding of Cp-
ox/AmBic to integrins expressed by HCPEpi cells 
could induce intracellular signalling like we observed 
in HaCat epithelial cells, we incubated HCPEpiC with 
either untreated or ox/AmBic-Cp stimulus, and 
analysed by Western blot the activation status of 
some molecules representative of the triggered 
integrin activation pathway already seen modified (in 
their phosphorylation rate) after HaCat cells 
stimulation (see chapter 3.2.6). 
After 120 min of treatment there was an increase in 
the phosphorylation of the activation residues of p-
Tyr397 FAK1 and p-Thr202Tyr204 ERK1/2, 
accompanied by the phosphorylation of inhibitory 
residue p-Ser9GSK3β which maintain β-catenin 
Figure 3.4.5: Epithelial cell markers expressed by HCPEpiC. (A) Cells 
showed an elongated unusual cellular shape compared to other 
epithelial cells; B) HCPEpi cells were tested by the expression of 
transthyretin (TTR); C) expression of vimentin and CK-19. Fibroblast and 
epithelia HaCat cell lysates were used as controls. D) Expression of 
ceruloplasmin in HCPEpiC cell lysate and as secreted form in the colture 
medium. 
 
Figure 3.4.4: Cp deamidation mediate HCPEpi cell adhesion via isoDGR-
integrins interaction. A) Adhesion of HCPEpiC to plates coated with 
different concentrations of either Cp (Untreated) or aged/oxidized-Cp 
(ox/AmBic). Adhesion was evaluated as absorbance at 570nm of the 
crystal violet stained cells. B) Adhesion of HCPEpi cells to plastic coated 
either with aged/oxidized-Cp (ox/AmBic): inhibition of cells adhesion 
occurred after treatment of coating proteins with PIMT (+) compared to 
the untreated wells (-). Images of stained cells adherent to ox/AmBic-Cp 
treated with (+) or without (-) PIMT enzyme are also reported. All the 
adhesion assays were performed in triplicate for 3 independent 
experiments (n= 3). Statistical significance reported as p values was 
evaluated by student’s t-test; **= p<0.01, ****=p<0.0001. 
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activity by preventing its phosphorylation. These 
results suggest that the signal mediated by 
deamidated-Cp mostly addressed gene activation 
regulation, cell cycle and MAPK signaling pathway, a 
pattern of activation that resembles the one seen in 
the HaCat cells after 30 min of stimulus (Chapter 
3.2.6). 
Figure 3.4.6: Phosphorylation rate analysis of representative proteins 
belonging to the integrins signalling pathway in choroid plexus epithelial 
cells treated with aged/oxidized ceruloplasmin (Cp-ox/AmBic);  expression 
level of focal adhesion kinase (FAK), extracellular-signal-regulated kinases 
(ERK), Glycogen synthase kinase-3 (GSK3-β) and the phosphorylation level 
of specific residues were investigated by Western blot performed on 
HCPEpi cell lysates after treatments  (30 min) with untreated Cp or 
aged/oxidized ceruloplasmin. Tubulin expression was evaluated for signal 
normalization. 
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4 Discussion 
 
Based on the first set of experimental evidences 
which revealed modifications in the CSF’ proteins of 
neurodegenerative diseases, we propose changes in 
Cp electrophoretic profile as a potential marker for 
the evaluation of oxidative stress levels in the CNS of 
PD and AD patients. This suggestion derives from the 
link between pI modification of Cp isoforms and CSF 
oxidation. The observed Cp oxidative modifications 
seem to be relevant in the neurological diseases in 
which damage is mostly confined to the brain, being 
AD patients Cp’s modifications similar (but 
distinguishable) from those observed in PD patients; 
on the contrary, ALS patients, in whom spinal motor 
neurons are involved, have not shown substantial Cp 
modifications. Alternatively, it might be that 
neurodegenerative diseases differ in the lead times 
they need before CNS oxidative damage becomes 
considerable; the analysis of CSF’ Cp oxidation during 
the progression of neurological disease could reveal 
a link between gradual CNS oxidative damage and 
specific pathological symptoms. Previous studies 
suggested a correlation of low serum Cp expression 
with the development of PD [359] and with nigral 
iron deposition [360], while other studies have 
concluded that Cp levels are not of diagnostic value 
[341, 361]. However, these studies evaluated Cp 
merely as an expression level in sera, where we have 
not found alterations: the novelty of our results, 
therefore, is that they introduce Cp isoform patterns 
in CSF as a way to discriminate between patients. 
Noticeable is, in fact, the correlation we observed 
between the PD clinical grading (UPDRS) and the 
amount of oxidized Cp, and the identification of 
representative pathological clusters by unsupervised 
pattern recognition procedures confirms the 
potential role of Cp analysis for clinical applications. 
Cp analysis in PD patients under treatment, for 
example, might be used to monitor therapy efficacy 
by modulating the iron chelator or antioxidant 
compound treatments.  
In vitro CSF oxidation induced Cp modifications 
similar to those observed in patients; moreover, CSF 
analysis of PD patients confirmed that carbonylation 
of total proteins increases and that this modification 
might affect Cp contributing, together with others 
additional oxidative modifications, to its pI shift. 
Although CSF protein carbonylation level has already 
been proposed as a marker for oxidative damage 
[344], the evaluation of Cp electrophoretic pattern 
seems to be the most sensitive technique for 
oxidative status analysis, probably due to the 
presence of six copper ions in the molecule [182]. In 
PD, imbalances between the generation of oxidant 
products and ROS scavenging systems, together with 
improper iron metabolism, contribute to neurological 
damage [362]; reduced CSF ferroxidase activity [345, 
346], increased oxidative stress in CNS, and iron 
overload in SN [363] are PD features that are 
potentially connected to the Cp oxidation here 
observed, being the functionality reduction that 
follows Cp oxidation correlated with a Cp 
electrophoretic pattern similar to that observed in 
CSF of PD. Given that CSF ferroxidase activity is 
substantially due to Cp [7], it is reasonable to 
associate the Cp oxidative modifications found in PD 
patients with the reported reduction in CSF 
ferroxidase activity [345, 346]. Furthermore, oxidative 
modification in Cp leads to copper release [182], 
possibly explaining why copper increases in the CSF 
of both PD and AD patients [346, 364]; copper ions 
are necessary for the Cp ferroxidase activity, thus 
when released from oxidized Cp impair its enzymatic 
function [184, 353]. Being similar pI shifts and 
increased carbonyl contents reported for serum Cp 
during aging [184], the changes observed in this 
work in CSF Cp from PD and AD patients might 
reflect accelerated protein aging induced by 
oxidative pathological conditions [365]. Iron 
metabolism impairment is the major consequence of 
the loss of Cp activity. Indeed, both 
aceruloplasminemia patients and the Cp-deficient 
mice are characterized by an increase in intracellular 
iron that correlates with motor dysfunction [123, 
366]. Intracellular iron concentration is controlled 
both by the storage protein ferritin, which 
accumulates Fe3+, and by Fe2+ efflux through Fpn 
accompanied by Cp extracellular ferroxidase activity 
[7]. In our experimental model, the absence of 
extracellular ferroxidase activity as a result of Cp 
oxidation leads to cellular iron retention both in SH-
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SY5Y cell line and in primary neuronal culture, which 
is more susceptible to intracellular iron accumulation 
than the cell line counterpart [349], a feature that 
presumably better reflects what occurs in vivo under 
pathological conditions. The weak Fpn down 
modulation and the lack of a complete intracellular 
iron retention that we observed suggested the 
presence of compensatory mechanisms. One of these 
may consist in the described role of the β-amyloid 
precursor protein (APP), which like Cp is expressed in 
trans-membrane and secreted forms, and has been 
reported to exert ferroxidase activity that in turn 
promotes neuronal iron export through the Fpn 
[189]. Also the inhibition of APP-ferroxidase activity 
results in neuronal iron accumulation, suggesting 
that various molecules in varying tissues and 
pathologies may share the same function. The iron 
retention we detected in the absence of extracellular 
ferroxidase activity might be generated by Fpn 
functionality impairment rather than by membrane 
down modulation. This explanation is supported by 
data reporting that Fpn expression does not change 
in the absence of extracellular ferroxidase activity in 
cells that do not express membrane GPI-Cp [8], as is 
the case in the neuroblastoma cell line we used. It has 
been proposed that 60% of brain ferroxidase activity 
derives from the membrane GPI-Cp isoform, which is 
expressed by astrocytes, and 40% from APP, which is 
expressed by neurons [189]. However, account must 
also be taken of the ferroxidase activity exerted by 
the soluble forms of Cp and APP contained in CSF, 
which permeates the brain. We hypothesize that 
increases in oxidative stress in PD patients, both at 
neuronal and CSF levels, induce the reduction of 
extracellular ferroxidase activity through the 
oxidation both of membrane-bound and of soluble 
Cp; in turn, this reduction might contribute to the 
iron loading observed in SN [360, 367]. The possibility 
that Cp plays a role in PD implies in the future the 
analysis of GPI-Cp expression and modifications on 
astrocytes, because this isoform is the predominant 
in the brain and can be modified too by oxidative 
environment. Interestingly, GPI-Cp has been reported 
to be down modulated by oxidative stress in 
astroglial cells, and as such to contribute to 
intracellular iron deposition [368].  
Considering that Cp showed oxidative modifications 
in the CSF of neurodegenerative diseases, we 
decided to investigate specific post-translational 
modfications fostered by oxidation. Among these, 
the asparagine (Asn) deamidation that leads to the 
formation of aspartate (Asp) and isoaspartate 
(isoAsp), resulted to be particularly intriguing 
because occurs in vivo during protein aging [309] 
and is accelerated under oxidative conditions [369]; 
aging under oxidative conditions is the condition 
that we hypothesise occurs for proteins in the CSF of 
AD and PD patients. The second reason that made 
Asn deamidation interesting was the fact that if it 
occurs at the level of the NGR-motif can give rise to 
the acquisition of integrin-binding function [6], and 
the Cp sequence contains two NGR-motifs in its 
amino acidic sequence. Thus we decided to evaluate 
in vitro primarily and successively ex-vivo whether 
this kind of modifications may occurred in Cp. 
The results of this second part of investigations 
demonstrated how AD and PD CSF favor Cp 
deamidation and how this effect manifests as a 
functional gain in cells-integrin binding with an 
intracellular signal transduction. This new pro-
adhesive function is derived from the deamidation at 
the NGR-sites within Cp, in particular the 962NGR, 
whose deamidation is promoted by prolonged 
oxidative conditions. Since asparagine deamidation 
during protein aging depends on neighbouring 
residues as well as on secondary and tertiary 
structural elements and by environmental factors 
such as pH, temperature and ionic strength [307, 
370], the combination of these features controls the 
kinetic of deamidation reactions, ranging from hours 
to years [307, 370]. Thus, for each protein it is 
important to assess whether specific Asn residues can 
undergo or not this post-translational modification: 
for example, the deamidation of an NGR-site of 
fibronectin and the consequent formation of isoDGR 
can work as a molecular switch for integrin-ligand 
recognition and does not occur in the intact protein, 
whereas it can rapidly occur in protein fragments 
[321]. It is of relevance that, in contrast to fibronectin, 
the binding to integrin occurs for the intact full 
length deamidated-Cp.  
Our results show that deamidation of the 568NGR-site, 
which is exposed on the protein surface, does not 
require structural changes. In contrast, deamidation 
of the 962NGR-site, which is buried inside two β-
strands of the protein structure and is blocked in a 
stable conformation by polar interactions with 
neighbouring aminoacids, can occur only after 
structural changes induced by an oxidative 
microenvironment. Conformational changes similar 
to those we reported after protein oxidation have 
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been described for Cp in the absence of copper ions 
[353]. 
The NGR-to-isoDGR conversion in Cp induces a gain-
of-function in terms of binding to several αv-integrins 
and the interaction of deamidated Cp with integrins 
can trigger an intracellular signalling cascade. 
Consistently with binding data, our docking studies 
show that at least the 568isoDGR motif of intact Cp can 
interact with the canonical RGD binding pocket of 
the αvβ6, having the stereochemical and electrostatic 
requirements for a correct recognition. Since it is not 
possible to predict a priori the putative structural 
rearrangement induced by the oxidation, we cannot 
describe in silico the possible interactions occurring 
between integrin and the 962isoDGR sequence in the 
context of full-length Cp. These findings, together 
with the high conservation of these tripeptide-
sequences across differing species from hamster to 
human (Figure 4.1), suggest that the Cp deamidation 
can produce a relevant biological gain-of-function. 
Remarkably, very few substitutions in various species 
were also shown in the 962NGR flanking sequences, 
which, as said above, are likely crucial for regulating 
the deamidation rate.  
Cp’s NGR-deamidation might occur in a relevant 
manner in certain pathological conditions, as 
suggested by the observation that Cp aged ex vivo in 
the CSF from AD and PD patients acquires integrin-
binding and cell adhesion properties. The faster 
kinetic of Cp-deamidation observed in CSF from AD 
and PD patients compared to the CSF from healthy 
subjects, supports the hypothesis of a generally 
accelerated protein aging in neurodegenerative 
diseases, as a consequence of pathological 
environment [4, 365]. Based on the observation that 
after 12 days of aging in the pathological CSF about 
40% of the Cp was able to bind integrin, and given 
that the Cp concentration in the CSF is about 2 μg/ml 
and that its physiological half-life is of about 5.5 days 
in vivo [342], it is conceivable that NGR deamidation 
might occur in patients to an extent that yields 
functionally relevant concentration of deamidated-
Cp (about 200 ng/ml). The observed Cp’s 
modifications suggest the presence of pro-oxidant 
compounds in patients CSF: the hydrogen peroxide 
concentration and the evidence that catalase 
prevents the acquisition of Cp integrin-binding 
properties in CSF suggest that H2O2 (known to be 
produced in neurodegeneration [371] can be one of 
them. However, an in-depth investigation of the 
differential composition of healthy and AD/PD CSFs, 
along with the identification of the crucial factors 
underlying increases in deamidation rates, are 
required. The ex vivo gain of function, besides making 
Cp-modifications an effective marker for the 
deleterious environment in patients, arises warnings 
about the therapeutic use of intravenous Cp-
administration proposed by Ayton and colleagues in 
order o reduce the iron accumulation at the brain 
level. In fact, in PD mice model Cp-administration 
ameliorated the pathological signs with a  reduction 
of iron deposition and neurodegeneration [372]. 
However, the proposed 
therapeutic usage of Cp 
in human must be 
carefully evaluated in 
the light of the reduced 
ferroxidase activity that 
can be fostered in the 
CSF and taking into 
account the possible 
side-effect due to the 
acquisition of integrin 
binding function. 
Referred to the latter, 
Cp-administration 
might be done, for 
example, in 
combination with 
helpful molecules like 
the isoDGR repairing 
enzyme PIMT. 
Figure 3.4.1: Analysis of the conservation of the Cp’s NGR motifs in different species, performed with ClustalX software 
(Conway Institute UCD, Dublin; www.clustal.org). The functional relevance of the Cp’s NGR motifs is underlined by their 
conservation along species; in particular the 962NGR motif is inserted in an amino acids stretch that shows very few 
substitutions. 
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As said before, since protein aging under oxidative 
stress is a condition that may occur in some 
neurodegenerative diseases [4, 373], we hypothesize 
that Cp aging under pathological conditions 
promotes modifications that favour structural 
changes which in turn foster both NGR-deamidation 
and Cu-ions release which subsequently results in 
loss of ferroxidase function and gain in integrin 
binding properties. Such Cu ions release from Cp 
might contribute to the reported increase of the pool 
of free-Cu and to the decrease of active Cp found in 
the CSF of AD patients [297, 299, 364]. Moreover, it is 
conceivable that this increase, affecting the redox 
environment [374], might contribute to the observed 
Cp modifications by a feed-back mechanism, 
facilitating Fenton's reaction and amplifying general 
protein damage [182]. The observed loss of 
ferroxidase activity of Cp aged in AD and PD CSF 
suggests again that changes in the Cp structure can 
be fostered also ex vivo. Given the role of Cp, 
ferroxidase activity reduction may affect the iron 
homeostasis [366], causing an increase in iron 
retention. A relationship between oxidation and 
protein deamidation in neurodegenerative disease is 
also suggested by the observation that several 
proteins found to be deamidated in the brain of 
PIMT-knock out mouse were oxidized in the brain of 
AD patients [356]. Thus, the Cp alterations observed 
in PD and AD patients might reflect accelerated 
protein aging, as a consequence of changes in the 
environmental redox status of pathological CSF [4, 
365]. Therefore, it is plausible that the reported Cp 
oxidation-induced changes also in vivo include Asn 
deamidation of NGR-motifs. Literature reports that 
Cp immunostaining on neurons was observed both 
in neurodegenerative diseases [375] and in ischemia, 
all of which generate reactive oxygen species [376]. 
However, Cp cellular expression is known to be 
restricted to astrocytes [342]; the reported neuronal 
staining may therefore be the consequence of the 
acquisition by Cp of integrin-binding properties 
[376]. Oxidative aggregation of Cp induced by H2O2 
has been reported [377], as the cooperative effect of 
Cp and H2O2 in inducing α-synuclein aggregation, 
which may have a role in PD [378]. It would be of 
interest to investigate in future whether the Cp 
aggregates we observed to be formed in vitro as 
consequence of aging under oxidative conditions, 
might have pro-fibrillogenic properties that can be 
favoured by asparagine deamidation, as is the case 
for β-amyloid in AD [369]. 
It is well known that integrin binding may activate 
intracellular signaling cascades, which in turn can 
affect cell differentiation, survival, growth and 
division [379]. Literature reports that an aberrant 
signalling mediated via integrin (e.g. αvβ1, α2β1, 
αvβ3 and αvβ5) engagement by fibrillar β-amyloid in 
the CNS resulted in an unconventional FAK activation 
and its down-stream signalling (i.e. MAPK, GSK3β 
etc.). This mechanism can lead to cell cycle arrest in 
the G1/S transition, neuronal dystrophy and death 
[380, 381]. A similar signalling mechanism is triggered 
by deamidated-Cp: after 2 hours of cell incubation 
with in vitro oxidized/aged-Cp, we observed an 
inhibition of FAK and MAPK signalling, which 
subsequently led to cell cycle arrest in the G0/G1 
phase and to proliferation inhibition in epithelial and 
neural stem cells. Thus, even when β-amyloid fibrils 
are absent, as in PD, deamidated-Cp might induce 
similar, detrimental effects. In addition, we 
demonstrated that not only the in vitro deamidated-
Cp, but also the protein deamidated ex vivo in the 
CSF of AD patients, is able to cause a proliferation 
arrest of epithelial cells.  It is interesting that the 
cellular integrin expression pattern can itself be 
modulated by the oxidative pathological 
environment [382], and thus alters cellular signal 
sensitivity. Various cell types in the CNS might be 
activated via integrins, including microglial cells, 
which contribute to the inflammation mechanisms in 
neurodegenerative diseases [383]; interestingly, it has 
been reported that Cp can activate microglial cells 
[305], although the receptor underlying this 
mechanism has not yet been identified: one 
possibility is that deamidated Cp interacts with 
integrins. Experimental evidence supports the idea 
that niches of neural stem cells (NSC) are in deep 
contact with the ependymal layer [384]. Thus, 
disruption of, or functional alteration to, both the 
ependymal epithelium and neural stem/progenitor 
cells, may alter the balance in CNS cells between 
injury and self-repair, and thus force the system 
toward neurodegeneration [385]. In this perspective, 
we can speculate that, in addition to alterations in 
epithelial cells, the observed inhibition of NSC 
proliferation as induced by the pro-adhesive 
deamidated-Cp might exert a deleterious in vivo 
effect on reparative systems, and thus facilitate 
neurodegeneration. An anomalous engagement of 
NSC’s integrins might also interfere with NSC-niche 
organization, as well as with functions that are 
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mediated by interaction with the extracellular matrix 
[27, 386].  
Further potential targets for deamidated Cp include 
the specialized epithelial cells of the ependymal layer 
and choroid plexus, which are directly in contact with 
the CSF. Morphometric and functional alterations to 
choroid plexus epithelia have been reported as age-
related deficiencies that are exacerbated in AD by β-
amyloid accumulation, which in turn can lead to CSF 
barrier dysfunction [387, 388]. Thus, the epithelial cell 
proliferation blockage and the cell cycle arrest we 
observed as consequences of deamidated-Cp 
treatment might approximate the detrimental effect 
that occurs in vivo on choroid plexus epithelia. Our 
characterization of the commercial line of human 
primary choroid plexus epithelial cells (HCPEpiC) 
allow us to perform, in the next future, proliferation, 
secretion and barrier-maintenance experiments after 
deamidated-Cp stimulation also on this highly 
specific cell type.  
In conclusion, our findings suggest that Cp oxidation 
in soluble and possibly in GPI-Cp forms might play a 
role in the pathogenesis of PD by contributing to iron 
dismetabolism, and that Cp should possibly be taken 
into consideration as a putative target of antioxidant 
therapies [182], though Cp ex vivo modifications 
suggest to keep the therapeutic approach aimed to 
the prevention of the upstream events occurring in 
patients rather than the Cp replacement; the study of 
these events (which can be responsible also of other 
protein-modifications seen in PD patients, like α-syn) 
would be important for the understanding of the 
pathology and for the design of a therapy which can 
be beneficial not only for the Cp activity alone, but 
for the CNS activity in toto. The putative pathogenic 
role of Cp is mirrored by variations in patient CSF Cp 
electrophoretic patterns, variations that, correlating 
with disease stage, can be considered as potential 
markers for the evaluation of oxidative damage in the 
CNS. Our results show also that Asn deamidation, 
which may occur in Cp upon aging, can convert this 
protein into an isoDGR-containing ligand of αv 
integrins, which can transduce an integrin-mediated 
intracellular signalling. In particular, oxidation-
induced structural changes foster the NGR-to-isoDGR 
transition at the NGR site buried in the protein 
structure. Even though the mechanism we described 
results from mainly in vitro observations, the ex vivo 
evidences that the CSF from AD and PD patients 
promotes Cp deamidation suggest that Cp 
modifications might occur also in patients. Further 
investigations are needed to assess the biological 
role of in vivo Cp-deamidation, and the consequences 
for neurodegenerative diseases. The Cp alterations 
induced by the pathological oxidative environment, 
might contribute to the pathological mechanisms of 
neurodegeneration via two distinct processes (Figure 
4.1): firstly, the described loss of ferroxidase function 
and consequent intracellular iron retention and 
secondly, by a de novo functional gain in integrin 
binding that enables transduction of an 
anomalous/unwanted intracellular signaling, which 
might represent a novel pathological mechanism 
that affects several cell types.  
Figure 3.4.2: schematic representation of the mechanism of action of the deamidated-Cp we purpose. 
 
Materials and methods 
 
55 
 
5 Materials and methods 
5.1  Methods related to Chapter 1 
results 
5.1.1 Patients  
Having secured approval from the ethical review 
board of the hospital, and informed consent from 
patients, CSF samples (0.8–1 ml) were collected by 
means of lumbar puncture in the framework of the 
Institute of Experimental Neurology INSPE-BioBank 
(San Raffaele Scientific Institute, Milan). The analyzed 
groups were as follows: sporadic PD (n=14; 8 males 
and 6 females), sporadic amyotrophic lateral sclerosis 
(ALS) (n = 16; 5 males and 11 females), peripheral 
neuropathies (PN) (n = 13; 8 males and 5 females), 
Alzheimer’s disease (AD) (n=14; 5 males and 9 
females), and healthy controls (CN) (n=15; 7 males 
and 8 females). Table 5.1 summarizes the 
demographic and clinical features of the patients and 
control subjects enrolled on this discovery study. All 
patients were at first diagnosis and drug-free. Current 
criteria for the diagnosis of PD [389], of ALS [390], and 
of AD [391] were used for the admission of patients 
into the study. PN diagnosis was as described by 
Conti et al. [392]. The Unified Parkinson’s Disease 
Rating Scale (UPDRS) [393, 394] was used to grade  
 
 
the disease. ALS and PN samples were from aliquots 
collected for previous studies [350, 392]. Exclusion  
criteria consisted of the following: HIV or HCV 
(hepatitis C virus) seropositivity, the appearance of 
other neurodegenerative diseases or previous 
cerebral ischemic events, and severe metabolic 
disorders (e.g., diabetes). Control CSF was obtained 
from patients who underwent lumbar puncture on 
account of a suspected neurological disease and who 
proved to be normal and free from pathological 
alterations after complete CSF analysis and thorough 
clinico-neuroimaging assessment. Sample selection 
ensured that age and gender distributions were 
homogeneous with those of the PD patients. 
5.1.2 Two-dimensional electrophoresis, 
Western blot and image analysis  
Immediately after collection, the CSF samples were 
centrifuged at 4°C to eliminate cells, and protein 
concentrations were determined. The samples were 
then either immediately processed, or stored at -80°C 
in an N2-supplemented atmosphere to avoid 
oxidation. Protein samples (30 μg) were resuspended 
in twodimensional electrophoresis (2DE) buffer (8 M 
urea, 4% w/v CHAPS, 65 mM DTT, 0.2% v/v IPG buffer 
3-10NL, and applied to 7 cm IPG strips pH 3-10NL (GE 
Table 5.1: Demographic and clinical features of patients and controls. Gender: No statistical differences among groups (Fisher’s exact test). Age: No 
statistical differences among groups (Student’s t test). Protein concentration [C]: No statistical differences among groups except for PD versus ALS, p=0.008, 
and PN versus ALS, p=0.020 (Mann–Whitney test). [C], CSF total protein concentration. 
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Healthcare). The 2DE separations were performed as 
described by Conti et al. [350]; briefly, focusing was 
performed with an IPGphor system (GE Healthcare) at 
50 μA max each IPG strip with a gradient voltage 
(5000 V max) for a total of 30 k•Vh. Strips were 
equilibrated for 15 min in 50 mM pH 8.8 Tris-HCl 
buffer containing 6 M urea, 30% glycerol, 2% SDS and 
2% DTT, then for 15 min in the same buffer replacing 
DTT by 2.5% iodoacetamide. The strips were then 
transferred onto 10% acrylamide SDS-PAGE gels for 
the second dimension separation. Proteins resolved 
by 2DE or by SDS-PAGE were electrotransferred onto 
nitrocellulose membranes and Western blot (WB) was 
performed as described by Conti et al. [350] 
incubating the membranes, previously blocked with 
5% dry-milk in TBS, 1h at 20°C with a sheep anti-
human Cp antibody (Abcam) diluted in 5% milk-TBS. 
After washing with 0.5/milk-TBS, the reactivity was 
revealed by incubation (1h at 20°C) with secondary 
donkey-anti-goat Ig antibody conjugated with horse 
radish peroxidase (Abcam) followed by enanched 
chemiluminescence (ECL, GE-Healthcare) reaction 
and films exposure.Images were acquired by means 
of a laser densitometer (GE Healthcare), and 
evaluation of relative abundance of Cp isoforms 
consisted in the analysis of optical density 
normalized to percentage by means of Progenesis 
PG240 software (Nonlinear Dynamics). 
5.1.3 CSF oxidation by treatment with Fe-
citrate and H2O2  
Proteins (100 μg) were oxidized by incubation (3 h at 
37°C) with differing concentrations of hydrogen 
peroxide (1, 5, and 10 mM) and were subsequently 
resolved by 2DE or SDS-PAGE; Cp profile was 
identified by WB. For the assessment of correlation 
between specific oxidative modifications 
(carbonylation) and Cp pI shift, CSF proteins were 
incubated (5 h at 37°C) with 25 mM sodium ascorbate 
with or without 100 μM ferrous chloride to induce 
protein carbonylation (as indicated by the OxyBlot kit 
manufacturer) [184]. Carbonylation was analyzed by 
means of the Oxy-Blot Protein Oxidation Detection 
Kit (Millipore Bioscience Research Reagents) on the 
basis of carbonyl group derivatization with 2,4-
dinitrophenilhydrazine (DNPH).  
Cp carbonylation was analyzed in two pools of CSF 
that were harvested from all PD patients and from CN 
subjects, respectively. Equal amounts (5 μg) of CSF 
proteins were taken from each patient to generate a 
total 70 μg of proteins per pool. After derivatization 
with DNPH, proteins were resolved either by 2DE or 
by SDS-PAGE, and carbonyl groups were detected by 
Western blot with an anti-DNPH antibody, while Cp 
profiles were detected by means of an anti-Cp 
antibody on the same nitrocellulose membrane. 
5.1.4 Bathophenanthroline assay 
Cp ferroxidase activity was analyzed by 
bathophenanthroline (Btp) assay. Purified Cp (1.25 
μg) (Alexis) was incubated with 80 μM FeSO4 (ferrous 
form) and analyzed with a solution of 1 mM Btp in 
acetate buffer, pH 6.2, at five intervals (0, 15, 30, 45, 
and 60 min). Decrease in Btp-Fe2+ complex 
absorbance at 535 nm derives from ferrous iron 
oxidation into ferric form (F3+). Cp ferroxidase activity 
was also analyzed after in vitro oxidation by hydrogen 
peroxide treatment, as described above (1, 5, 10 mM 
H2O2; Cp vs H2O2 molar ratio, 1/3000, 1/15,000, 
1/30,000, respectively), and after heat treatment 
(99°C for 30 min). To identify the interference of 
copper released during protein 
oxidation/denaturation, we performed Btp assay 
without Cp, but in the presence of 20 nM Cu. 
5.1.5 Cell cultures and iron challenge 
The human neuroblastoma SH-SY5Y (American Type 
Culture Collection) was cultured (37°C in a 5% CO2 
atmosphere) in a 1:1 mixture of Eagle’s Minimum 
Essential Medium (ATCC) and F12 medium (ATCC) 
supplemented with 10% fetal bovine serum.  
Primary rat hippocampal neurons (~80% purity) or 
pure astrocytes were prepared from 2- to 3-d-old 
Sprague Dawley rats, in respective accordance with 
Codazzi et al. [395] and Bettegazzi et al. [396]. The 
Institutional Animal Care and Use Committee of the 
San Raffaele Scientific Institute approved the 
experimental procedures. Briefly, after subdivision of 
hippocampus matter into small sections, the tissue 
was incubated into Hanks solution that contained 3.5 
mg/ml trypsin type IX (Sigma-Aldrich) and 0.5 mg/ml 
DNase type IV (Calbiochem). After mechanical 
dissociation, cells were plated onto poly-ornithine-
coated coverslips and maintained in MEM 
supplemented with 5% fetal calf serum, B27 
supplements (Invitrogen), and 3 μM Ara-C (1-β-D-
cytosinearabinofuranoside) (Sigma-Aldrich). Neuron 
cultures were maintained at 37°C in a 5% CO2 
humidified incubator and used as of 8-10 d from 
plating.  
Pure astrocytes were grown in MEM supplemented 
with 10% horse serum. Two steps of overnight 
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shaking at 230 rpm were performed to induce 
selective detachment of microglia. Upon 
achievement of confluence, astrocytes were 
trypsinized and replated onto poly-lysine-coated 
plastic multiwells. Experiments were performed 
within 3 d of replating. Protein expression was tested 
in cell lysates by WB as realized with anti-H-Ferritin 
[397] (donated by Dr. S. Levi, Vita-Salute San Raffaele 
University, Milan, Italy) and with anti-Ferroportin 
(Fpn) (Abcam). To induce iron loading, cells were 
cultured for 20 h in a medium containing 10 and 5% 
serum for the SH-SY5Y cell line and the primary 
culture, respectively. The medium was supplemented 
with ferric ammonium citrate (FAC) (100 μM) and 
with ascorbic acid (200 μM) to cause iron reduction 
and its internalization by DMT1 transporter. 
Extracellular iron and ascorbate (Asc) were 
subsequently removed, and the expression of 
ferroportin and ferritin were analyzed after further 
cell incubations (24 h), either with serum-free 
medium for SH-SY5Y or with low serum (1.25% 
derived from the presence of neuron culture 
conditioned medium) for primary neuron, in the 
absence of Cp or with functionally active purified Cp 
(5 μg/ml), or with inactive oxidized Cp. This latter was 
obtained by treatment with 5 mM hydrogen 
peroxide, as described above. Iron loading was also 
monitored through evaluation of 55Fe retained in, and 
released by, the SH-SY5Y cells. SHSY5Y cells (2 x 105 
cells/well, in triplicate) were iron loaded, as 
previously described, with FAC (95 μM) 
supplemented with 5 μM 55Fe-citrate (PerkinElmer) as 
a tracer. After 20 h incubation, the cells were washed, 
and one aliquot was kept for iron-loading evaluation 
and considered as 100%, while other aliquots 
underwent further incubation (24 h) in 250 μl of 
serum-free medium containing 60 μM apo-transferrin 
(Sigma-Aldrich), with or without extracellular 
ferroxidase activity, as previously described. After 24 
h of incubation, media were collected, and cells were 
washed and lysed. Media (50 μl) and cell lysates (10 
μl) were each mixed with 0.5 ml of Ultima Gold 
(Packard) and counted (3 min) in a scintillation 
counter (Packard). Total protein content of cellular 
extracts was used to normalize radioactive counts 
both of lysates and of related media. Results were 
used to evaluate the differences in percentages of 
total iron contents.  
To determine whether GPI-anchored membrane Cp 
as expressed by astrocytes was also susceptible to 
oxidation, we cultured pure rat astrocytes primary 
cultures either under resting conditions or upon 
treatment for 1 h with 0.6 mM H2O2. Cell lysates (30 
μg) were then analyzed by 2DE and WB to reveal the 
Cp electrophoretic pattern.  
5.1.6 Densitometric analysis 
Anti-Cp reactivity was quantified by laser 
densitometric analysis (GE Healthcare), as normalized 
by protein loading and total protein staining. The 
distribution of the Cp isoforms was evaluated by 
densitometric analysis of 2D spot optical density, 
which in turn was normalized as a percentage of total 
anti-Cp antibody reactivity. Signals obtained from 
OxyBlot were quantified by means of densitometric 
analysis and normalized by total protein loading. 
Ferritin expression was evaluated by densitometric 
analysis, and normalized by β-tubulin expression for 
SH-SY5Y cell line, and by βIII-tubulin expression for 
primary neuron.  
5.1.7 Statistical analysis  
Gender distribution was assessed by 2 x 2 
contingency table analysis, which in turn used 
Fisher’s exact test and two-tailed p value. Continuous 
data (age distribution, CSF protein concentration, 
and spot/band volume) were evaluated by unpaired 
Student’s t test, if the data passed the normality test 
for Gaussian distribution as assessed by the 
Kolmogorov-Smirnov test, or were evaluated by 
Mann–Whitney test; two-tailed p value was used for 
the comparison of two means and SE. Parametric 
one-way ANOVA was used to evaluate the statistical 
difference between three or more independent 
groups; postanalysis performed with Tukey’s 
multiple-comparison tests was included. The receiver 
operating characteristic (ROC) curve was used to 
define the ability of the assay to discriminate 
between groups, and to define the threshold value at 
which optical density (OD) gave the best ratio 
between sensitivity and specificity. Correlation 
analysis was evaluated as Pearson’s coefficient (r). In 
all analyses, p<0.05 was considered to be statistically 
significant. The analysis was performed with Prism, 
version 4.03, software (GraphPad).  
5.1.8 Image processing and unsupervised 
machine learning techniques for 2DE-
Western blot image analysis (performed 
by Eng. C. V. Cannistraci)  
Denoising was executed by nonlinear spatial 
adaptive image filtering, and background removal 
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was obtained by 3D-morphological operators [398]. 
After preprocessing, each 2DE-WB image was aligned 
by raw vectorization of its pixel intensity; each pixel 
intensity accordingly became a feature in a vector 
that characterized the Cp image sample. To 
implement the subsequent machine learning 
analysis, features (pixels) with small profile variance 
were filtered out to reduce the number of low 
informative features [399]. Classification of Cp 
profiles was provided by the combined application of 
(1) unsupervised machine learning approaches 
designed to reduce linear dimensionality and 
executed by principal component analysis, and of (2) 
minimum curvilinear affinity propagation (MCAP) as a 
method for clustering analysis [400]. Said tool was 
applied to the two-dimensional projection space 
obtained as the outcome of dimensionality 
reduction. 
 
5.2  Methods related to Chapter 2 
results 
5.2.1 Patients 
For detailed description see chapter 5.1.1.  The 
analysed groups were: Alzheimer’s disease patients 
(AD, n= 16) and healthy controls (CN, n= 16). Table 
5.2 summarizes the demographic and clinical 
features of the patients and control subjects enrolled 
on this discovery study. 
5.2.2 Cell cultures and reagents 
Human glioblastoma T98G, keratinocyte HaCaT and 
endothelial EA.hy926 cell lines (America Type Culture 
Collection, ATCC) were cultured (37°C in a 5% CO2 
atmosphere) in DMEM medium (ATCC) 
supplemented with L-glutamine, and 10% fetal 
bovine serum (FBS). Human integrins α5β1, αvβ3, and 
αvβ5 (Immunological Sciences), recombinant αvβ6 
and αvβ8 (R&D System), and human plasma purified 
Cp (Alexis Biochemicals) were used. 
5.2.3 Oxidation and asparagine accelerated 
aging treatments 
Oxidation and accelerated Asn-aging treatments 
were performed by incubating purified Cp at 37°C in 
various buffers as described below. Oxidized Cp was 
prepared incubating for 16h at 37°C Cp (1 mg/ml) in 
PBS buffer containing 10 mM H2O2 solution. 
Deamidated Cp was prepared incubating for 16h at 
37°C Cp (1 mg/ml) in 100 mM ammonium 
bicarbonate (AmBic) buffer, pH 8.5. This condition is 
known to favour Asn deamidation at the NGR site 
[321]. Before use in the assays Cp was dyalized 
against PBS using Slide-A-lyzer dialysis cassette 10K 
MWCO (Pierce Biotechnologies). Oxidized and 
deamidated Cp was obtained by combining the 
above treatments. Aging 
of Cp in CSF was 
performed by adding 
purified-Cp (20 μg/ml, 
final concentration) to 
CSF either from healthy 
subjects or from AD 
patients. CSF samples 
Table 5.2: Demographic and 
clinical features of patients and 
controls.Gender: no statistical 
differences among groups 
(Fischer’s exact test). Age: no 
statistical differences among 
groups (Mann-Whitney test). 
Protein concentration [C]: no 
statistical differences among 
groups (Mann-Whitney test). CN= 
controls; AD= Alzheimer disease; 
[C] mg/ml= CSF total protein 
concentration; MMSE= Mini 
Mental State Examination; m= 
mean; sd= standard deviation. 
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were then left to incubate for different time (0, 3, 6, 9, 
and 12 days) at 37°C under nitrogen conditioned 
atmosphere, in order to avoid the exposure to 
atmospheric oxidative-environment. 
5.2.4 Binding of Cp to integrins and 
competition with isoDGR peptide 
α5β1, αvβ3, αvβ5, αvβ6 and αvβ8 integrin (1 μg/ml in 
PBS with Ca2+/Mg2+; DPBS, Cambrex), were added to 
96-well polyvinylchloride plates (BD Biosciences) and 
incubated 12 h at 4°C. Subsequent steps were carried 
out at 20°C. After blocking (3% BSA-PBS) the plates 
were filled with: Cp solutions (2-20 ug/ml in binding 
buffer; 25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM 
MgCl2, 1 mM MnCl2, 0,05% Tween, 1% BSA); or CSF 
samples from healthy subjects or AD patients 
supplemented with Cp (prepared as described above, 
diluted in binding buffer) and incubated for 2 h. 
Binding was detected using a polyclonal sheep anti-
human Cp Ab (Abcam ab8813) followed by a 
secondary HRP-conjugate Ab (Abcam) and by o-
phenylendiamine chromogenic substrate.  
Competitive binding assays were performed by 
mixing 10 μg/ml of either the acetyl-
CisoDGRCGVRSSSRTPSDKY peptide (isoDGR-peptide) 
or the control peptide CARACGVRSSSRTPSDKY (ARA-
peptide) [335] with Cp-ox/Ambic solutions (20 μg/ml) 
or mixing isoDGR-peptide (30 μg/ml ) with CSF 
samples spiked with Cp (20 μg/ml ). The mixtures 
were added to microtiter plates coated with integrin 
and the binding assay was carried out as described 
above. Cp bound to the αvβ6 coated plates was 
analyzed for biochemical features as follow; after the 
binding the plates were washed and incubated with 
Laemmli buffer (5 min at 100°C) to promote protein 
detachment, the solution was then collected and 
subjected to SDS-PAGE and Western blot (WB) 
analyses as described in 5.1.2  with a polyclonal anti-
human Cp Ab (Abcam). Images were acquired using a 
laser densitometer (Molecular Dynamics). 
5.2.5 Cell adhesion assay and protein L-
isoaspartyl methyltransferase (PIMT) 
treatment 
96-well polyvinyl chloride microtiter plates were 
coated with either untreated-, treated-Cp or Cp 
immunoprecipitated (see below) after aging in 
healthy or AD CSF (1-20 μg/ml in 50 mM Na 3PO4, pH 
7.3, 150 mM NaCl, 16 h at 4°C). After washing and 
blocking with 3% BSA-DPBS the plates were seeded 
with HaCaT, EA.hy926, T98G cells diluted in 0.1% BSA-
DMEM (40,000 cells/well), and left to adhere for 3 h at 
37°C. Adherent cells were fixed with 3% 
paraformaldehyde, 2% sucrose in PBS (pH 7.3), and 
stained with 0.5% crystal violet (Fluka Chemie, Buchs, 
Switzerland); adhesion evaluated as adsorbance at 
570 nm. Cells spreading was evaluated comparing 
cell’s area (pixels) automatically detected by image 
software analysis (Progenesis PG240, Nonlinear 
Dynamics) in different microscopy fields for each 
treatment conditions. For PIMT treatment, plates 
coated as described above, were washed and filled 
with 45 μl of 0.02 mM S -adenosyl-L-methionine in 50 
mM Na3PO4, pH 6.8 and 5 μl of PIMT solution (from 
IsoQuant isoaspartate detection kit; Promega), and 
incubated at 37°C for 16 h. Then plates were washed, 
and cell adhesion assay performed as described 
above. 
5.2.6 Immunoprecipitation of Cp from CSF 
After incubation either in healthy or AD CSF, spiked 
purified Cp was immunoprecipitated using protein-G 
Agarose Beads (Invitrogen) coated with an anti-Cp 
antibody (Abcam ab8813). The antibodies were 
crosslinked to the beads with 20 mM dimethyl 
pimelimidate (Sigma) and added to the CSF 
supplemented with Cp; the solution was then 
incubated for 24 h at 4°C under gently stirring. Beads 
were washed and Cp was eluted with 0.1 M glycin 
solution, pH 2.5; samples were immediately 
diafiltered with PBS using an Amicon filter device.  
5.2.7 Bathophenanthroline assay 
Ferroxidase activity of Cp after aging in CSF was 
evaluated on immunoprecipitated Cp by 
bathophenanthroline (Btp) assay as in 5.1.4. Briefly, 
immunoprecipitated Cp (1.25 μg) was incubated with 
80 mM FeSO4 (ferrous form) and analyzed after 1 h 
with a solution of 1 mM Btp in acetate buffer, pH 6.2. 
Decrease in Btp-Fe2+ complex absorbance at 535 nm 
derives from ferrous iron oxidation into ferric form 
(Fe3+). 
5.2.8 Mass spectrometry analysis 
Samples were dialyzed against digestion buffer (50 
mM Na3PO4 pH 7.3, 150 mM NaCl, 25 mM HEPES) and 
incubated 2 h at 20°C with trypsin (10 ng/µl, Roche). 
Digested samples were desalted (Stage tips C18, 
ThermoScientific) and injected in a capillary 
chromatographic system (EasyLC, Proxeon 
Biosystem). Peptide separations occurred on a 25 cm 
reverse phase silica capillary column, packed with 3-
µm ReproSil 100Å C18 AQ. A gradient of acetonitrile 
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eluents was used to achieve separation (0.15 µL/min 
flow rate). Mass spectrometry (MS) analysis was 
performed by nanoLC-MS/MS using an LTQ-Orbitrap 
(ThermoScientific) equipped with a nanoelectrospray 
ion source (Proxeon Biosystems). Full scan spectra 
were acquired with the lock-mass option, resolution 
set to 60,000, and mass range from m/z 350 to 
1700 Da. The six most intense doubly and triply 
charged ions were selected and fragmented in the 
ion trap. All MS/MS samples were analyzed using 
Mascot (v.2.2.07, Matrix Science) and X!Tandem 
(within Scaffold software, v.2_06_00, 2007, Proteome 
Software Inc.) search engines to search the 
UniProt_Human Complete 
Proteome_cp_hum_2012_07. Searches were 
performed with 3-missed cleavages allowed, N-
terminus-acetylation, methionine oxidation and 
deamidation of asparagine/glutamine as variable 
modifications. Mass tolerance was set to 5 ppm and 
0.6 Da for precursor and fragment ions, respectively. 
Scaffold was used to validate MS/MS based peptide 
and protein identifications. Protein thresholds were 
set to 99.0% and two peptides minimum while 
peptide thresholds were set to 95% minimum. 
5.2.9 Circular dichroism and melting curves 
Circular dichroism (CD) spectra were acquired for Cp 
and Cp after oxidative and aging treatments (at 1 µM 
in 50 mM PBS pH 7), on a Jasco J-815 CD 
spectrometer at 20°C. Each spectrum was averaged 
using four accumulations collected in 0.1 nm 
intervals with an average time of 0.5 sec. The protein 
spectra were corrected by subtracting the 
corresponding buffer spectra and then smoothed. 
The observed ellipticity (mdeg) was converted into 
molar residue ellipticity [θ] (deg cm 2 dmol-1), which is 
the circular dichroism corrected for concentration. 
Melting curves were calculated recording CD spectra 
in continuous from 20 °C to 96°C (1°C intervals) in a 
wavelength range from 190 to 260 nm in order to 
achieve the better resolution. Melting temperature 
(Tm) was calculated by nonlinear fitting Boltzmann 
sigmoidal with Prism V4.03 software (GraphPad Inc.). 
5.2.10 Molecular dynamics simulations and 
docking calculations (performed by 
Dr. A. Spitaleri) 
Homology modeling: I-TASSER server was used to 
predict the secondary and tertiary structure of αvβ6 
integrin [401]. Molecular dynamics (MD) simulations: 
were performed on Cp wild type (P00450; PDB 2j5w), 
using the GROMACS 4.5.4 package [402] with the 
optimized parameters for liquid simulation (OPLS) 
force field. The 568isoDGR-Cp and αvβ6 systems have 
been simulated in the same manner. Three 
independent 50 ns long MD simulations (150 ns 
production run) were performed for Cp to allow for 
better conformational sampling, while three 
independent 10 ns long MD simulations (30 ns) were 
performed for αvβ6 in order to get a set of structures 
to be used in docking calculations. All the analyses 
were performed using the Gromacs utilities on the 
last 40 ns of each simulation concatenated in a single 
trajectory (120 ns total). In particular, cluster analysis 
were performed using gromos algorithm. Docking 
calculations: Docking calculations of 568isoDGR-Cp on 
the globular head of the extracellular part of αvβ6 
have been performed using the docking program 
HADDOCK2.0 [403] with the OPLS force field. We 
have docked a bundle of 27 568isoDGR-Cp structures 
onto a bundle of 10 αvβ6 structures, which 
correspond to the centers of the clusters obtained 
from MD simulations. The protocol follows a three-
stage docking procedure: (a) randomization of 
orientations and rigid body minimization, (b) 
simulated annealing in torsion angle space, and (c) 
refinement in Cartesian space with explicit water. 
Ambiguous interaction restraints (αvβ6: residues 150, 
218, 506, 547, 548, 601, 815; 568isoDGR-Cp: residues 
568 to 570) were derived from the known 
interactions of the isoDGR motif of the cyclic-peptide 
with αvβ6 [355]. The best 200 solutions in terms of 
intermolecular energies were selected for a 
semiflexible simulated annealing in which the side-
chains of αvβ6 and of the 568isoDGR-Cp located at the 
binding interface were allowed to move in a semi-
rigid body docking protocol to search for 
conformational rearrangements. The models were 
then subjected to a water refinement step. The single 
best docked solutions were analyzed according to 
hydrogen bonds, salt bridges contact and buried 
surface accessibility.  
5.2.11 Statistical Analysis 
Categorical data were analyzed by using Fisher’s 
exact test and two-tailed p value. Continuous data 
were evaluated by unpaired student’s t-test, if the 
data passed the normality test for Gaussian 
distribution as assessed by the Kolmogorov-Smirnov 
test, or were evaluated by Mann Whitney test; two-
tailed p value was used for the comparison of two 
means and standard error. In all analyses, p<0.05 was 
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considered to be statistically significant. The analysis 
was performed with Prism V4.03 software (GraphPad 
Inc.). 
5.2.12 Reverse phase protein array (RPPA) 
analysis 
HaCaT cells were incubated (30 or 120 minutes) with 
either Cp or aged/oxidized-Cp. Cells lysates obtained 
with Zeptosens CLB1 Lysis Buffer(Bayer) were 
spotted on arrays and analyzed using Zeptosens 
custom service  (Bayer). A set of 40 antibodies (Abs, 
see Table 5.3), either specific for protein expression or 
for residues phosphorylation, that identify 25 pairs of 
phosphorylation rate for 16 different proteins 
belonging to the integrin signaling pathway 
(www.kegg.com/kegg-bin/show pathway?ko04510; 
and ko04810) were reacted in a standard Zeptosens 
profiling assay. Mean Referenced Fluorescence 
Intensity (RFI) obtained from Abs reactivity were used 
to evaluate the proportion of specific residues 
phosphorylation [RFI-(phos-protein-x) / RFI-(protein-
x)] for each protein. Then, the phosphorylation 
proportion of the cell treated with aged/oxidized-Cp 
were compared with that of the time-related control 
Cp (Cp-ox/Cp 30 min; Cp-ox/Cp 120 min) as to define 
whether the phosphorylation rate was unaffected 
(value = 1), induced (value > 1) or inhibited (value<1) 
by Cp-ox. Phosphorylation rate was analyzed by 
hierarchical clustering performed with Mev4.6 v10.2 
software [404]; the 25 data series of protein 
phosphorylation rate in the 2 different conditions 
(Cp-ox/Cp 30 min; Cp-ox/Cp 120 min) were clustered 
into groups on the basis of the distances between the 
data series reported as covariance correlation.  
Table 5.3: List of antibodies used in integrins signaling pathway analysis performed by reverse phase 
protein array (Zeptosens™, Bayer). 
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5.3 Methods related to Chapter 3 
results 
5.3.1 Patients 
For details see chapter 5.1.1. The analysed groups 
were: sporadic PD (n= 21), peripheral neuropathies 
(PN, n= 11) and healthy controls (CN, n= 16). Table 5.4 
summarizes the demographic and clinical features of 
the patients and control subjects enrolled on this 
discovery study. 
5.3.2 Oxidation and aging treatments of Cp 
and CSF  
In-vitro accelerated aging under oxidative conditions 
was performed incubating purified Cp (Alexis 
biochemical) 16 h at 37°C with 10 mM H2O2 in 100 
mM ammonium bicarbonate buffer pH 8.5 (ox-
AmBic) (see 5.2.3). Aging of purified-Cp ex-vivo in CSF 
was achieved by incubating Cp (20-80 μg/ml) in CSF 
from healthy subjects or from patients, at 37°C (3-12 
days) under nitrogen-conditioned atmosphere, to 
avoid the exposure to atmospheric oxidative-
environment; in selected experiments, aging was 
performed in presence of catalase (60 μg/ml, Sigma). 
5.3.3 Cp immunoprecipitation from CSF 
Immunoprecipitation of Cp from CSF was performed 
as in 5.2.6. For mass spectrometry analysis, samples 
were diafiltered against digestion buffer (50 mM 
Na3PO4 pH 7.3, 150 mM NaCl, 25 mM HEPES) and 
incubated 2 h at 20°C in the presence of trypsin (10 
ng/μl, Roche). 
5.3.4 Mass spectrometry analysis 
Cp samples after trypsin digestion were desalted 
(Stage tips C18, Thermo Scientific) and injected in a 
capillary chromatographic system (EasyLC, Proxeon 
Biosystem). MS analysis was performed as in 5.2.8. To 
quantify deamidation the raw data were loaded into 
the MaxQuant 
software v1.2.2.5. 
Label-free protein 
quantification was 
based on the 
intensities of 
precursors. 
Peptides and 
proteins were 
accepted with a 
FDR of 0.01, two 
minimum peptides 
per protein with 
one unique. 
5.3.5 Cp 
sensitivity to 
limited 
proteolysis 
Spiked Cp after 
aging in CSF was 
immunoprecipitat
ed from CSF and 
100 ng were 
resuspended in 25 
µl of digestion 
buffer followed by 
incubation for 2 h 
at 20°C in the 
presence of 
agarose-
Table 5.4: Demographic and clinical features of patients and controls. Gender: no statistical differences among groups 
(Fischer’s exact test); Age: no statistical differences among Cn vs. PD; CN vs. PN p=0.018; PD vs. PN p=0.0025 (Student’s t-
test); Protein concentration [C]: no statistical differences among groups (Student’s t-test). CN= controls; PD= Parkinson’s 
disease; PN= peripheral neuropathies. [C] mg/ml= CSF total protein concentration; UPDRS= Unified Parkinson’s Disease 
Rating Scale; m= mean; sd= standard deviation; LBD= Lewy body dementia; Pkins= Parkinsonism; D=dementia; cve= 
chronic vascular encephalopathy; at-PD= atypical PD; pnp-infl= peripheral neuropathy inflammatory; pnp-idio= pnp-
idiopathic; pnp-tox= pnp-toxic. 
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immobilized trypsin (0.5 U) (Sigma). Trypsin was 
removed by centrifugation, and samples were 
analysed by SDS-PAGE and WB. 
5.3.6 Hydrogen peroxide assay kit 
For the evaluation of the hydrogen peroxide 
concentration in the CSFs, Hydrogen Peroxide Assay Kit 
(BioVision) was used. The principle of the assay is 
based on the reaction between the hydrogen 
peroxide and a non-fluorescent probe, (AmplexRed®: 
10-acetyl-3,7-dihydroxyphenoxazine) which, the 
presence of hydrogen peroxide  produces the red-
fluorescent compound resorufin. For each sample, 
three replicate were made, diluting 0.5 μl  of CSF 
1:100 in the assay buffer provided by the 
manufacturer. Samples were assayed according to 
the protocol, and H2O2 concentration was evaluated 
as fluorescence at 590 nm. 
5.3.7 Additional methods 
Cp binding to integrins, competition with peptide 
and mass spectrometry analysis were performed as in 
5.2; Western blot, Cp-ferroxidase activity (1.25 μg of 
immunoprecipited protein), and Cp-carbonylation 
assay (300 ng of immunoprecipited protein) were 
performed as in 5.1 and 5.2. 
 
5.4 Methods related to Chapter 4 
results  
5.4.1  Patients 
For details, see chapter 5.1.1. For the proliferation 
assay performed in this chapter, samples from #9 to 
#16 (both of CN and AD patients) of Table 5.2 were 
used. 
5.4.2  Oxidation and asparagine accelerated 
aging treatments 
See chapter 5.2.3. 
5.4.3  Cell culture and reagents 
Keratinocyte HaCaT human cell lines (America Type 
Culture Collection, ATCC) were cultured (37°C in a 5% 
CO2 atmosphere) in DMEM medium (ATCC) 
supplemented with L-glutamine, and 10% fetal 
bovine serum (FBS). Neural stem cells (NSCs) isolated 
from the subventircular zone of postnatal day 40 FVB 
mice were isolated and cultured as previously 
described [405], and maintained in DMEM/F12 
medium supplemented with epidermal growth factor 
and fibroblast growth factor-2. Human primary 
fibroblasts (obtained from skin biopsies and made 
available by Dr. G. Zerbini, OSR) were grown on 
DMEM medium supplemented with L-glutamine and 
10% fetal bovine serum (FBS). Human choroid plexus 
epithelial cells (HCPEpiC, ScienCell, Carlsbad CA) were 
cultured as indicated by the manufacturer in EpiCM 
(ScienCell) medium supplemented with 2% fetal 
bovine serum (FBS) and 5 ml of epithelial cell growth 
supplement (ScienCell). Cells were used within three 
culture passage to exclude un-differentiation to 
mesenchimal cells 
Human plasma purified Cp was from Alexis 
Biochemicals. Anti-Vimentin antibody was from 
Sigma (V6630) and anti-CK-19 from GeneTex 
(GTX27755). Anti-Transthyretin antibody (AB16006) 
was from Abcam and anti β -Tubulin was from Sigma 
(T6199). The antibodies used for the signaling 
analysis (FAK #3528, P-FAK #3283, ERK1/2 #9102, P-
ERK1/2 #9101, GSK3β #9315, P-GSK3β #9336) were 
from Cell Signaling Technology.  
5.4.4 Cell proliferation assay, cell cycle and 
apoptosis 
HaCaT cells were cultured on a 96-well tissue culture 
treated plate (10,000 cells/well) for 16 h, then 
medium was replaced with medium containing 0.1% 
FBS and further cultured for 24 h. Next, the cells were 
incubated for 24 or 48 h with various doses (0, 1, 5 
and 20 μg/ml) of untreated- or treated-Cp diluted in 
medium containing 0.1% FBS, or as control the same 
amount of BSA-ox/AmBic; cells were treated also for 
72 h with 2 μg/ml of purified Cp immunoprecipitated 
after aging in healthy or AD CSF. For the treatments 
protocols, see chapter 5.2.3. Cell proliferation was 
determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay using a 
calibration curve generated by plating different 
amounts of cells. For short-term proliferation assay, 
NSCs cells were plated (8x103 cells/cm2) in mitogen-
containing medium in the presence of Cp, Cp-
ox/AmBic or BSA-ox/AmBic (5 and 20 μg/ml); the 
formed neurospheres were collected 96 h later and 
mechanically dissociated. The total number of viable 
cells was assessed by Trypan Blue exclusion. Cells 
treated as for the proliferation assay (for 24-72 h) 
were used for flow cytometry evaluation of cell cycle 
and apoptosis using an LSR Fortessa cell analyzer 
(Becton Dickinson). Cells were labeled with a 
thymidine analog in order to separate cells in S phase 
from those in G0/G1 and G2/M exploiting the Click-
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iT®EdU Flow Cytometry Assay Kit (Invitrogen,) 
containing the Alexa Fluor®647 detection fluorophore 
and the Vybrant® DyeCycle™Violet (Invitrogen) dye for 
total DNA detection. Cells were also stained with the 
FITC Annexin V Apoptosis Detection Kit I (BD 
Biosciences) to detect externalization of 
phosphatidylserine, an early apoptotic indicator. 
5.4.5  Western blot analysis 
For the HCPEpiC epithelial markers and signaling 
experiments, cells were lysed in lysis buffer (50 mM 
TRIS, 150 mM NaCl, 1 mM EDTA, 1% Triton-X, 0,1% 
SDS and protease inhibitors cocktail P2714 from 
Sigma) and quantified with Bradford assay (Bio-Rad, 
500-0006). Subsequently, cell lysates were resolved 
by 10%-acrylamide SDS-PAGE and analyzed by 
Western blot with specific antibodies. 
5.4.6  Anti Transthyretin immunofluorescence 
HCPEpi cells were seeded (250.000 cells/coverslip) on 
10 Ø mm sterile round coverslips treated with poly-L-
lysine (2 μg/cm2) and let to adhere for 24 h in 
complete EpiCM medium (37°C in a 5% CO2 
atmosphere). Cells were then washed 3 times in PBS 
(5 min each) and fixed for 15 min with a 4% PFA 
solution at 20°C. After 3 washing in PBS, fixed cell 
layer was blocked for 1 h with blocking solution (5% 
normal goat serum, 0.3% Triton-X in PBS) at 20°C and 
subsequently incubated with anti-transthyretin 
antibody diluted 1:250 in binding solution (1% BSA, 
0.3% Triton-X in PBS).  Following three washes the 
coverslips were incubated with donkey anti-rabbit 
Alexa-488 antibody (Life Technologies), and, after 
further three washing, the coverslips were incubated 
in Hoechst solution (Sigma) for 10 min at 20°C. 
Coverslips were then washed in H2O and mounted on 
microscope slides for the inspection performed on 
Leica DM 5500B microscope equipped with 
epifluorescence. 
5.4.7 Cell adhesion assay and protein L-
isoaspartyl methyltransferase (PIMT) 
treatment 
Adhesion assay with HCPEpi cells and PIMT treatment 
were performed as in 5.2.5. 
5.4.8  HCPEpi cells stimulation 
HCPEpi cells were cultured on a 10 cm tissue culture 
plate (1.000.000 cells/plate) for 16 h, then the 
medium containing 10% FBS was replaced with a 
medium containing 0.1% FBS and further cultured for 
24 h. Next, the cells were incubated for 2 h with 10 
μg/ml of untreated- or ox/AmBic-Cp diluted in 
medium containing 0.1% FBS. Subsequently cells 
were lysed and analyzed by WB. 
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